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Heart failure (HF) is the leading cause of hospitalization in patients older than 
65 years of age and a major public health problem1. Hospital admissions for acutely 
decompensated heart failure (ADHF) are frequent and accompanied by high 
percentages of hospital complications and mortality2. There is a paucity of data derived 
from controlled clinical trials to define optimal treatment for patients with acute HF 
which is largely based on loop diuretics and vasodilators for congestion relief3.  
The pathophysiology of ADHF is characterized by abnormal neurohormonal 
activation, leading to an increase of sodium and water retention, arterial 
vasoconstriction, and activation of inflammatory cascades4,5. Excessive neurohormonal 
activation may lead to several harmful effects6, including renal dysfunction and 
myocardial injury7. The recognition of neurohormonal activation in HF has led to the 
development of therapies able to inhibit inappropriate neurohormonal enhancement, 
particularly the renin-angiotensin-aldosterone system (RAAS). The advent of these 
therapies had high impact on morbidity and mortality of these patients4.  
Despite the use of angiotensin-converting enzyme inhibitors (ACEIs), 
angiotensin receptor blockers (ARBs), and beta-blockers (BBs), neurohormonal 
activation remains inappropriately elevated in patients hospitalized with ADHF8-10. 
Furthermore, there is growing evidence suggesting that aldosterone may only 
transiently be suppressed with ACEIs/ARBs. This phenomenon termed “aldosterone 
breakthrough” can have important clinical consequences given aldosterone sodium-
retaining, profibrotic, and inflammatory properties11-13. The addition of mineralocorticoid 
receptor antagonists (MRAs) on top of ACEIs/ARBs and BBs has been shown to 
improve clinical outcomes14. The use of MRAs reduced morbidity and mortality in 
patients with chronic, severe systolic heart failure (HF)14, in chronic HF with mild 
symptoms15, and after myocardial infarction16. The improved morbidity and mortality 
observed in these trials is thought to be in part due to suppression of neurohormonal 
activation by MRAs, suggesting a potential interest in early initiation of MRAs in the 
ADHF setting. 
Considering the anti-hypertensive and diuretic properties of MRAs, the ideal 
candidate for this therapy should be hyper- or normotensive and fluid overloaded, 
without evidence of cardiogenic shock. In addition, patients with systemic congestion, 
and/or with predominantly right-sided HF may have hepatic congestion and 
consequently have impaired clearance of neurohormonal factors8, providing an 
attractive subset of patients likely to take the most benefit out of MRA therapy. 
Mineralocorticoid Receptor Antagonists and Diuretic Resistance  
Resistance to loop diuretics has been associated to a much higher plasma 
aldosterone concentration17-19. Chronic administration of loop diuretics has been shown 
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to cause hypertrophy of the distal nephron and increase expression of the sodium 
chloride cotransporter, which is an aldosterone-induced protein. These structural 
changes can lead to loop diuretic resistance and these effects are potentially reversed 
by a mineralocorticoid antagonist20.  
Congestion refractory to oral diuretics may be responsible for up to one-third of 
hospital admissions due to ADHF1, and unresolved congestion may contribute to the 
high readmission rates observed in these patients1. Furthermore, approximately 30% of 
patients admitted for ADHF develop diuretic resistance, defined as reduced diuresis 
and natriuresis in response to a constant high dose of loop diuretics21. Strategies to 
overcome this clinical problem still have limited success. The use of diuretics to treat 
persistent congestion may lead to kidney injury and worsening renal function. 
Venovenous ultrafiltration is an option in these patients, however it is an expensive and 
invasive procedure that requires hospitalization. Most importantly, this technique did 
not reduce mortality or hospitalizations for HF compared to strategy of stepped diuretic-
based therapy22. Therefore, the use of this technique does not seem justified for 
patients hospitalized for ADHF, worsened renal function, and persistent congestion. 
The use of natriuretic doses of MRAs in this setting may be an attractive alternative to 
reverse diuretic resistance and inappropriate RAAS activation23.  
Mineralocorticoid Receptor Antagonists May Prevent Myocardial Injury, 
Remodelling and Fibrosis  
Myocardial injury, indicated by troponin release, is common in ADHF7,24-27. The 
ADHF episodes are associated with increased mechanical strain on the heart, 
activation of neurohormonal systems, and increased and oxidative stress28. These 
stimuli are known to mediate myocardial injury and accelerating myocyte loss28. 
Improvements in analytical sensitivity have transformed circulating troponin from a 
biomarker that was only detectable in a minority of patients to one that is detectable in 
the vast majority of patients with HF25. The high sensitivity troponin-T (hsTnT) test can 
detect very small changes in the circulating troponin levels25,29. Elevations in baseline 
troponin levels were demonstrated to be independent predictors of events during the 
acute hospitalization (worsening or persistent HF, death, and increased length of stay) 
and also independent predictors of post-discharge outcomes24,27,30-33. Accordingly, 
changes in troponin status during initial treatment for ADHF have been proposed as 
potentially important targets for drug development34.  
Mineralocorticoid receptor antagonists decrease myocardial fibrosis, 
inflammation, oxidative stress, apoptosis, neurohormonal activation, and remodelling in 
animal models and patients with HF35,36. The anti-fibrotic influence of MRAs in patients 
with ischaemic myocardial necrosis provides an additional therapeutic benefit as 
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demonstrated in post-myocardial infarction patients with left ventricular (LV) 
dysfunction in the EPHESUS trial16. Additionally, MRA therapy reduces biochemical 
markers of ventricular remodelling and improves LV function and structure37. Matrix 
metalloproteinases (MMPs) are a family of enzymes important for the resorption of 
extracellular matrices (ECM), control of vascular remodelling and repair. MMPs are 
important for proteolysis that can affect the composition of ECM and consequently 
myocardial remodelling. Additionally, increased ECM turnover may be associated with 
pathological myocardial remodelling, that is accelerated in ADHF29,38. Increased activity 
of matrix metalloproteinase-2 (MMP2) has been demonstrated in ADHF and a 
decrease of circulating MMPs has been demonstrated along with ADHF successful 
treatment38,39. Hence, a reduction in markers of ECM turnover may serve as a 
surrogate marker for deceleration of myocardial turnover and remodelling.  
Cardiorenal Interactions and Mineralocorticoid Receptor Antagonists 
Interactions between the heart and the kidneys are increasingly acknowledged 
by clinicians. The term cardiorenal syndrome (CRS) applies to the bidirectional nature 
of how disease in one organ system affects the function of the other organ system40. 
Despite the notable advance in the understanding of this area, management of 
patients presenting with ADHF and concomitant renal dysfunction remains challenging. 
Loop diuretics are the mainstay pharmacologic treatment for the management of ADHF 
patients presenting with volume overload41. Their use is likely to lead to improvement of 
symptoms and may even improve kidney function by decreasing renal venous 
pressure42. A recent study, showed an albuminuria decrease after ADHF treatment43. 
Unfortunately, the use of loop diuretics has several pitfalls. Loop diuretics can cause 
significant electrolyte abnormalities, hypotension, and increased neurohormonal 
activation41. Increased neurohormonal activation, particularly the overactivation of the 
RAAS, is one of the most important mechanism leading to diuretic resistance44. A 
possible approach to overcome diuretic resistance is administration of a second 
diuretic agent as an MRA in natriuretic doses. 
Drug Selection: Is Spironolactone a Good Candidate to be Used In the Acutely 
Decompensated Heart Failure Setting? 
 In addition to patient and clinical setting selection, it is necessary to know which 
drug to use and in which dose. 
 Spironolactone is a non-selective MRA with moderate affinity for both 
progesterone and androgen receptors. The latter property increases the likelihood of 
endocrine side effects with spironolactone including loss of libido, menstrual 
irregularities, gynecomastia and impotence45. Spironolactone has extensive and 
complex metabolism in humans, its absorption can reach 80-90% and it is not affected 
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by food46, however it undergoes extensive hepatic metabolism into the active 
metabolites - canrenone and sulfur-containing metabolites: 7 alpha-
thiomethylspirolactone (IV) and 6 beta-hydroxy-7 alpha-thiomethylspirolactone (V), with 
prolonged half-lives ranging from 14 to 17 hours (h). The sulfur-containing metabolite 
IV rather than canrenone is the major metabolite in serum following single or repeated 
doses of spironolactone47. Spironolactone is poorly soluble in aqueous fluids and an 
intravenous formulation is not available for routine clinical use45. Following a single 
dose of oral spironolactone, peak serum concentrations of the drug and its metabolites 
occur at 1–2 and 2–4 h, respectively48. The peak response for spironolactone 
natriuretic effect can occur until 48 hours after the first administration45. This relatively 
slow peak of action has been related to the time active metabolites take to reach 
steady-state plasma levels45. Interestingly, a single intravenous dose of the 
spironolactone metabolite potassium canrenoate has demonstrated a rapid natriuretic 
effect (within 6 hours after administration), possibly by avoiding the first-pass 
metabolism, accelerating the obtainment of steady-state49. 
 Overall, spironolactone is an attractive option to use in this setting, given the 
wide experience with the drug, the low incidence of side effects, and the rapid onset of 
action. 
Blocking the Mineralocorticoid Receptor: Titration and Monitorization  
 Although the pharmacological blockade of RAAS is one of the mainstays of HF 
treatment, a suboptimal neurohormonal inhibition is still a critical issue in standard 
practice. 
Measuring the activation and the effective blockade of RAAS would help us to 
enhance its inhibition and to tailor these therapies to the individual HF patients50. Thus 
reliable and practical biomarkers are warranted to establish the activity of the RAAS in 
clinical practice51. Taking advantage of the renal physiological action of aldosterone, 
the urinary sodium to potassium (uNa/K) ratio is an attractive candidate biomarker of 
RAAS modulation51. 
Aldosterone regulates sodium balance by increasing the expression of the 
epithelial Na+ channel and the Na+/K+-ATPase pump found on the distal nephron 
epithelial cells52, promoting reabsorption of Na+ and the excretion of K+53. Previous 
reports had indicated a measurable effect of MRA on uNa/K ratio consistent with 
effects of aldosterone on electrolyte balance54,55. Mineralocorticoid receptor blockade 
elicited an increase in uNa/K ratio in rats in a dose-dependent manner51, supporting the 
use of uNa/K ratio as a translatable biomarker of MRA with the potential to enable dose 
selection for clinical trials51.  
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 This project was designed to answer the questions elaborated in the 
Introduction.  
a) Is high-dose spironolactone safe in ADHF? 
b) Can spironolactone overcome diuretic resistance? 
c) Can spironolactone mitigate myocardial and renal injury during the ADHF 
episode? 
d) Can spironolactone reduce turnover and fibrosis biomarkers? 
e) Does high-dose spironolactone affect the RAAS? 
f) Is there an easily available surrogate marker for spironolactone use?  
 
In order to answer these questions we designed a prospective, non-
randomized, experimental, single-centre, and single-blinded trial conducted in Centro 
Hospitalar do Porto enrolling participants between February 2012 and February 2013.  
Patients were eligible for enrollment if they presented with decompensation of 
chronic HF with symptoms leading to hospitalization. HF was diagnosed on the basis of 
the presence of history of chronic heart failure and at least one symptom (dyspnea, 
orthopnea, or edema) and one sign (rales, peripheral edema, ascites, or pulmonary 
vascular congestion on chest radiography). Exclusion criteria were: chronic use of 
MRAs, cardiac surgery within 60 days of enrollment, cardiac mechanical support, 
cardiac resynchronization-therapy within the last 60 days, comorbid conditions with an 
expected survival of less than 6 months, acute myocardial infarction at time of 
hospitalization, hemodynamically significant uncorrected primary cardiac valvular 
disease, patients requiring intravenous vasodilators or inotropic agents, supine systolic 
arterial blood pressure <90 mmHg, serum creatinine level >1.5 mg/dL, serum 
potassium level >5.0 mmol/L, hemoglobin level <9 g/dL, and sepsis. 
Patients were non-randomly assigned in a sequential 1:1 ratio to the 
intervention or standard treatment. Chief investigator was responsible to assess the 
eligibility criteria and to allocate the intervention after being contacted by the patient 
assistant physician. Patients were blinded to the intervention allocation. Assistant 
physicians were not blinded to intervention allocation. Assistant physicians were 
Attending Physicians or Fellows of Internal Medicine or Cardiology depending on the 
ward where each patient was admitted. The assistant physicians evaluated the clinical 
signs and symptoms and registered their evaluation in the clinical diaries and then 
transcribed to our database by the authors. 
Patients were assigned to either oral spironolactone (minimum and maximum 
initial dose of 50 - 100 mg/d, according to assistant physician) plus standard AHF 
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therapy or standard AHF therapy alone. Standard AHF therapy included intra-venous 
(i.v.) furosemide (bolus or continuous infusion), digoxin, ACEi, ARB, nitrates, and/or 
non-invasive ventilation (NIV), according to attending physician decision. At day 2, the 
attending physician had the option of adjusting spironolactone dose on the basis of the 
clinical judgment and laboratory results. At this time, the physician could decrease the 
dose by 50%, to a minimum of 50 mg/d, or maintain the same strategy.  
Patient`s clinical status was prospectively recorded, by the assistant physicians, 
according to previous defined parameters. 
An assessment of biomarkers, including plasma creatinine (pCr), ions, N-
terminal pro-brain natriuretic peptide (NTproBNP), high sensitivity troponin T (hsTnT) 
and microalbuminuria was performed at a central core laboratory at admission day (day 
1) and day 3. Clinical assessment and routine analyses were performed daily during 
hospital stay. All patients performed a transthoracic echocardiography within 72 hours 
upon admission. Left-ventricular ejection fraction was estimated by transthoracic 
echocardiography using the biplane Simpson method. 
Patients characteristics are describe in Table 1. 
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Table 1. Baseline Characteristics of the Study Population 
 Control Group Spironolactone Group  p Value 
Age (yrs) 78,8 ± 9,3 73,2 ± 11,7 0,01 
Male sex – no. (%) 17 (34) 22 (44) 0,31** 
Ejection Fraction (%) 45,5 ± 10,7 41,4 ± 12,4 0,08** 
HFrEF – no. (%) 13 (26) 18 (36) 0,28** 
HgB (g/dL) 12,2 ± 1,8 12,7 ± 2,3 0,22 
Etiology of Heart 
Failure – no. (%) 
   
Ischemic 24 (48) 26 (52) 0,69** 
Non-Ischemic 26 (52) 24 (48) 0,84** 
Basal NYHA class – 
no. (%) 
   
II 41 (82) 44 (88) 0,4** 
III 9 (18) 6 (12) 0,4** 
History of Atrial 
Fibrillation or Flutter - 
no. (%) 
 
34 (68) 
 
25 (50) 
 
0,07** 
Outpatients 
Medications – no. (%) 
   
Furosemide 37 (74) 35 (70) 0,65** 
ACE Inhibitors 24 (48) 18 (36) 0,22** 
Beta-Blockers 26 (52) 10 (20) <0,01** 
Outpatients Oral Dose 
(mg) 
   
Furosemide 69,2 ± 37,8 68 ± 30 0,89 
ACE Inhibitors 5 ± 3 4,3 ± 2,5 0,43 
Beta-Blockers 4,4 ± 2,7 4,5 ± 1,1 0,90 
BMI ≥ 30 (Kg/m2) – no. 
(%) 
14 (28) 19 (38) 0,29** 
Diabetes Mellitus – no. 
(%) 
25 (50) 20 (40) 0,31** 
Glycated Hemoglobin 
(%) 
6,9 ± 0,7 7,1 ± 1,2 0,43** 
Obstructive Sleep 
Apnea Syndrome – no. 
(%) 
5 (10) 13 (26) 0,32** 
AHF precipitant (n)    
Undertreatment 34 (68) 29 (58) 0,30** 
Dysrythmia 10 (20) 9 (18) 0,80** 
Non-compliance 6 (12) 8 (16) 0,56** 
NSAIDs 0 4 (8) 0,04** 
Continuous variables are presented as mean value ± standard deviation [SD], p value. 
Categorical variables are presented as absolute number (%), p value. **Chi-square 
test. 
HgB = hemoglobin; ACE = angiotensin-converting enzyme; BMI = Body Mass Index; 
NYHA = New York Heart Association; AHF = Acute Heart Failure; NSAID = Non-
Steroidal Anti-Inflammatory Drug; HFrEF, heart failure with reduced ejection fraction. 
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Outcomes 
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 The outcomes of our study were: 
a) To test the influence of high-dose spironolactone in congestion assessment, 
evaluating the proportion of patients who were free of congestion at day 3 
(defined as jugular venous pressure of < 8 cm, no orthopnea and no peripheral 
edema), weight change and also in congestion surrogate markers variation, 
such as N-terminal pro-brain natriuretic peptide (NT-pro BNP); 
b) To test the safety of spironolactone use in ADHF, assessing creatinine and 
potassium change between day 1 and day 3; 
c) To test the influence of spironolactone in surrogate markers such as 
albuminuria, hsTnT, uNa/K, MMP2, renin and aldosterone. 
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Abstract 
Background/Objectives: Mineralocorticoid receptor antagonists (MRAs) use in acutely 
decompensated chronic heart failure (ADCHF) may improve congestion through 
diuretic effect and prevent neurohormonal activation. We aimed to evaluate the clinical 
effect and safety of spironolactone in ADCHF. 
Methods: Prospective, experimental, single-centre, and single-blinded trial. Patients 
were treated with: standard ADCHF therapy or oral spironolactone 50 - 100 mg/d plus 
standard ADCHF therapy. 
Results: During 1 year period, 100 patients were enrolled, 50 included in the treatment 
group. Mean (SD) spironolactone dose (mg) at day 1 was 94,5 ± 23,3 and at day 3 was 
62,7 ± 24,3. Worsening renal function (increase in pCr ≥ 0,3 mg/dL from day 1 to day 
3) was more likely to occur in control group (20% vs. 4%; p = 0,038), serum potassium 
did not differ between groups, and plasma NTproBNP had a significant decrease in 
spironolactone group at day 3 (median [IQR], 2488 [4579] vs. 1555 [1832]; p = 0,05). 
Furthermore, a greater proportion of patients in the treatment group were free of 
congestion at day 3:  less edema, rales, jugular venous pressure (JVP) and orthopnea 
(all, p < 0,05). In addition, a significantly higher proportion of patients were on oral 
furosemide at day 3 (44% vs. 82%; p < 0,001).  
Conclusions:  Our study supports the safety of high dose spironolactone in ADCHF and 
suggests a positive impact in the resolution of congestion. The important findings of our 
pilot study need to be confirmed in larger trials. 
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Introduction 
The recognition of the importance of chronic neurohormonal activation in heart 
failure (HF) pathophysiology was crucial to the development of new therapies beyond 
diuretics and digoxin. Pharmacological inhibition of renin-angiotensin-aldosterone 
system (RAAS) had a remarkable impact on morbidity and mortality of HF patients1. 
Likewise, mineralocorticoid receptor antagonists (MRAs) showed to be effective in 
reducing hospitalizations and mortality in systolic HF2, 3. 
The natural history of HF is characterized by recurrent episodes of acute HF 
(AHF). AHF defines a new onset HF or acutely decompensated chronic HF (ADCHF). 
Patients present with signs and symptoms needing urgent therapy4. Despite the 
prominent therapeutic advances in ambulatory HF patient, little progress has been 
made in the improvement of ADCHF patients treatment5. 
Aldosterone levels are elevated in patients with ADCHF despite the use of 
angiotensin-converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARB), 
and beta-blockers (BB)6. In this setting, aldosterone elevation may contribute to 
cardiorenal dysfunction, increasing the risk of death and ventricular arrhythmias6-8. 
Therefore, MRAs use in ADCHF treatment has two major putative advantages: improve 
congestion and hypervolemia through its diuretic effect and prevent the neurohormonal 
activation that characterizes ADCHF, and that is enhanced by loop diuretics5, 9, 10. 
The impact of MRAs in ADCHF patients has not been well-studied.  We aimed 
to evaluate the short-term clinical effect and safety of the MRA antagonist 
spironolactone in worsening chronic HF patients. 
 
Methods 
Study Design 
Prospective, experimental, single-centre, and single-blinded trial conducted in a 
Portuguese tertiary hospital enrolling participants between February 2012 and 
February 2013.  
 
Study Participants  
Patients were eligible for enrollment if they presented with decompensation of 
chronic HF with symptoms leading to hospitalization. HF was diagnosed on the basis of 
the presence of history of chronic heart failure and at least one symptom (dyspnea, 
orthopnea, or edema) and one sign (rales, peripheral edema, ascites, or pulmonary 
vascular congestion on chest radiography). Exclusion criteria were: chronic use of 
MRAs, cardiac surgery within 60 days of enrollment, cardiac mechanical support, 
cardiac resynchronization-therapy within the last 60 days, comorbid conditions with an 
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expected survival of less than 6 months, acute myocardial infarction at time of 
hospitalization, hemodynamically significant uncorrected primary cardiac valvular 
disease, patients requiring intravenous vasodilators or inotropic agents, supine systolic 
arterial blood pressure <90 mmHg, serum creatinine level >1.5 mg/dL, serum 
potassium level >5.0 mmol/L, hemoglobin level <9 g/dL, and sepsis. 
Institutional review board or ethics committee approval was obtained. All 
patients provided written informed consent to participate in the study. 
 
Treatment Assignments 
Patients were non-randomly assigned in a sequential 1:1 ratio to the 
intervention or standard treatment. Chief investigator was responsible to assess the 
eligibility criteria and to allocate the intervention after being contacted by the patient 
assistant physician. Patients were blinded to the intervention allocation. Assistant 
physicians were not blinded to intervention allocation. Assistant physicians were 
Attending Physicians or Fellows of Internal Medicine or Cardiology depending on the 
ward where each patient was admitted. The assistant physicians evaluated the clinical 
signs and symptoms and registered their evaluation in the clinical diaries and then 
transcribed to our database by the authors.   
 
Trial Intervention 
Patients were assigned to either oral spironolactone (minimum and maximum 
initial dose of 50 - 100 mg/d, according to assistant physician) plus standard AHF 
therapy or standard AHF therapy alone. Standard AHF therapy included intra-venous 
(i.v.) furosemide (bolus or continuous infusion), digoxin, ACEi, ARB, nitrates, and/or 
non-invasive ventilation (NIV), according to attending physician. At day 2, the attending 
physician had the option of adjusting spironolactone dose on the basis of the clinical 
judgment and laboratory results. At this time, the physician could decrease the dose by 
50%, to a minimum of 50 mg/d, or maintain the same strategy.  
 
Study assessments 
Patient`s clinical status was prospectively recorded, by the assistant physicians, 
according to previous defined parameters. 
An assessment of biomarkers, including plasma creatinine (pCr), ions, N-terminal pro-
brain natriuretic peptide (NTproBNP), high sensitivity troponin T (hsTnT) and 
microalbuminuria was performed at a central core laboratory at admission day (day 1) 
and day 3. Clinical assessment and routine analyses were performed daily during 
hospital stay. All patients performed a transthoracic echocardiography within 72 hours 
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upon admission. Ejection fraction was calculated according to biplane Simpson 
method. 
 
End Points 
 The primary end point was the proportion of patients who were free of 
congestion at day 3 (defined as jugular venous pressure of < 8 cm, no orthopnea and 
no peripheral edema). 
Two safety outcomes (pCr change between day 1 and day 3 plus potassium 
change between day 1 and day 3) were considered. 
Secondary end points included changes in: body weight; NTproBNP levels; 
microalbuminuria; serum sodium; ionized calcium; serum magnesium; hsTnT; urinary 
sodium, potassium, urea; and the proportion of patients: taking oral furosemide at day 
3; with increase in pCr ≥ 0,3 mg/dL from day 1 to day 3; and with hyper or hypokalemia 
during the study period. 
 
Statistical Analysis 
 Comparison between groups was performed using parametric or non-
parametric tests, as appropriate. Continuous variables are expressed as mean 
(standard deviation, SD) or median (inter-quartile range, IQR). Categorical variables 
are expressed in absolute numbers (no.) and proportions.  
Association between different variables was tested by univariate analysis.  
Significant association was defined by a p value ≤ 0,05.  
Statistical analysis was performed using SPSS software (version 19, Chicago, 
IL, USA). 
 
Results 
The pre-specified duration of the enrolment period was one year and during that 
time we enrolled a total of 100 patients. Fifty patients were allocated to the treatment 
group. Despite the study protocol referred a range spironolactone dose of 50 to 100 
mg/d, one patient had 200 mg at day 1. The mean ± (SD) spironolactone dose at day 1 
was 94,5 ± 23,3 mg and at day 3 was 62,7 ± 24,3 mg. 
Baseline characteristics of patients in each of the treatment groups are shown 
in Table 1. Patients in the control group were significantly older (mean ± (SD), 78,8 ± 
9,3 vs. 73,2 ± 11,7 years; p = 0,01). The study groups were well balanced in most 
clinical characteristics, namely: gender, ejection fraction, baseline HF medications 
(except for beta-blockers, more common in control group – no. (%): 26 (52) vs. 10 (20); 
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p = 0,001), comorbidities11, and risk stratification for in-hospital mortality 12, 13. All 
patients were in New York Heart Association (NYHA) class IV upon admission. 
Analysed end-points are shown in Table 2. Patients in the treatment group had a 
significant respiratory rate (cycles/minute) reduction at day 3 (median [IQR], 20 [2] vs. 
18 [3]; p < 0,001). No differences were observed in weight reduction, heart rate and 
systolic blood pressure (SBP). No patient developed hypotension (SBP < 90 mmHg). 
A greater proportion of patients in the treatment group was free of congestion at day 3: 
no edema (32% vs. 66%; p = 0,001), no rales (24% vs. 66%; p < 0,001), jugular 
venous pressure (JVP) ≤ 8 cm (90% vs. 100%; p = 0,02) and no orthopnea (76% vs. 
96%; p = 0,004). In addition, a significantly higher proportion of patients were switched 
to oral furosemide at day 3 (44% vs. 82%; p < 0,001) – Figure 1. Furosemide dose was 
not significantly different in patients who remained on i.v. administration. ACEi and BB 
doses did not differ between study groups. 
Worsening renal function (increase in pCr ≥ 0,3 mg/dL from day 1 to day 3) was 
more frequent in control group (20% vs. 4%; p = 0,038). 
Indirect markers of glomerular damage were not significantly different between groups, 
but the treatment group appeared to have less glomerular damage after 3 days of 
treatment i.e. greater albuminuria reduction (median [IQR], – 7,3 [45,8] vs. -10,1 [71,2]; 
p = 0,32), and lower albuminuria ratio (median [IQR], 0,9 [0,8] vs. 0,7 [0,7]; p = 0,19). 
Fractional excretion of sodium (FENa) and urea (FEUr) did not differ between groups, 
however urine sodium to potassium (UNa/K) ratio significantly increased at day 3 in the 
spironolactone group (median [IQR], 2,1 [3,1] vs. 4,0 [3,9]; p = 0,007).  
Serum potassium (K+) levels did not differ significantly between groups – Figure 
2. No patients developed hyperkalemia (serum potassium ≥ 5,5 mmol/L). More patients 
in the control group developed hypokalemia (serum potassium ≤ 3,5 mmol/L) but no 
significant differences were found (26% vs. 14%; p = 0,13). 
Plasma NTproBNP had a significant decrease in spironolactone group at day 3 
(median [IQR], 2488 [4579] vs. 1555 [1832]; p = 0,05) – Figure 3. 
No significant differences were observed in hsTnT (median [IQR], - 0,0005 
[0,01] vs. - 0,001 [0,01]; p = 0,57). 
Hospital length of stay did not differ between the two groups [median [IQR], 9 
[5] vs. 8 [5]; p = 0,8). 
 
Discussion 
Our study strongly suggests that the use of spironolactone in ADCHF patients is 
safe. Furthermore, spironolactone treatment was also associated with an earlier 
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resolution of symptoms and signs of congestion, as well as a more pronounced 
NTproBNP reduction.  
Baseline clinical characteristics were well balanced between the two groups. 
Although control participants were older than those in the treatment group, that 
difference did not significantly change the mortality risk prediction scores. The control 
group had also higher proportion of baseline beta-blockers prescription. However, 
during hospitalization the beta-blocker treatment did not differ between groups. 
The concern about hyperkalemia erroneously precludes the judicious 
prescription of MRAs in many clinical settings. Our study findings show that this 
therapy is safe in ADCHF as the use of spironolactone in this setting was not 
associated with renal dysfunction or hyperkalemia. The concomitant use of i.v. diuretics 
with kaliuretic properties could contributed to the absence of hyperkalemia19. In clinical 
trials enrolling chronic HF patients, MRAs were well tolerated when patients with pCr > 
2,5 mg/dL and serum potassium > 5 mmol/L were excluded2, 20. Still regarding the 
potassium levels, we observed a trend to hypokalemia in the control group compared 
to the treatment group. These result is concordant with a previous study where the risk 
of hypokalemia was significantly reduced among patients receiving MRAs3. Reducing 
the risk of hypokalemia is a significant issue due to the fact that a potassium level 
below 4,0 mmol/L has been associated with an increased risk of death from any cause 
among patients with systolic heart failure21.  
Moreover, worsening renal function occurred more frequently in control group. 
Previous studies suggest that high i.v. diuretic dose is associated with worsening renal 
function in the short term17, 18. The frequent congestion status of ADHF and the diuretic 
therapy activate the RAAS and SNS, which induce renal arteriolar vasoconstriction, 
endothelial dysfunction and increased tubular reabsorption of sodium and urea18. The 
spironolactone diuretic and renoprotective potential can contribute to these clinical 
important findings.  
We found that patients submitted to high dose spironolactone as add-on to 
standard AHF therapy had a faster resolution of congestive signs and an earlier switch 
to oral furosemide. The diuretic effect of spironolactone and possibly the attenuation of 
the pathological effects of mineralocorticoid receptor (MR) activation14, 15 could explain 
these findings. In a previous study including 21 AHF patients with insufficient response 
to loop diuretics, 16 patients (76%) were submitted to 100 mg spironolactone once a 
day for 7 days in addition to high-dose loop diuretic (10 mg oral bumetanide) in 
combination with the maximum tolerable dose of an ACEi. 
Spironolactone coadministration was highly effective in 13 of 16 patients (81%). 
Marked natriuresis and diuresis were achieved within the next week of treatment, and 
31 
 
HF symptoms decreased or disappeared16. Despite the earlier resolution of congestive 
signs found in the treatment group, no significant differences were observed in body 
weight change; this finding can be explained by the multiple patterns of congestion 
found i.e., many patients had left heart predominance with little weight change, and 
patients with right heart predominance presented with different levels of congestion. 
These differences (not discriminated in the study) may contribute for this apparent 
mismatch. 
Consistent with the faster resolution of congestive signs and with the 
preservation of the renal function discussed above, we documented a significant 
reduction in NTproBNP within the spironolactone group. This is a notable finding since 
natriuretic peptides have shown to correlate with changes in ventricular wall stress, are 
inversely related to the severity of left ventricular dysfunction, and are robust prognostic 
predictors in HF22-26. 
Despite no significant differences were found, patients in the treatment group 
had greater albuminuria reduction during the treatment period. Albuminuria is an 
important predictor of adverse cardiovascular events in various populations and MRAs 
have been shown to attenuate vascular hypertrophy and reduce albuminuria27, 28. The 
improvement of this surrogate endpoint gives additional insight on possible benefits of 
MRA in ADCHF. 
Mineralocorticoid receptor antagonists have been observed to stimulate 
natriuresis and improve diuretic responsiveness in patients with HF29. Although FENa 
did not differ between groups, urine sodium to potassium (UNa/K) ratio significantly 
increased at day 3 in the spironolactone group. Elevation of UNa/K ratio has been 
demonstrated to be a translatable biomarker of MRA effect30. These findings were 
reproducible in our study. Future research should be conducted to validate this 
promising neurohormonal biomarker in the ADHF setting.  
Several limitations in this study should be noted. Firstly, given that no 
randomization or concealed allocation was performed, we cannot exclude a selection 
bias, which can impact on our conclusions’ external validity. Secondly, the assistant 
physicians performed the congestive signs assessment, therefore, we cannot exclude 
an ascertainment bias. This can affect the internal validity of the comparison of 
subjective outcomes such as congestive signs or symptoms. Though, we had included 
an important internal control such as plasma NTproBNP that is unaffected by this bias 
and appear to be consistent with the earlier resolution of the congestive signs in the 
treatment group. Lastly, our study was underpowered to detect the differences of the 
expected low rate of adverse events between groups. Thus, our safety data should be 
viewed as exploratory. 
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Conclusion 
Our study shows that treating ADHF patients with spironolactone was safe. It 
was also associated with an earlier resolution of the congestive signs and with a more 
pronounced NTproBNP reduction. Despite its exploratory nature, our study highlights 
the need to improve the treatment of ADHF and points out the direction of future 
investigation towards MRAs. 
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Tables 
Table 1. Baseline Characteristics of the Study Population 
 Control Group Spironolactone 
Group 
 
p value 
Age (yrs) 78,8 ± 9,3 73,2 ± 11,7 0,01 
Male sex – no. (%) 17 (34) 22 (44) 0,31** 
    
Ejection Fraction 
(%) 
45,5 ± 10,7 41,4 ± 12,4 0,08 
Left Atrial Size 
(mm) 
47,4 ± 5,3 46,3 ± 7,1 0,40 
Charlson Index 
(pts) 
6, 1 ± 1,1 5,9 ± 0,9 0,38 
HgB (g/dL) 12,2 ± 1,8 12,7 ± 2,3 0,22 
Albumin (mg/dL) 3,7 ± 0,4 3,6 ± 0,4 0,63 
TSH (mUI/L) 2,8 ± 3,0 2,6 ± 2,8 0,79 
Etiology of Heart 
Failure – no. (%) 
   
Ischemic 24 (48) 26 (52) 0,69** 
Non-Ischemic 26 (52) 24 (48) 0,84** 
Basal NYHA class 
– no. (%) 
   
II 41 (82) 44 (88) 0,40** 
III 9 (18) 6 (12) 0,40** 
History of Atrial 
Fibrillation or 
Flutter - no. (%) 
 
34 (68) 
 
25 (50) 
 
0,07** 
Outpatients 
Medications – no. 
(%) 
   
Furosemide 37 (74) 35 (70) 0,65** 
ACE Inhibitors 24 (48) 18 (36) 0,22** 
Beta-Blockers 26 (52) 10 (20) 0,001** 
Outpatients Oral 
Dose (mg) 
   
Furosemide 69,2 ± 37,8 68 ± 30 0,89 
ACE Inhibitors 5 ± 3 4,3 ± 2,5 0,43 
Beta-Blockers 4,4 ± 2,7 4,5 ± 1,1 0,90 
ADHERE: in-
hospital mortality 
risk – no. (%) 
   
Low 44 (88) 40 (80) 0,27** 
Intermediate 2 2 (4) 3 (6) 0,65** 
Intermediate 3 4 (8) 7 (14) 0,34** 
EFFECT: Heart 
Failure Mortality 
Risk Prediction – 
no. (%) 
   
Low 4 (8) 8 (16) 0,22** 
Intermediate 27 (54) 25 (50) 0,69** 
High 18 (36) 17 (34) 0,83** 
BMI ≥ 30 (Kg/m2) – 
no. (%) 
14 (28) 19 (38) 0,29** 
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Diabetes Mellitus – 
no. (%) 
25 (50) 20 (40) 0,31** 
Glycated 
Hemoglobin (%) 
6,9 ± 0,7 7,1 ± 1,2 0,43 
Obstructive Sleep 
Apnea Syndrome – 
no. (%) 
5 (10) 13 (26) 0,32** 
Non-Invasive 
Ventilation – no. 
(%) 
7 (14) 10 (20) 0,42** 
AHF precipitant (n)    
Undertreatment 34 (68) 29 (58) 0,30** 
Dysrythmia 10 (20) 9 (18) 0,80** 
Non-compliance 6 (12) 8 (16) 0,56** 
NSAIDs 0 4 (8) 0,04** 
Continuous variables are presented as mean value ± standard deviation [SD], p value. 
Categorical variables are presented as absolute number (%), p value. **Chi-square 
test. 
HgB = hemoglobin; ACE = angiotensin-converting enzyme; BMI = Body Mass Index; 
NYHA = New York Heart Association; AHF = Acute Heart Failure; NSAID = Non-
Steroidal Anti-Inflammatory Drug. 
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Table 2. Study End-Points. 
 Control 
Group  
Spironolactone 
Group  
 
p Value 
Heart Rate (beats/min)    
Day 1 91,2 ± 24,7 96,1 ± 23,9 0,30 
Day 3 74,9 ± 12,4 77,9 ± 11,4 0,20 
SBP (mmHg)    
Day 1 140,5 ± 23,9 139 ± 27,9 0,80 
Day 3 122 ± 15,6 121,9 ± 16,8 0,97 
RR (cycles/min)    
Day 1 35 [5] 33,5 [6] 0,90* 
Day 3 20 [2] 18 [3] < 0,001* 
BMI (Kg/m2)    
Day 1 29,3 ± 5,7 29,5 ± 6,6 0,90 
Day 3 28,1 ± 5,4 27,7 ± 6,6 0,76 
Peripheral Edema – no. (%)    
Day 1 50 (100) 50 (100)  
Day 3 34 (68) 17 (34) 0,001** 
Rales – no. (%)    
Day 1 50 (100) 50 (100)  
Day 3 38 (76) 17 (34) <0,001** 
JVP ≥ 8 cm – no. (%)    
Day 1 32 (64) 28 (56) 0,41** 
Day 3 5 (10) 0 0,02** 
Orthopnea – no. (%)    
Day 1 50 (100) 50 (100) - 
Day 3 12 (24) 2 (4) 0,004** 
pCr (mg/dL) 
Day 1  
Day 3 
 
1,15 ± 0,27 
1,23 ± 0,43  
 
1,03 ± 0,29 
1,06 ± 0,33 
 
0,026 
0,035 
pCr Change(mg/dL)    
Day 3 – Day 1 0,075 ± 0,3 0,038 ± 0,17 0,47 
Increase in pCr ≥ 0,3 mg/dL 
from Day 1 to Day 3 – no. (%) 
 
10 (20) 
 
2 (4) 
 
0,038** 
pUrea 
Day 1 
Day 3 
 
59,32 ± 
22,27 
67,08 ± 
27,09 
 
51,10 ± 18,63 
57,54 ± 23,03 
 
0,048 
0,061 
pUrea Change (mg/dL)    
Day 3 – Day 1 7,7 ± 22,9 6,4 ± 17,9 0,75 
Albuminuria (mg/g) 
Day 1 
Day 3 
 
73,50 [196,5] 
60,16 [203] 
 
54,05 [203,7] 
27,9 [80,2] 
 
0,521* 
0,118* 
Albuminuria Change (mg/g)    
Day 3 – Day 1 - 7,3 [45,8] - 10,1 [71,2] 0,32* 
Albuminuria ratio 
Day 3 / Day 1 
 
0,9 [0,8] 
 
0,7 [0,7] 
 
0,19* 
FENa (%)    
Day 1 1,4 [2] 2,4 [3,5] 0,24* 
Day 3 1,2 [2] 1,6 [2,5] 0,27* 
FEUr (%)    
Day 1 38,9 ± 12,7 38,2 ± 11,1 0,47 
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Day 3 39,5 ± 13,2 37,1 ± 10,5 0,31 
UNa/K Ratio    
Day 1 2,7 [3,7] 3,6 [4,7] 0,18* 
Day 3 2,1 [3,1] 4,0 [3,9] 0,007* 
Serum Potassium (mmol/L)    
Day 1 4,1 ± 0,4 4,0 ± 0,6 0,33 
Day 3 3,9 ± 0,5 4,1 ± 0,5 0,15 
Hypokalemia (mmol/L) at Day 
3 – no. (%) 
 
13 (26) 
 
7 (14) 
 
0,13** 
Serum Sodium (mmol/L)    
Day 1 140 [7] 141 [4] 0,9* 
Day 3 141,2 ± 4,3 140,2 ± 3,5 0,2 
Serum Ionized Calcium 
(mmol/L) 
   
Day 1 1,2 [0,1] 1,2 [0,1] 0,6* 
Day 3 1,2 [0,1] 1,2 [0,1] 0,1* 
Serum Magnesium (mmol/L)    
Day 1 0,84 [0,1] 0,8 [0,1] 0,2* 
Day 3 0,87 [0,1] 0,85 [0,1] 0,6* 
ProBNP (pg/ml)    
Day 1 3102 [6408] 2701 [3541] 0,17* 
Day 3 2488 [4579] 1555 [1832] 0,05* 
TnT (ng/mL)    
Day 1 0,034 [0,035] 0,03 [0,032] 0,5* 
Day 3 0,032 [0,036] 0,029 [0,028] 0,3* 
TnT Reduction (ng/mL)    
Day 3 – Day 1 - 0,0005 
[0,01] 
- 0,001 [0,01] 0,57* 
CkMB (UI/L)    
Day 1 15,5 [9] 14 [9] 0,14* 
Day 3 14 [8] 12 [8] 0,13* 
CkMB Reduction (UI/mL)    
Day 3 – Day 1 - 1,7 ± 6,2 - 2,3 ± 4,3 0,63 
IV Furosemide Dose (mg)    
Day 1 80 [20] 80 [30] 0,86* 
Day 3 60 [20] 60 [30] 0,22* 
Oral Furosemide at Day 3 – 
no. (%) 
 
22 (44) 
 
41 (82) 
 
< 0,001** 
ACE Inhibitors Dose (mg)    
Day 1 2,5 [3,8] 2,5 [2,5] 0,75* 
Day 3 2,5 [3,8] 2,5 [3,8] 0,72* 
ACE Inhibitors – no. (%)    
Day 1 19 (38) 25 (50) 0,20** 
Day 3 30 (60) 31 (62) 0,80** 
Beta-Blockers Dose (mg)    
Day 1 2,5 [0] 2,5 [2,5] 0,95* 
Day 3 2,5 [2,5] 2,5 [1,25] 0,46* 
Beta-Blockers - no. (%)    
Day 1 21 (42) 16 (32) 0,30** 
Day 3 27 (54) 30 (60) 0,50** 
Length of Stay (days) 9 [5] 8 [5] 0,8* 
Continuous variables are presented as mean value ± standard deviation [SD], p value 
or median [inter-quartile range, IQR], p value. Categorical variables are presented as 
absolute number (%), p value. *Non-parametric test; **Chi-square test. 
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SBP = systolic blood pressure; RR = respiratory rate; JVP = jugular venous pressure; 
BMI = Body Mass Index; PaO2/FiO2 = partial pressure arterial oxygen/fraction inspired 
oxygen; pCr = plasma creatinine; FENa = spot urine fractional excretion of sodium; 
FEUr = spot urine fractional excretion of urea; UNa/K = urinary sodium to potassium 
ratio; proBNP = N-terminal pro brain natriuretic peptide; TnT = high-sensitivity troponin 
T; CkMB = creatine kinase-MB; ACE = angiotensin-converting enzyme. 
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Figures 
Graph 1. Changes in Congestive Signs and Patients Taking Oral Furosemide at Day 3 
(%) in the Control and Spironolactone Groups. 
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Graph 2. Changes in Serum Potassium (K+) from Day 1 to Day 3 in the Control and 
Spironolactone Groups.  
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Graph 3. Changes in Mean Plasma Levels of NT Pro-Brain Natriuretic Peptide 
(NTproBNP) from Day 1 to Day 3 in the Control and Spironolactone Groups. 
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Abstract 
Background/Objectives: Few data exist to help physicians how to use diuretics to 
provide the greatest symptomatic benefit with the least adverse effect and to select 
which subset of patients require a more aggressive diuretic strategy and monitorization. 
The aim of this study is to identify early predictors of diuretic response in a selected 
group of patients with acutely decompensated chronic heart failure (ADCHF). 
Methods: Observational, retrospective secondary analysis of a study including 100 
patients with ADCHF. 
Results: Mean ± standard deviation (SD) age was 76,0 ± 10,9 years. Sixty-one patients 
were female. Due to the persistence of congestive signs after three days of inpatient 
treatment, 16 (16%) patients maintained or increased i.v. furosemide dose (slow 
diuretic response, SDR) during the study period. The other 84 patients had greater 
congestion relief and decreased i.v. furosemide dose or switched furosemide to oral 
route (fast diuretic response, FDR). Admission day factors predicting SDR were: higher 
levels of pUr (mean ± SD, 69,6 ± 20,9 vs 52,5 ± 19,8, p = 0,002); higher levels of pUr / 
pCr ratio (mean ± SD, 58,3 ± 15,2 vs 49,6 ± 15,1, p = 0,036); higher levels of 
albuminuria (median [IQR], 131,5 [396,9] vs 47,1 [143,6], p = 0,011); higher levels of 
RDW (median [IQR], 16,0 [1,9] vs 15,1 [1,5], p = 0,039); lower levels of HgB (mean ± 
SD, 11,5 ± 1,8 vs 12,6 ± 2,1, p = 0,04); and higher levels of hsTnT (median [IQR], 0,05 
[0,05] vs 0,03 [0,03], p = 0,026). By multivariate analysis the strongest independent 
early predictors of SDR were: pUr (OR [95%CI], 1,04 [1,01 – 1,07], p = 0,006), and red-
cell distribution width (RDW) (OR [95%CI], 1,47 [1,07 – 2,02], p = 0,018). During the first 
three days of hospitalisation the strongest independent factor associated with SDR was 
NTproBNP increase or decrease by less than 30% from day 1 to day 3 (OR [95%CI], 
4,84 [1,14 – 20,55], p = 0,032). No use of spironolactone increases the risk of SDR 
(OR [95%CI], 5,98 [1,17 – 30,42], p = 0,031). 
Conclusions: High RDW and high levels of pUr at admission are strong predictors of 
slower diuretic response. No change or increase in NTproBNP in the first three days of 
treatment is associated with slower diuretic response. On the other hand, the use of 
high dose spironolactone is associated with faster diuretic response. 
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Introduction 
 Acutely decompensated chronic heart failure (ADCHF) is a common cause of 
hospitalization, in particular among patients over 65 years old1, 2. Most patients present 
with normal or high blood pressure and with fluid overload3. In this common clinical 
scenario, the relief of congestion is a critical goal and intravenous loop diuretics are 
used for that goal in approximately 90% of patients4. Monitorization of therapy 
response is mainly performed through assessment of congestive signs (rales, edema, 
jugular venous pressure, weight), symptoms (dyspnea, orthopnea, nocturnal 
paroxysmal dyspnea) and net fluid loss5. 
 Despite the wide clinical experience, few data exist to help physicians how to 
use diuretics to provide the greatest symptomatic benefit with the least adverse effect 
and to select the subset of patients who require a more aggressive diuretic strategy2, 6, 
7. In addition, high doses of loop diuretics may have deleterious effects, including 
activation of the renin-angiotensin-aldosterone system (RAAS) and sympathetic 
nervous system, electrolyte disturbances, and worsening of renal function4, 8. Given 
that the majority of therapeutic advances in heart failure have been centered on the 
concept of neurohormonal antagonism, it is not surprising that there has been a great 
interest regarding the influence of diuretics on outcomes in patients with heart failure9. 
 The aim of this study is to identify early predictors of slower diuretic response in 
a selected group of patients with ADCHF in order to help the tailoring of diuretic 
therapy in this common clinical scenario.  
 
Methods 
Study Design 
We analysed a database from a previous conducted prospective, interventional 
trial that we performed. In that study we enrolled a 100 consecutive patients who 
presented in a Portuguese tertiary hospital with ADCHF, between February 2012 and 
February 2013. They were assigned in a sequential 1:1 ratio to spironolactone plus 
standard ADCHF therapy or standard ADCHF therapy alone. Patients were eligible for 
enrollment if they presented with decompensation of chronic heart failure (HF) with 
symptoms leading to hospitalization. ADCHF was diagnosed on the basis of the 
presence of history of chronic HF and at least one symptom (dyspnea, orthopnea, or 
edema) and one sign (rales, peripheral edema, ascites, or pulmonary vascular 
congestion on chest radiography). Exclusion criteria were: chronic use of 
mineralocorticoid receptor antagonists (MRAs), cardiac surgery within 60 days of 
enrollment, cardiac mechanical support, cardiac resynchronization-therapy within the 
last 60 days, comorbid conditions with an expected survival of less than 6 months, 
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acute myocardial infarction at time of hospitalization, hemodynamically significant 
uncorrected primary cardiac valvular disease, patients requiring intravenous 
vasodilators or inotropic agents, supine systolic arterial blood pressure <90 mmHg, 
plasma creatinine (pCr) level >1,5 mg/dL, serum potassium level >5,0 mmol/L, 
hemoglobin (HgB) level <9 g/dL, and sepsis. 
During the study period 50 patients were non-randomly assigned to take oral 
spironolactone (minimum and maximum initial doses of 50 - 100 mg/d). 
Institutional review board or ethics committee approval was obtained. All 
patients provided written informed consent to participate in the study. 
 
Study assessments 
Patient`s clinical status including physical examination and was prospectively 
recorded by the same assistant physician at day 1 and day 3. 
Medications and respective dosages were prospectively recorded by the 
investigators according to the assistant physician prescriptions. 
An assessment of biomarkers, including pCr, electrolytes, N-terminal pro-brain 
natriuretic peptide (NTproBNP), high-sensitivity troponin T (hsTnT) and albuminuria 
was performed at a central core laboratory at admission day (day 1) and day 3. Clinical 
assessment and routine analyses were performed daily during hospital stay. All 
patients performed a transthoracic echocardiography within 72 hours upon admission. 
Ejection fraction was calculated according to biplane Simpson method. 
 
Variable definitions 
 We classified patients according to their response to diuretic therapy. Patients 
were considered to be fast diuretic responders (FDR) if they had a decrease in 
intravenous (i.v.) furosemide or a switch to oral furosemide in the first three days of in-
hospital treatment. On the other hand, we defined a slower diuretic response (SDR) if 
the assistant physician increased or maintained i.v. furosemide dosage after three days 
of in-hospital treatment.  
We compared these two different groups regarding the following covariates: 
comorbidities such as diabetes mellitus, chronic obstructive pulmonary disease 
(COPD), and sleep apnea; indirect signs of congestion including body mass index 
(BMI); heart failure etiology; echocardiographic parameters such as ejection fraction 
and left atrial size; furosemide ambulatory dose, proportion of outpatients on 
angiotensin converting enzyme inhibitors (ACEi) and beta-blockers (BB); i.v. 
furosemide at day 1; pCr, plasma urea (pUr), NTproBNP levels, hsTnT, sodium, 
potassium and albuminuria at day 1 and day 3; HgB, serum albumin, renin, aldosterone 
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and red cell distribution width (RDW) at day 1; proportion of inpatients on 
spironolactone, ACEi, and BB. 
 
Statistical Analysis 
 Comparison between groups (versus [vs]) was performed using parametric, 
non-parametric tests, or chi-square tests, as appropriate.  
Continuous variables are expressed as mean (standard deviation, SD) or 
median (inter-quartile range, IQR). Categorical variables are expressed in absolute 
numbers (no.) and proportions (%).  
Association between different variables was tested by univariate analysis. 
Variables with significant association were tested by multivariate analysis in a stepwise 
manner. Predictors of outcome were identified by logistic regression analyses. 
Significant association was defined by a p value < 0,05.  
Statistical analysis was performed using SPSS software (version 19, Chicago, 
IL, USA). 
 
Results 
Mean ± SD age was 76,0 ± 10,9 years. Sixty-one patients were female.  
All patients had congestive signs at admission. After three days of inpatient 
treatment, 16 (16%) patients maintained or increased i.v. furosemide dose (SDR). This 
group of patients had more indirect signs of fluid overload (rales: 87,5% vs 48,8%, p = 
0,004; peripheral edema: 81,3% vs 45,2%, p = 0,008; orthopnea: 37,5% vs 9,5%, p = 
0,008; JVP ≥ 8 cm: 18,8% vs 2,4%, p = 0,006). Body mass index also increased in 
SDR group (mean ± SD, 31,3 ± 5,4 vs 27,8 ± 6,2, p = 0,038). The other 84 patients had 
FDR, greater congestion relief and a decrease in i.v. furosemide dose or oral route 
furosemide switch (dose reduction – no. [%] = 21 [25]; oral route – no. [%] = 63 [75]) – 
table 1. 
We did not find any significant differences between both groups (SDR vs FDR) 
regarding baseline characteristics, comorbidities, and BMI - table 1. 
All patients received i.v. bolus furosemide. Combination therapy with thiazide 
diuretics was not used. Intravenous bolus furosemide dose (mg) on admission day did 
not differ between groups (mean ± SD, 72,5 ± 20,5 vs 76,4 ± 21,8). 
Univariate analysis of the variables potentially linked to SDR is shown in table 2. 
Admission day covariates predicting SDR were: higher levels of pUr (mean ± 
SD, 69,6 ± 20,9 vs 52,5 ± 19,8, p = 0,002); higher levels of pUr / pCr ratio (mean ± SD, 
58,3 ± 15,2 vs 49,6 ± 15,1, p = 0,036); higher levels of albuminuria (median [IQR], 
131,5 [396,9] vs 47,1 [143,6], p = 0,011) – figure 1.; higher levels of RDW (median 
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[IQR], 16,0 [1,9] vs 15,1 [1,5], p = 0,039); lower levels of HgB (mean ± SD, 11,5 ± 1,8 
vs 12,6 ± 2,1, p = 0,04); and higher levels of hsTnT (median [IQR], 0,05 [0,05] vs 0,03 
[0,03], p = 0,026). Higher levels of pCr at day 1 are also likely to predict SDR (mean ± 
SD, 1,21 ± 0,28 vs 1,06 ± 0,28, p = 0,06) and a trend to higher levels of renin on 
admission day was found in SDR patients (8,1 [14,3] vs 4,1 [6,7],  p = 0,098). 
During the first three days of hospitalisation the covariates associated with SDR 
were: higher levels of pCr at day 3 (mean ± SD, 1,40 ± 0,46 vs 1,1 ± 0,36, p = 0,004); 
increment in pCr ≥ 0,3 mg/dL from day 1 to day 3 (37,5% vs 7,1%, p = 0,001) – figure 
2.; higher levels of pUr at day 3 (mean ± SD, 79,7 ± 24,9 vs 59,0 ± 24,3, p = 0,002); 
higher levels of albuminuria at day 3 (median [IQR], 123,9 [358,4] vs 26,4 [85,2], p = 
0,001) – figure 1.; higher levels of NTproBNP at day 3 (median [IQR], 3013 [4116] vs 
1701 [2563], p = 0,009); NTproBNP maintenance or increment (37,5% vs 13,1%, p = 
0,017) – figure 3.; higher levels of hsTnT at day 3 (median [IQR], 0,06 [0,04] vs 0,03 
[0,03], p = 0,004). 
Patients treated with spironolactone had FDR (12,5% vs 57,1%, p = 0,001) – 
figure 4. Such differences were not found in patients taking ACEi and BB. 
Multivariate analysis results are shown in table 3. The strongest independent 
early predictors of SDR were: pUr (OR [95%CI], 1,04 [1,01 – 1,07], p = 0,006), and red-
cell distribution width (RDW) (OR [95%CI], 1,47 [1,07 – 2,02], p = 0,018). NTproBNP 
increase or decrease by less than 30% from day 1 to day 3 was the strongest 
independent factor associated with SDR (OR [95%CI], 4,84 [1,14 – 20,55], p = 0,032). 
Noteworthy, no use of spironolactone increases the risk of SDR (OR [95%CI], 5,98 [1,17 
– 30,42], p = 0,031). 
Time to oral furosemide (in days) was longer in patients with SDR (mean ± SD, 
5,9 ± 1,7 vs 3,6 ± 2,2, p < 0,0001) and hospital length of stay (in days) was also longer 
in SDR group (mean ± SD, 10,9 ± 3,2 vs 8,5 ± 3,3, p = 0,008). No deaths or complete 
treatment failure occurred. 
 
Discussion 
 Our study suggests that higher levels of pUr and RDW at admission can predict 
a subset of ADCHF patients with a slow diuretic response. Moreover, patients with little 
reduction or increase in NTProBNP levels during the first few days of hospitalisation 
needed to maintain high doses of i.v. diuretics. On the contrary, patients taking 
spironolactone had faster diuretic response. 
 Urea is freely filtered through the glomerulus and undergoes substantial tubular 
reabsorption9. This reabsorption of pUr is flow dependent so that more urea is 
reabsorbed at lower urine flow rates10. The neurohormonal response in HF involves the 
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nonosmotic secretion of arginine vasopressin (AVP), stimulation of the RAAS and 
sympathetic nervous system10, which cause decrease of renal blood flow by renal 
vasoconstriction, and increased proximal tubular reabsorption of sodium and water. 
These changes will result in increased urea reabsorption caused by slow tubular flow in 
the collecting duct and higher AVP plasma concentration11, 12. This neurohormonal 
activation is exacerbated by loop diuretics because they block sodium chloride 
absorption at the macula densa and consequently increase renin secretion by the 
juxtaglomerular apparatus 13. In HF patients with higher pUr, neurohormonal activation 
with high-dose loop diuretics can be greater than the withdrawal of neurohormonal 
activation resulting from decongestion, leading to a poorer survival9, 14. Components of 
the neurohormonal axis are not routinely measured in HF patients. Therefore, the rise 
in pUr may serve as an indirect marker of neurohormonal activation10. Higher plasma 
concentrations of plasma renin activity are associated with increased risk of death in 
HF, as occurred with the higher admission pUr values and changes in pUr values 
during hospitalization10.  Volume management strategies based on pUr concentration 
or other markers of renal neurohormonal activation is a potential field for clinical 
investigation. In this regard, the use of natriuretic doses of potassium-sparing diuretics 
may allow both the minimization of loop diuretic doses and the maintenance of 
euvolemia9. Furthermore, an elevated admission pUr / Cr ratio has been associated 
with an increased incidence of post-discharge WRF, independent of the discharge 
glomerular filtration rate (GFR)15. In our study, high pUr and pUr / pCr ratio at 
admission predicted SDR. High renin also seemed to predict SDR. These results at 
day 1 are independent of the use of i.v. diuretics. These findings can lead to an early 
identification of patients who should have tighter follow-up and individualized diuretic 
approach, particularly the use of high dose spironolactone which showed to increase 
diuretic response in this pool of patients without severe renal dysfunction.  
 Red blood cell distribution width (RDW) is a percentual measure of the 
variability in the size of circulating erythrocytes, recorded during a standard complete 
blood count16. Disorders related to ineffective erythropoiesis or increased destruction 
cause greater heterogeneity in size and a higher RDW17. High RDW may reﬂect 
nutritional deﬁciencies, bone marrow dysfunction, or systemic inﬂammation, 
representing an integrative measure of the pathological processes occurring in HF18. 
Higher RDW was shown to be a strong independent predictor of greater morbidity and 
mortality in patients with chronic HF17, 19, but the mechanism underlying the association 
between RDW and death in patients with HF is unclear18. Higher RDW level at 
discharge as also associated with a worse long-term outcome in patients hospitalized 
with acute heart failure (AHF), regardless of anemia status18. In our population higher 
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RDW predicted SDR, to the best of our knowledge this was the first report of this 
association. 
 Excessive activation of the RAAS causes glomerular hypertension and 
proteinuria20. A close correlation between increased excretion of urinary albumin and 
mortality in chronic HF has been reported21, 22. Our results suggests that increased 
albuminuria may also predict a subset of SDR in ADCHF patients. 
An elevation in cardiac troponin indicates the presence of myocyte injury or 
death23. Myocyte loss is recognized to be a prominent pathophysiological mechanism 
in the evolution of cardiac dysfunction24. The pathophysiological factors that that are 
thought to be responsible for ongoing myocyte injury include neurohormonal activation 
and abnormalities in inflammatory cytokines, oxidative and mechanical stress25. An 
association between higher mortality and positive troponin in patients with ADCHF has 
been demonstrated26, 27. In our study higher levels of hsTnT at admission also predict 
SDR, adding an additional marker for early identification of patients who will require 
early implementation of aggressive therapy and monitorization. 
Worsening renal function with persistence of congestive signs is associated with 
SDR. This observation is consistent with recent findings suggesting that the link 
between high-dose diuretics and poor outcomes may reflect the severity of the illness 
rather than an independent harmful effect of diuretics6. We also found an association 
between maintenance or increase in NTProBNP and SDR, suggesting that NTProBNP 
is a reliable biomarker for the evaluation of treatment efficacy and might help clinicians 
to reconsider treatment strategies in the first days of hospitalization. This is another 
potential role for this biomarker, since variations in NTproBNP levels during 
hospitalization are also associated with higher hospital readmission rates and 6-month 
mortality28. 
Our study has several limitations that need to be considered. First, it was a 
single-centre investigation of a small sample size. Second, the decision to withdraw 
diuretic therapy was based on subjective assessment of congestive signs and 
symptoms so we cannot rule out the inter-observer variability. However, in real-life 
patients, the decision to step down diuretic therapy is also based on subjective clinical 
evaluation. Finally, the external validity of our conclusions is limited to patients with 
mild renal failure HF patients since pCr level ≤ 1,5 mg/dl was an inclusion criteria. 
 
Conclusion 
 High RDW and high levels of pUr at admission are strong predictors of slower 
diuretic response. No change or increase in NTproBNP and worsening renal function in 
the first three days of treatment are associated with slower diuretic response. On the 
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other hand, the use of high dose spironolactone is associated with faster diuretic 
response. 
 Our findings warrant further investigation to establish the value of these 
predictors in guiding diuretic strategies in hospitalised ADCHF patients. 
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Tables 
Table 1. Baseline Characteristics and Differences in Congestive Signs at Day 1 and 
Day 3 
 Furosemide 
Maintenance or 
Increase (n=16) 
Furosemide 
Decrease or Oral 
Administration 
(n=84) 
p Value 
Age (yrs) 78,8 ± 6,9 75,5 ± 11,4 0,13 
Male Sex – no. (%) 5 (31,3) 34 (40,5) 0,49** 
Diabetes Mellitus – no. (%) 10 (62,5) 35 (41,7) 0,13** 
COPD – no. (%) 2 (12,5) 15 (17,9) 0,46** 
Dementia – no. (%) 3 (18,8) 9 (10,7) 0,40** 
Sleep Apnea – no. (%) 3 (42,9) 15 (40,5) 0,61** 
BMI (%) 29,7 ± 5,5 29,4 ± 6,3 0,83 
Charlson Index (pts) 6,38 ± 0,6 5,9 ± 1,1 0,29 
Ischemic Etiology for Heart 
Failure – no. (%) 
 
10 (62,5) 
 
40 (47,6) 
 
0,28** 
Furosemide Ambulatory 
Dose (mg) 
 
68,3 ± 30,1 
 
68,8 ± 33,6 
 
0,98 
Outpatients on ACEi – no. 
(%) 
8 (50) 34 (40,5) 0,48** 
Outpatients on Beta-
blockers – no. (%) 
 
7 (43,8) 
 
50 (59,5) 
 
0,24 
Left Atrial Size (mm) 48,6 ± 5,3 46,6 ± 6,4 0,42 
Ejection Fraction (%) 43,0 ± 11,2 43,6 ± 11,9 0,86 
Rales – no. (%) 
Day 1 
Day 3 
 
16 (100) 
14 (87,5) 
 
84 (100) 
41 (48,8) 
 
- 
0,004** 
Peripheral Edema – no. (%) 
Day 1 
Day 3 
 
16 (100) 
13 (81,3) 
 
84 (100) 
38 (45,2) 
 
- 
0,008** 
Orthopnea – no. (%) 
Day 1 
Day 3 
 
16 (100) 
6 (37,5) 
 
84 (100) 
8 (9,5) 
 
- 
0,003** 
JVP ≥ 8 cm – no. (%) 
Day 1 
Day 3 
 
12 (75) 
3 (18,8) 
 
48 (57,1) 
2 (2,4) 
 
0,18 
0,006** 
BMI (Kg/m2) 
Day 1 
Day 3 
 
29,7 ± 5,5 
31,3 ± 5,4 
 
29,4 ± 6,3 
27,8 ± 6,2 
 
0,83 
0,038 
Continuous variables are presented as mean value ± standard deviation [SD], p value. 
Categorical variables are presented as absolute number (%), p value. **Chi-square 
test. 
COPD = chronic obstructive pulmonary disease; BMI = Body Mass Index; ACEi = 
angiotensin-converting enzyme inhibitors; JVP = jugular venous pressure. 
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Table 2. Univariate Analysis for Furosemide Response Predictors, Furosemide 
Response Associations, Time to Oral Furosemide and Hospital Length of Stay 
 Furosemide 
Maintenance or 
Increase 
Furosemide 
Decrease or Oral 
Administration 
p Value 
IV Furosemide at Day 1 
(mg) 
72,5 ± 20,5 76,4 ± 21,8 0,51 
pCr (mg/dL) 
Day 1 
Day 3 
 
1,21 ± 0,28 
1,40 ± 0,46 
 
1,06 ± 0,28 
1,1 ± 0,36 
 
0,06 
0,004 
Increase in pCr ≥ 0,3 mg/dL 
from Day 1 to Day 3 – no. 
(%) 
 
6 (37,5) 
 
6 (7,1) 
 
0,001** 
pUrea (mg/dL) 
Day 1 
Day 3 
 
69,6 ± 20,9 
79,7 ± 24,9 
 
52,5 ± 19,8 
59,0 ± 24,3 
 
0,002 
0,002 
pUrea Change from Day 1 
to Day 3 
 
10,1 ± 30,0 
 
6,5 ± 19,4 
 
0,52 
pUrea to pCr ratio 
Day 1 
Day 3 
 
58,3 ± 15,2 
58,8 ± 12,4 
 
49,6 ± 15,1 
54,3 ± 16,7 
 
0,036 
0,32 
Albuminuria (mg/g) 
Day 1 
Day 3 
 
131,5 [396,9] 
123,9 [358,4] 
 
47,1 [143,6] 
26,4 [85,2] 
 
0,011* 
0,001* 
Albuminuria Change from 
Day 1 to Day 3 
 
-13,3 [67,8] 
 
-7,8 [56,1] 
 
0,84* 
Serum Potassium (mmol/L) 
Day 1 
Day 3 
 
3,9 ± 0,5 
3,8 ± 0,6 
 
4,1 ± 0,5 
4,1 ± 0,5 
 
0,28 
0,08 
Serum Sodium (mmol/L) 
Day 1 
Day 3 
 
140,6 ± 4,1 
140,8 ± 4,7 
 
140,5 ± 4,5 
140,7 ± 3,8 
 
0,98 
0,89 
HgB at Day 1 (g/dL) 11,5 ± 1,8 12,6 ± 2,1 0,04 
RDW at Day 1 16,0 [1,9] 15,1 [1,5] 0,039* 
Albumin at Day 1 (mg/dL) 3,8 ± 0,4 3,6 ± 0,4 0,08 
NTproBNP (pg/mL) 
Day 1 
Day 3 
 
3390 [4511] 
3013 [4116] 
 
2698 [4577] 
1701 [2563] 
 
0,26 
0,009* 
NTproBNP Decrease by 
Less than 30% or Increase 
from Day 1 to Day 3 – no. 
(%) 
 
6 (37,5) 
 
11 (13,1) 
 
0,017** 
hsTnT (ng/mL) 
Day 1 
Day 3 
 
0,05 [0,05] 
0,06 [0,04] 
 
0,03 [0,03] 
0,03 [0,03] 
 
0,026* 
0,004* 
hsTnT Change from Day 1 
to Day 3 
 
-0,0005 [0,01] 
 
-0,001 [0,01] 
 
0,51* 
Aldosterone at Day 1 
(ng/dL) 
34 [98,3] 35,5 [75,7] 0,84* 
Renin at Day 1 (pg/mL) 8,1 [14,3] 4,1 [6,7] 0,098* 
Inpatients on 
Spironolactone – no. (%) 
 
2 (12,5) 
 
48 (57,1) 
 
0,001** 
Inpatients on ACEi – no (%) 7 (43,8) 37 (44) 0,98** 
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Inpatients on Beta-Blockers 
– no (%) 
 
7 (43,8) 
 
30 (35,7) 
 
0,54** 
Time to Oral Furosemide 
(days) 
 
5,9 ± 1,7 
 
3,6 ± 2,2 
 
<0,0001 
Hospital Length of Stay 
(days) 
10,9 ± 3,2 8,5 ± 3,3 0,008 
Continuous variables are presented as mean value ± standard deviation [SD], p value 
or median [inter-quartile range, IQR], p value. Categorical variables are presented as 
absolute number (%), p value. *Non-parametric test; **Chi-square test. 
pCr = plasma creatinine; pUrea = plasma urea; HgB = hemoglobin; RDW = red cell 
distribution width; NTProBNP = N-terminal pro-brain natriuretic peptide; hsTnT = high-
sensitivity troponin T; ACEi = angiotensin-converting enzyme inhibitors. 
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Table 3. Multivariate Analysis: Odds Ratios (OR) and 95% Confidence Intervals (95%CI) 
for Predictors and Factors Associated with Slow Diuretic Response. 
 Furosemide Maintenance or 
Increase, OR (95%CI) 
 
p Value 
RDW at Day 1 1,47 (1,07 – 2,02) 0,018 
pUrea at Day 1 1,04 (1,01 – 1,07) 0,006 
No Spironolactone Use 5,98 (1,17 – 30,42) 0,031 
NTProBNP Increase or Decrease 
by Less than 30% from Day 1 to 
Day 3 
 
4,84 (1,14 – 20,55) 
 
0,032 
Increase in pCr ≥ 0,3 mg/dL from 
Day 1 to Day 3 
 
4,07 (0,85 – 19,45) 
 
0,079 
pUrea at Day 3 1,02 (1,00 – 1,05) 0,087 
RDW = red cell distribution width; pUrea = plasma urea; NTproBNP = N-terminal pro-
brain natriuretic peptide; pCr = plasma creatinine; pUrea = plasma urea. 
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Figures 
Figure 1. Comparison of Albuminuria (mg/g) in Slow versus Fast Diuretic Responders 
at Day 1 and Day 3 of Hospitalization. 
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Figure 2. Proportion (%) of Patients with Worsening Renal Function From Day 1 to Day 
3. Comparison Between Slow and Fast Diuretic Responders. 
 
Legend: SDR, Slow Diuretic Responders; FDR, Fast Diuretic Responders 
 
  
p = 0,001 
0
5
10
15
20
25
30
35
40
SDR 
FDR 
P
ro
p
o
rt
io
n
 o
f 
P
a
ti
e
n
ts
 W
ith
 I
n
c
re
a
s
e
 i
n
 p
C
r 
≥
 0
,3
 m
g
/d
L
 (
%
) 
59 
 
Figure 3. Comparison of N-Terminal Pro-Brain Natriuretic Peptide (NTproBNP) in Slow 
versus Fast Diuretic Responders at Day 1 and Day 3 of Hospitalization.  
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Figure 4. Proportion (%) of Patients Using Spironolactone (dose range: 50 -100 
mg/day) in the First Three Days of Hospitalization. Comparison Between Slow and Fast 
Diuretic Responders. 
 
 Legend: SDR, Slow Diuretic Responders; FDR, Fast Diuretic Responders 
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Abstract 
Background/Objectives: Albuminuria is a robust, validated cardiovascular risk factor. It 
is a simple and widely available test that was shown to be a powerful and independent 
predictor of prognosis in chronic heart failure. Mineralocorticoid receptor antagonists 
may reduce the acute and chronic harmful effects of mineralocorticoid receptor 
activation on the kidney. The objectives of the trial were to compare the effect of 
spironolactone versus standard acutely decompensated heart failure (ADHF) therapy 
on albuminuria and to investigate the role of albuminuria as a prognostic marker in 
patients with ADHF. 
Methods: Secondary analysis of a prospective, interventional study including 100 
patients with ADHF. Fifty patients were non-randomly assigned to spironolactone 100 
mg/day plus standard ADHF therapy (intervention group) or standard ADHF therapy 
alone (control group). 
Results: Patients in control group were older, had higher creatinine and urea levels, 
and had higher proportion of microalbuminuria (all, p < 0,05). Paired comparison of 
baseline and day 3 log albuminuria within each group, showed a more pronounced 
decrease in the intervention group (1,79 ± 0,75 to 1,59 ± 0,67, p = 0,003 vs. 1,89 ± 
0,70 to 1,79 ± 0,74, p = 0,096). In addition, the proportion of patients with 
normoalbuminuria increased from baseline to day 3 in spironolactone group (20 (40%) 
to 27 (54%), p < 001), accordingly the number of patients in the micro and 
macroalbuminuria groups was reduced. Day 1 albuminuria was positively correlated 
with day 1 N-terminal pro-brain natriuretic peptide (0,260 [0,105 to 0,758], p = 0,009).  
Conclusions: High-dose spironolactone added to standard ADHF therapy is likely to 
induce a more pronounced albuminuria decrease and a significant reduction in the 
proportion of micro and macroalbuminuria. 
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Introduction 
Albuminuria is a robust, validated cardiovascular (CV) risk factor. It is 
independently associated with major adverse events such as stroke, myocardial 
infarction (MI) and CV death1. 
Screening for increased albuminuria is recommended for risk stratification of patients 
with diabetes and hypertension in order to adequate the treatment aggressiveness2,3.  
Albuminuria determination is a simple and widely available test that was shown 
to be important for the risk stratiﬁcation of patients with heart failure (HF), and a 
powerful and independent predictor of prognosis in HF4. In these patients, increased 
albuminuria could be a consequence of the increased neurohormonal activation, 
endothelial injury, systemic inflammation, and renal dysfunction5,6. These mechanisms 
are also involved in the pathophysiology of acute decompensated heart failure (ADHF) 
4,7, 8 and have a multitude of effects in the kidney, including arteriolar vasoconstriction 
and increased tubular reabsorption of sodium and urea9,10. However, the prognostic 
value of albuminuria is not yet established in this clinical setting. 
Mineralocorticoid receptor antagonists (MRAs) have been shown to attenuate 
ventricular and vascular hypertrophy, potassium and magnesium loss, 
glomerulosclerosis, renal interstitial fibrosis and proteinuria in patients with chronic 
kidney disease (CKD)11,12. Thus, MRAs may reduce the acute and chronic harmful 
effects of mineralocorticoid receptor activation on the kidney, effectively augment 
diuresis in diuretic-resistant patients, and attenuate the development of the vasomotor 
nephropathy in ADHF patients13.   
Our aims were to compare the effect of spironolactone versus standard acutely 
decompensated heart failure (ADHF) therapy on albuminuria and to investigate the role 
of albuminuria as a prognostic marker in patients with ADHF. 
 
Methods 
Study Design 
We analysed data from a previous prospective, interventional, clinical trial that 
we performed. In that study we enrolled 100 consecutive patients who presented in a 
Portuguese tertiary hospital with ADCHF, between February 2012 and February 2013. 
Patients were eligible for enrollment if they presented with decompensation of chronic 
HF with symptoms leading to hospitalization. ADCHF was diagnosed on the basis of 
the presence of history of chronic HF and at least one symptom (dyspnea, orthopnea, 
or edema) and one sign (rales, peripheral edema, ascites, or pulmonary vascular 
congestion on chest radiography). Patients were non-randomly assigned in a 
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sequential 1:1 ratio to spironolactone plus standard ADCHF therapy or standard 
ADCHF therapy alone, 50 patients within each arm (i.e. patients were alternatively 
assigned to spironolactone arm or standard ADCHF therapy arm in a sequential 
manner - the first patient to one arm and the next to the other arm. This sequence was 
repeated until we reach 100 patients, 50 patients within spironolactone group and 50 
patients within control group). Patients were blinded to the allocation, and the clinicians 
were not blinded to the allocation. The recommended spironolactone dose was 100 
mg/day, however the assistant physician could decrease the spironolactone dose to 50 
mg/day after 48h upon admission. After 72h the study was open label. Furosemide 
dose and route of administration was adjusted clinically according to the hydration 
status of the patients – Figure 1. 
Exclusion criteria were: chronic use of mineralocorticoid receptor antagonists 
(MRAs), cardiac surgery within 60 days of enrollment, cardiac mechanical support, 
cardiac resynchronization-therapy within the last 60 days, comorbid conditions with an 
expected survival of less than 6 months, acute MI at time of hospitalization, 
hemodynamically significant uncorrected primary cardiac valvular disease, patients 
requiring intravenous vasodilators or inotropic agents, supine systolic arterial blood 
pressure <90 mmHg, plasma creatinine (pCr) level >1,5 mg/dL, serum potassium level 
>5,0 mmol/L, hemoglobin (HgB) level <9 g/dL, and sepsis. 
Institutional review board or ethics committee approval was obtained. All 
patients provided written informed consent to participate in the study. 
Clinical assessment of participants 
Patient`s clinical status including physical examination and was prospectively 
recorded by the same assistant physician at day 1 and day 3. Medications and 
respective dosages were prospectively recorded by the investigators according to the 
assistant physician prescriptions. 
Blood and spot urine samples were collected in the first 24 hours (h) after 
admission (day 1) of the patient to the hospital, and the day 3 samples were collected 
between 72 and 96 h of hospitalization. Samples were analysed at a central core 
laboratory, and included pCr, plasma urea (pUr), electrolytes, N-terminal pro-brain 
natriuretic peptide (NTproBNP), high-sensitivity troponin T (hsTnT) and albuminuria. 
Clinical assessment and routine analyses were performed daily during hospital stay. 
Estimated glomerular filtration rate (eGFR) was determined using the Chronic Kidney 
Disease Epidemiology Collaboration (CKD-EPI) equation14. All patients performed a 
transthoracic echocardiography within 72 hours upon admission. Left ventricular 
ejection fraction (LVEF) was calculated according to biplane Simpson method. 
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Albuminuria and urine creatinine were measured using the COBAS INTEGRA 
Tina-quant Albumin Gen.2 urine application (Roche Diagnostics) and expressed as 
mg/g of Cr.  
We categorized albuminuria using standard cut-off points: normoalbuminuria 
(<30 mg/gCr), microalbuminuria (30-299 mg/gCr), and macroalbuminuria 
(≥300mg/gCr). 
Variable definitions 
  We studied albuminuria regarding the following covariates: comorbidities such 
as diabetes mellitus (DM), chronic obstructive pulmonary disease (COPD), and sleep 
apnea; body mass index (BMI); heart rate (HR); systolic blood pressure (SBP); atrial 
fibrillation (AFib); HF etiology; echocardiographic parameters such as EF; furosemide 
dose, proportion of patients on angiotensin converting enzyme inhibitors (ACEi), beta-
blockers (BB), and spironolactone; pCr, pUr, NTproBNP, hsTnT, sodium, potassium; 
HgB and serum albumin. 
Statistical Analysis 
Normally distributed continuous variables are expressed as mean ± standard 
deviation (SD), and skewed distributions are presented as median [inter-quartile range, 
IQR].  
Because of the positively skewed distributions of BMI, HR, SBP, pCr, eGFR, 
NTproBNP, hsTnT, and albuminuria, these variables were log transformed for analysis. 
Categorical variables are expressed in absolute numbers (no.) and proportions 
(%). 
Comparison between groups was performed using parametric, non-parametric 
tests, or chi-square tests, as appropriate. A p value < 0,05 was considered statistically 
significant.  
The relationships between baseline characteristics, day 3 and changes (Δ) in 
albuminuria during the first 3 days and baseline, day 3 or Δ in other variables were 
tested by univariate analysis linear regression. Factors with a probability value of ≤0.10 
by single variable linear regression analyses were included in a multivariable linear 
regression analyses together with age and sex. In other words, simple linear regression 
analyses were performed to examine the relationship between baseline characteristics, 
day 3 and Δ in other variables and albuminuria. Thereafter, a multivariable linear 
regression analysis was performed, which included age, sex, and the factors with a 
probability value of ≤0.10 in the bivariate analyses. Simple linear regression values are 
presented as non-adjusted coefficient (NAC) plus 95% confidence interval (95%CI). 
Multiple regression values are presented as adjusted coefficient (AC) plus (95%CI). 
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Statistical analysis was performed using SPSS software (version 19, Chicago, 
IL, USA). 
 
Results 
Baseline Patients Characteristics in Treatment and Control Groups 
Patients in control group were older (78,8 ± 9,3 versus [vs.] 73,2 ± 11,7 years, p 
= 0,01), had higher creatinine and urea levels (1,15 ± 0,27 vs. 1,03 ± 0,30, p = 0,026 
and 59,32 ± 22,27 vs. 51,10 ± 18,63, p = 0,048), and had higher proportion of 
microalbuminuria (58% vs. 38%, p = 0,045). No differences between groups were 
found regarding sex, DM, COPD, dementia, sleep apnea, NIV, IHD, AFib, LVEF, BMI, 
HR, SBP, potassium, sodium, HgB, albumin, NTproBNP, hsTnT, albuminuria, 
furosemide dose and in the proportion of patients on ACEi and BB – Table 1. 
Spironolactone Influence on Albuminuria Dynamic Changes 
Change in albuminuria levels from baseline to day 3 was not significantly 
different between groups, despite the reduction was more pronounced in 
spironolactone group (-0,09 ± 0,40 vs. -0,20 ± 0,44, p = 0,226) – Table 2. However, 
paired comparison of baseline and day 3 log albuminuria within each group, showed a 
more pronounced decrease in the intervention group (1,79 ± 0,75 to 1,59 ± 0,67, p = 
0,003 - within spironolactone group - and  1,89 ± 0,70 to 1,79 ± 0,74, p = 0,096 - within 
control group) – Figure 2. In addition, the proportion of patients with normoalbuminuria 
increased from baseline to day 3 in spironolactone group (20 (40%) to 27 (54%), p < 
001), accordingly the number of patients in the micro and macroalbuminuria groups 
was reduced (19 (38%) to 16 (32%), p = 0,014 and 11 (22%) to 7 (14), p < 0,001, 
respectively) – Figure 3. 
Albuminuria Correlations  
 By bivariate analysis, day 1 albuminuria was positively correlated with day 1 
NTproBNP (0,260 [0,105 to 0,758], p = 0,009). Day 3 albuminuria was positively 
correlated with day 3 BMI (0,254 [0,025 to 0,047], p = 0,011), SBP (0,447 [0,006 to 
0,027], p < 0,001), log hsTnT (0,220 [0,037 to 0,849], p = 0,028), and log pCr (0,248 
[0,266 to 2,185), p = 0,013), and negatively correlated with log eGFR (-0,251 [-1,915 to 
-0,246], p = 0,012). Albuminuria decrease was negatively correlated with beta-blocker 
use during hospitalization (-0,243 [-0,355 to – 0,036], p = 0,015). By multivariate 
analysis, day 1 albuminuria correlated with NTproBNP (0,298 [0,167 to 0,830], p = 
0,004), and day 3 albuminuria correlated with SBP (0,394 [0,009 to 0,025], p < 0,001) 
and log hsTnT (0,198 [0,043 to 0,759], p = 0,028) – Table 3. 
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Discussion 
 Our study showed a more pronounced albuminuria decrease and a significant 
reduction in the proportion of micro and macroalbuminuria in ADHF patients submitted 
to spironolactone treatment.  
 Increased albuminuria in patients with HF was found to be associated with 
increased risk of adverse clinical outcomes, including death4,15. Most patients in the 
Studies of Left Ventricular Dysfunction (SOLVD) had a urine dipstick test for protein at 
baseline16. Of 5487 (81% of total) tested, 177 (3%) had proteinuria. This subset of 
patients was more symptomatic, had higher blood pressure, higher prevalence of DM, 
and also greater left ventricular systolic dysfunction. Urinary albumin to creatinine ratio 
(UACR) was measured at baseline and during follow-up in the Candesartan in Heart 
failure: Assessment of Reduction in Mortality and morbidity (CHARM) Programme4. Of 
2310 patients, 1349 (58%) had a normal UACR, 704 (30%) had microalbuminuria, and 
257 (11%) had macroalbuminuria. Patients with an increased UACR were older, had 
more cardiovascular comorbidity, worse renal function, and a higher prevalence of DM 
than did those with normoalbuminuria. Elevated UACR was associated with increased 
risk of the composite outcome and death even after adjustment for other prognostic 
variables including renal function, DM, and HgBA1c. Interestingly, albuminuria per se 
has been associated with subsequent heart failure, even in individuals with few 
cardiovascular risk factors and UACR within the normal range17. 
Despite the strong body of evidence in chronic HF, few studies approach 
albuminuria in the acute HF setting. In a recently published study8, albuminuria was 
assessed at day 1 and 7 of hospitalization in 115 patients presenting with acute HF. 
Nearly 70% of patients had elevated UACR at admission. UACR decreased 
significantly after 7 days of treatment (from 83 to 22 mg/gCr, p <0,0001). The decrease 
was correlated with serum NTproBNP and bilirubin, but not with changes in renal 
function. Despite the evidence that effective HF treatment may reduce albuminuria 
during the acute episode, our study points towards an additional and interesting 
potential effect of MRAs in this setting. Neurohormonal activation causes 
vasoconstriction of both the afferent and efferent renal arterioles, and stimulates 
mesangial contraction in glomeruli, thus diminishing the glomerular filtration surface18. 
Excessive activation of the renin–angiotensin–aldosterone system (RAAS) causes 
glomerular hypertension and proteinuria, whereas its inhibition reduces proteinuria19,20. 
Excessive activation of the sympathetic nervous system also causes proteinuria21,22. 
Therefore, inhibition of neurohormonal activation is determinant to improve outcomes in 
patients with HF23-28. In our study, the increased albuminuria at admission might also 
reflect an excessive neurohormonal activation. This hypothesis is reinforced by the 
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greater decrease in albuminuria observed in patients submitted to spironolactone 
treatment. The MRAs have shown to reduce proteinuria in CKD patients already on 
ACEis and ARBs, however with an increased risk for hyperkalemia29, and a reduction 
of albuminuria was also observed with MRAs in the setting of chronic heart failure30. 
However, to the best of our knowledge our results are the first to demonstrate a greater 
reduction in albuminuria in ADHF patients submitted to spironolactone treatment. The 
rationale for this effect may rely on effective neurohormonal blockade, particularly on 
the activated the RAAS9, suggesting a potential renal protective effect of this treatment. 
Studies in animals have shown that increasing renal venous pressure leads to a 
reduction in glomerular filtration, which was probably mediated by a decreased renal 
perfusion31. Increased renal vein pressure in heart failure patients showed a marked 
reduction in renal blood flow as well as water and salt excretion32,33. Acute HF was 
correlated with higher albuminuria in patients with acute myocardial infarction34. Thus 
one can hypothesize that elevation of albuminuria can be a surrogate marker of severe 
volume overload. This hypothesis is reinforced by the positive correlation of 
albuminuria with NTproBNP at admission. Increased albuminuria probably has a 
hemodynamic basis in HF, particularly when renal venous congestion is associated 
with reduced renal blood flow, since urinary albumin excretion was inversely related to 
renal blood flow in patients with heart failure35,36. In addition, renal venous congestion 
caused proteinuria in dogs37. These findings support albuminuria as a surrogate marker 
of volume overload. High-dose spironolactone has shown to potentiate NTproBNP 
reduction and probably greater congestion relief in ADHF patients38, these findings 
provide additional clues to explain the observed reduction of albuminuria in patients 
submitted to spironolactone treatment – these patients may have greater congestion 
relief in addition to the effective neurohormonal blockade.  
Our study has several limitations that need to be considered. First, it was a 
single-centre investigation of a small sample size. Second, we used a single spot urine 
sample to determine albuminuria, which can be insufficient, as it might fluctuate. 
Finally, the external validity of our conclusions is limited to normo-hypertensive and 
fluid overloaded HF patients with mild renal failure, since all these factors were 
considered inclusion criteria. On the other hand, our conclusions can be reproducible in 
this set of patients widely common in clinical practice. 
 
Conclusions 
High-dose spironolactone added to standard ADHF therapy is likely to induce a 
more pronounced albuminuria decrease and a significant reduction in the proportion of 
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micro and macroalbuminuria. Further studies are required to explore the role of 
albuminuria as a prognostic marker in ADHF. 
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Tables 
Table 1. Baseline Population Characteristics, Laboratory Results and Medications in 
Treatment and Control Groups 
 Control Group 
(n = 50) 
Spironolactone 
Group 
(n = 50) 
p Value 
Age (yrs) 78,8 ± 9,3 73,2 ± 11,7 0,010 
Male Sex – % 34 44 0,31** 
Diabetes Mellitus - % 
Glycated HgB (%) 
50 
6,9 ± 0,7 
40 
7,1 ± 1,2 
0,31** 
0,43 
COPD - % 10 26 0,32** 
Dementia - % 16 8 0,22** 
Sleep Apnea - % 10 26 0,32** 
Non-Invasive Ventilation - % 14 20 0,42** 
Ischemic Heart Disease -% 48 52 0,69** 
Atrial Fibrillation - % 68 50 0,07** 
LV Ejection Fraction (%) 45,5 ± 10,7 41,4 ± 12,4 0,08 
LV Ejection Fraction ≥ 40% - % 70 64 0,52** 
Body Mass Index (Kg/m2) 29,3 ± 5,7 29,5 ± 6,6 0,90 
Heart Rate (bpm) 91,2 ± 24,7 96,1 ± 23,9 0,30 
SBP (mmHg) 140,5 ± 23,9 139 ± 27,9 0,80 
Plasma Creatinine (mg/dL) 1,15 ± 0,27 1,03 ± 0,30 0,026 
eGFR (mL/min/1,73 m2) 54,48 ± 16,45 68,28 ± 23,55 0,001 
Plasma Urea (mg/dL) 59,32 ± 22,27 51,10 ± 18,63 0,048 
Serum Potassium (mmol/L) 4,1 ± 0,4 4,0 ± 0,6 0,33 
Serum Sodium (mmol/L) 140,52 ± 5,04 140,56 ± 3,65 0,964 
Hemoglobin (g/dL) 12,2 ± 1,8 12,7 ± 2,3 0,22 
Albumin (mg/dL) 3,7 ± 0,4 3,6 ± 0,4 0,63 
NTproBNP (pg/mL) 3102 [1797 – 8204] 2701 [1463 – 5004] 0,167* 
hsTnT (ng/mL) 0,034 [0,023 – 0,059] 0,030 [0,018 – 0,049] 0,490* 
Albuminuria (mg/g) 73,50 [28,83 – 225,45] 54,05 [17,43 – 
221,10] 
0,521* 
Normoalbuminuria - % 26 40 0,137** 
Microalbuminuria - % 58 38 0,045** 
Macrolbuminuria - % 16 22 0,444** 
IV Furosemide Dose (mg/d) 75,60 ± 20,72 76,00 ± 25,50 0,927 
ACEi – no. (%) 19 (38) 25 (50) 0,201** 
Ramipril Eq. Dose (mg/d) 3,16 ± 2,21 3,15 ± 1,94 0,990 
Beta-Blocker - % 21 (42) 16 (32) 0,302** 
Bisoprolol Eq. Dose (mg/d) 2,98 ± 1,01 3,05 ± 1,20 0,847 
Spironolactone Dose (mg/d) - 94,5 ± 23,3 - 
Continuous variables are presented as mean value ± standard deviation [SD], p value or 
median [inter-quartile range, IQR], p value. Categorical variables are presented as absolute 
number (%), p value.  
*Non-parametric paired sample test; ** Chi-square test. 
Legend: COPD = chronic obstructive pulmonary disease; LV = left ventricular; eGFR = estimated 
glomerular filtration rate; NTproBNP = N-terminal pro brain natriuretic peptide; hsTnT = high 
sensitivity troponin T; IV = intra-venous; ACEi = angiotensin converting enzyme inhibitors. 
74 
 
Normoalbuminuria < 30 mg/gCr; Microalbuminuria 30 – 299 mg/gCr; Macroalbuminuria ≥ 300 
mg/gCr.  
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Table 2. Change (Δ) in Albuminuria Between the Study Groups 
 Control Group Spironolactone 
Group 
p Value 
Log Albuminuria 
Baseline 
Day 3 
Δ (day 3 – 
Baseline) 
 
1,89 ± 0,70 
1,79 ± 0,74 
-0,09 ± 0,40 
 
1,79 ± 0,75 
1,59 ± 0,67 
-0,20 ± 0,44 
 
0,499 
0,159 
0,226 
Legend: Comparison between groups was performed using independent samples t 
test. 
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Table 3. Crude and Adjusted β Coefficients (95%CI) for the Change (Δ) in Log 
Albuminuria as Prognostic indicator in Acutely Decompensated Heart Failure 
 Nonadjusted 
Coefficient 
for Log 
Albuminuria 
95%CI p Value Adjusted 
Coefficient for 
Log 
Albuminuria 
95%CI p 
Value 
Age 0,192 -0,001 to 
0,017 
0,056    
Male Sex -0,102 -0,257 to 
0,076 
0,313    
DM 0,109 -0,077 to 
0,258 
0,278    
HgBA1c -0,038 -0,138 to 
0,108 
0,805    
LVEF 0,084 -0,002 to 
0,006 
0,408    
Ischemic HF 0,128 -0,057 to 
0,215 
0,206    
Beta Blocker -0,162 -0,310 to 
0,031 
0,108    
ACEi -0,099 -0,250 to 
0,084 
0,329    
Spironolactone -0,122 -0,265 to 
0,058 
0,226    
BMI       
Baseline 0,167 -0,003 to 
0,036 
0,099    
Day 3 0,254 0,025 to 
0,047 
0,011    
Δ BMI 0,167 -0,008 to 
0,089 
0,099    
HR       
Baseline -0,58 -0,006 to 
0,00 
0,565    
Day 3 -0,075 -0,017 to 
0,006 
0,457    
Δ HR 0,040 -0,007 to 
0,006 
0,696    
SBP       
Baseline 0,176 -0,001 to 
0,025 
0,080    
Day 3 0,447 0,006 to 
0,027 
<0,001 0,394 0,009 to 
0,025 
<0,00
1 
Δ SBP 0,057 -0,007 to 
0,025 
0,576    
Log 
NTproBNP 
      
Baseline 0,260 0,105 to 
0,758 
0,009 0,298 0,167 to 
0,830 
0,004 
Day 3 0,160 -0,058 to 
0,509 
0,114    
Δ Log 
NTproBNP 
0,060 -0,215 to 
0,408 
0,551    
Log hsTnT       
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Baseline 0,131 -0,125 to 
0,626 
0,193    
Day 3 0,220 0,037 to 
0,849 
0,028 0,198 0,043 to 
0,759 
0,028 
Δ Log hsTnT 0,099 -0,265 to 
0,791 
0,325    
Log eGFR       
Baseline -0,098 -1,486 to 
0,507 
0,332    
Day 3 -0,251 -1,915 to -
0,246 
0,012    
Δ Log eGFR -0,025 -0,915 to 
0,706 
0,802    
Log pCr       
Baseline 0,149 -0,278 to 
2,125 
0,140    
Day 3 0,248 0,266 to 
2,185 
0,013    
Δ Log pCr -0,009 -1,025 to 
0,936 
0,926    
pUrea       
Day 1 0,134 -0,001 to 
0,007 
0,184    
Day 3 0,132 -0,003 to 
0,005 
0,190    
Δ pUrea -0,097 -0,007 to 
0,004 
0,338    
Albumin at 
Day 1 
-0,153 -0,636 to 
0,075 
0,129    
Hemoglobin at 
Day 1 
0,114 -0,029 to 
0,108 
0,258    
Day 1 values are compared with day 1 Albuminuria and hsTnT; day 3 values are compared with 
day 3 albuminuria and hsTnT; Δ, age, sex, DM, HgBA1c, LVEF, ischemic HF, and medications are 
compared with changes (Δ) in albuminuria and hsTnT between day 1 and day 3 (day 3 – day 1). 
Legend: DM = diabetes mellitus; HgBA1c = glycated hemoglobin; LVEF = left ventricular ejection 
fraction; HF = heart failure; ACEi = angiotensin converting enzyme inhibitors; BMI = body mass 
index; HR = heart rate; SBP = systolic blood pressure; NTproBNP = N-terminal pro brain natriuretic 
peptide; hsTnT = high sensitivity troponin T; eGFR = estimated glomerular filtration rate; pCr = 
plasma creatinine; pUrea = plasma urea; Δ = changes between day 3 and day 1 (day 3 – day 1). 
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Figures 
Figure 1. Study Consort Diagram 
 
Legend: ADCHF, acutely decompensated chronic heart failure; ED, emergency department; pCr, plasma 
creatinine. 
All patients included in the study completed the study, we had no dropouts, therefore all patients counted 
to the final results in the per-protocol analysis. 
All patients admitted to ED for ADCHF 
were potential study candidates. 
Important exclusion criteria were: 
a) pCr > 1,5 mg/dL 
b) Potassium level >5,0 mmol/L 
c) Sepsis 
d) Severe valvular disease 
e) Acute miocardial infarction 
 
Spironolactone (100 mg/d) plus 
standard ADCHF therapy 
(n = 50) 
Standard ADCHF therapy alone 
(n = 50) 
72h to 96h: 
Clinical and analytical data 
First 24h upon ED admission: 
a) Informed consent 
c) Baseline clinical and analytical data 
d) Non-random, sequential patient 
allocation to spironolactone or control 
group in a 1:1 ratio manner during 1 
year period 
e) 100 patients were included 
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Figure 2. Albuminuria at Day 1 and Day 3 Within Control and Treatment Groups. 
 
Legend: Log albuminuria had a more pronounced decrease in the intervention group 
than in control group. Comparison was performed comparing baseline and day 3 log 
albuminuria values using paired sample t tests within each group (1,79 ± 0,75 to 1,59 ± 
0,67, p = 0,003 and  1,89 ± 0,70 to 1,79 ± 0,74, p = 0,096, respectively). 
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Figure 3. Comparison of the Prevalence of Normo, Micro, and Macroalbuminuria at 
Baseline and Day 3 within Spironolactone Group. 
 
Legend: Normoalbuminuria: 20 (40%) to 27 (54%), p < 001; Microalbuminuria: 19 
(38%) to 16 (32%), p = 0,014; Macroalbuminuria: 11 (22%) to 7 (14), p < 0,001. Data 
are presented in absolute number (%). Comparison between groups was performed 
using chi-square test. 
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Abstract 
Background: In acutely decompensated heart failure (ADHF) patients higher 
aldosterone levels correlate with worse post-discharge outcomes, suggesting that 
further modulation of the mineralocorticoid system during or immediately after 
hospitalization might favourably improve outcomes. 
Methods and Results: This was an observational, retrospective secondary analysis of a 
study including 100 patients with ADHF. In that study 50 patients were submitted to 
spironolactone treatment (50 – 100 mg/day). A higher proportion of patients with renin 
levels above 16,5 pg/mL and aldosterone levels above 100 ng/dL was observed in 
subjects submitted to spironolactone treatment (44,7% vs. 66,7% and 56% vs. 64,7%, 
respectively, both p < 0,05). In the group of patients submitted to spironolactone 
treatment the proportion of patients with renin and aldosterone levels above the cutoff 
had a significant increase from baseline to day 3 (24% to 32% and 16% to 44%, 
respectively, both p < 0,05). Log renin and aldosterone were higher in patients with 
renin and aldosterone levels above the cutoff point (both p < 0,05). 
Conclusions: High-dose spironolactone added to standard ADHF therapy induces an 
additional increase in renin and aldosterone levels. Whether higher levels of renin and 
aldosterone due to the reactive response to full MRA still have prognostic value 
requires further investigation. 
Key-words: mineralocorticoid receptor antagonism; renin; aldosterone; acute heart 
failure. 
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Introduction 
 The use of mineralocorticoid receptor antagonists (MRAs) has demonstrated to 
improve outcomes and reduce mortality in chronic heart failure (HF) and post-
myocardial infarction1-3. The benefit observed with MRAs is probably due to excessive 
neurohormonal activation blockade.  
 Particularly, aldosterone is probably essential for the progression of HF. Higher 
aldosterone levels were found in patients with chronic HF when compared with 
controls, and were found to be associated with poor outcome4-7. A rise in aldosterone 
levels was also observed in the acute myocardial infarction setting8,9, and likewise 
associated with worse outcomes in this setting10. 
 In acutely decompensated heart failure (ADHF) patients with ejection fraction 
(EF) < 40%, higher aldosterone levels correlate with worse post-discharge outcomes11, 
suggesting that further modulation of the mineralocorticoid system during or 
immediately after hospitalization might favourably improve outcomes. Regarding this 
matter, high dose spironolactone as add-on therapy in the acutely decompensated 
heart failure (ADHF) setting has demonstrated to be safe and likely to provide greater 
symptomatic relief translated into a more pronounced decrease in natriuretic 
peptides12.  
 We used an ADHF model to study the influence of the MRA spironolactone on 
renin and aldosterone. The aim of this study is to demonstrate the renin and 
aldosterone associations and changes before and after spironolactone introduction. 
 
Methods 
Study Design 
This study is based on analysed data from a previous prospective, 
interventional, clinical trial that we performed12. In that study we enrolled 100 
consecutive patients who presented in a Portuguese tertiary hospital with ADHF, 
between February 2012 and February 2013. They were non-randomly assigned in a 
sequential 1:1 ratio to spironolactone plus standard ADHF therapy or standard ADHF 
therapy alone, 50 patients within each arm (i.e. patients were alternatively assigned to 
spironolactone arm or standard ADHF therapy arm in a sequential manner - the first 
patient to one arm and the next to the other arm. This sequence was repeated until we 
reach 100 patients, 50 patients within spironolactone group and 50 patients within 
control group). Patients were blinded to the allocation, and the clinicians were not 
blinded to the allocation. The recommended spironolactone dose was 100 mg/day, 
however the assistant physician could decrease the spironolactone dose to 50 mg/day 
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after 48h upon admission. After 72h the study was open label. Furosemide dose and 
form of administration was performed according to the treating physician. 
Patients were eligible for enrollment if they presented with decompensation of 
chronic HF with symptoms leading to hospitalization. All patients presented at the 
emergency department severely symptomatic in NYHA class IV. ADHF was diagnosed 
on the basis of the presence of history of chronic HF, at least one symptom (dyspnea, 
orthopnea, or edema), one sign (rales, peripheral edema, ascites, or pulmonary 
vascular congestion on chest radiography) and elevated natriuretic peptides. Exclusion 
criteria were: chronic use of MRAs, cardiac surgery within 60 days of enrollment, 
cardiac mechanical support, cardiac resynchronization-therapy within the last 60 days, 
comorbid conditions with an expected survival of less than 6 months, acute MI at time 
of hospitalization, hemodynamically significant uncorrected primary cardiac valvular 
disease, patients requiring intravenous vasodilators or inotropic agents, supine systolic 
arterial blood pressure <90 mmHg, plasma creatinine (pCr) level >1,5 mg/dL, serum 
potassium level >5,0 mmol/L, hemoglobin (HgB) level <9 g/dL, and sepsis. 
Institutional review board or ethics committee approval was obtained. All 
patients provided written informed consent to participate in the study. 
 
Study assessments 
Patient`s clinical status including physical examination and was prospectively 
recorded by the same assistant physician at day 1 and day 3. 
Medications and respective dosages were prospectively recorded by the 
investigators according to the assistant physician prescriptions. 
Blood and spot urine samples were collected in the first 24 hours (h) after 
admission (day 1) of the patient to the hospital. The first dose of spironolactone was 
only administered after the first sample was collected. Fifty patients had daily oral 
spironolactone according to the study protocol described above. The day 3 samples 
were collected between 72 and 96 h of hospitalization. All samples were collected in 
the morning with the patient in supine position, and first-morning spot urine was used. 
All patients had low-salt, low-calorie hospital diet. Extra fruit and vegetables 
administration was not allowed. An assessment of biomarkers (including pCr, plasma 
urea [pUr], electrolytes, N-terminal pro-brain natriuretic peptide [NTproBNP], high-
sensitivity troponin T [hsTnT] and proteinuria) was performed at a central core 
laboratory at day 1 and day 3. Clinical assessment and routine analyses were 
performed daily during hospital stay. All patients performed a transthoracic 
echocardiography within 72 hours upon admission. Left ventricle ejection fraction 
(LVEF) was calculated according to biplane Simpson method. 
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Aldosterone was measured using radioimmunoassay (RIA) Coat-a-Count® 
(Siemens) and renin with RIA (DiaSource®). 
 
Variable definitions 
  We defined high renin levels when values were above the 16,5 pg/mL cutoff, 
and high aldosterone levels when values were above the 100 ng/dL cutoff. The 
manufacturer suggested a cutoff of 16,5 pg/mL for renin and a cutoff of 160 ng/dL for 
aldosterone. We lowered aldosterone cutoff to 100 ng/dL to increase test sensitivity, 
although levels above 160 ng/dL are more specific, we might miss important 
information, since p.e. in the EVEREST trial only 33,2% of patients had aldosterone 
levels above 160 ng/dL11, and increased mortality was also observed in lower 
aldosterone quartiles.   
We studied aldosterone (ng/dL) and renin (pg/mL) regarding the following covariates: 
age; sex; diabetes mellitus (DM); ischemic HF; EF (%); atrial fibrillation (AF); systolic 
blood pressure (SBP); intravenous (IV) furosemide dose; proportion of patients with IV 
furosemide at day 3; proportion of patients on angiotensin converting enzyme inhibitors 
(ACEi), angiotensin receptor blockers (ARB), beta-blockers (BB), and spironolactone; 
pCr (mg/dL), pUr (mg/dL), NTproBNP (pg/mL), hsTnT (ng/mL), sodium (mmol/L), 
potassium (mmol/L), uNa/K ratio, proteinuria (g/g), red-cell distribution width (RDW), 
HgB (g/dL), and length of stay. 
 
Statistical Analysis 
Normally distributed continuous variables are expressed as mean ± standard 
deviation (SD), and skewed distributions are presented as median [inter-quartile range, 
IQR].  
Because of the positively skewed distributions of aldosterone, renin, pCr, 
proteinuria, RDW, NTproBNP, hsTnT and uNa/K ratio, these variables were log 
transformed for analysis. 
Categorical variables are expressed in proportions (%). 
Comparison between groups was performed using parametric, non-parametric 
tests, or chi-square tests, as appropriate. Significant association was defined by a 
probability (p) value ≤0,05.  
Statistical analysis was performed using SPSS software (version 19, Chicago, 
IL, USA). 
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Results 
Baseline Characteristics, Medications and Lab Results 
Mean ± SD age of the 100 patients admitted due to ADHF was 76,0 ± 10,9 
years. Thirty-nine patients were male; 50 patients had documented ischemic heart 
disease (IHD); 45 had DM; 59 had AF; 32 patients had EF < 40%. 
Furosemide dose, SBP, proteinuria, NTproBNP, renin, aldosterone and hsTnT 
decreased from admission to day 3 (all, p <0,05). The proportion of patients taking 
ACEi/ARB and BB did not differ between admission and day 3.  
Patient characteristics, lab results at admission day and hospital length of stay 
are shown in Table 1. 
Comparison Between Normal and High Renin Values at Admission  
A higher proportion of patients with renin levels above 16,5 pg/mL had AF 
(52,5% vs. 85%, p = 0,008). Log RDW, log renin, and hospital length of stay were 
higher in patients with renin levels above the cutoff (1,18 ± 0,03 vs. 1,21 ± 0,06, p = 
0,004 and 8,36 ± 3,21 vs. 10,85 ± 3,25, p = 0,006, respectively) – Table 2. On the other 
hand, U Na/K ratio was lower in patients with higher renin levels (0,50 ± 0,38 vs. 0,22 ± 
0,31, p = 0,003) – Table 2. and Figure 1. 
Comparison Between Normal and High Aldosterone Values at Admission  
 Patients with lower aldosterone levels were more often male (45,5% vs. 17,4%, 
p = 0,015). Higher levels of serum potassium, log proteinuria, log RDW, log NTproBNP, 
log aldosterone, and plasma urea were observed in patients with aldosterone levels 
above the 100 ng/dL cutoff (all p < 0,05) – Table 2. Similarly to renin findings, a lower 
uNa/K ratio was observed in patients with higher aldosterone levels (0,49 ± 0,37 vs. 
0,29 ± 0,37, p = 0,026) – Table 2. and Figure 1. 
Comparison Between Normal and High Renin Values at Day 3 
 A higher proportion of patients with renin levels above 16,5 pg/mL was 
observed in subjects submitted to spironolactone treatment (44,7% vs. 66,7%, p = 
0,050). Log renin and aldosterone levels were higher in patients with renin levels above 
the cutoff point (both, p < 0,05). Contrary to the findings at admission, uNa/K ratio did 
not differ between groups – Table 3. 
Comparison Between Normal and High Aldosterone Values at Day 3 
 Patients with lower aldosterone levels were older (78,02 ± 9,28 vs. 72,09 ± 
12,70, p = 0,009). Similarly to the findings described for renin at day 3, a higher 
proportion of patients with aldosterone levels above 100 ng/dL was observed in 
subjects submitted to spironolactone treatment (56% vs. 64,7%, p = 0,035). Log renin 
and aldosterone were also higher in this group of patients (both, p < 0,05), and uNa/K 
ratio did not differ between groups – Table 3. 
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Spironolactone Influence in Renin and Aldosterone Levels 
After three days of spironolactone administration the proportion of patients with 
renin and aldosterone levels above the cutoff had a significant increase (from 24% to 
32%, p = 0,003, and from 16% to 44%, p < 0,001, respectively) – Table 4. and Figure 
2. 
 
Discussion 
 The main results of our pilot study suggest that in patients submitted to 
spironolactone treatment the levels of renin and aldosterone increase. Higher levels of 
renin and aldosterone were not observed with the use of drugs other than 
spironolactone (p.e. ACEi/ARBs, BB or loop diuretics).  
At admission higher renin and aldosterone levels were associated with lower 
urinary Na/K ratio levels, these findings were not reproduced when patients were 
submitted to MRA. In addition, higher levels of renin and aldosterone at admission 
were associated with higher RDW. Higher renin was associated with longer length of 
stay, and higher aldosterone with higher NTproBNP.  
Baseline aldosterone blood levels measured in chronic HF patients with LVEF < 
40% during the first days after admission for AHF were significantly correlated with 
higher mortality and re-hospitalization for HF11. Aldosterone levels were found to 
increase substantially during hospitalization and remain elevated after discharge, 
despite excellent background RAAS inhibitor therapy. The association between higher 
aldosterone levels and worse outcome remains positive, although weaker, when 
considering discharge aldosterone measurement11. Based on these findings the 
authors of this trial suggest that further neurohormonal modulation may be required in 
order to improve outcomes. In our interventional trial12 we demonstrated that additional 
MR blockade during the acute decompensation is not associated with electrolyte 
disorders or kidney dysfunction and probably portends greater congestion relief, 
translated into a steep natriuretic peptide decrease. In this secondary analysis we 
demonstrated that renin and aldosterone levels are increased by spironolactone and 
not by ACEi/ARB, beta blockers or diuretics, as shown by the significant higher 
proportion of patients with levels of renin and aldosterone above the cutoff within 
spironolactone group, and not in patients under ACEi/ARB, beta blockers or diuretics. 
Furthermore, blood pressure and electrolytes are not likely to influence the observed 
variation in these hormones. These findings are concordant with previous reports in 
which the physiological elevation in plasma renin activity (PRA) and aldosterone were 
demonstrated in response to eplerenone and spironolactone treatment13-17. A previous 
study reported an increase in both PRA and aldosterone after eplerenone treatment for 
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10 days in dogs18. Similarly, in humans, eplerenone resulted in elevations in serum 
aldosterone and PRA when administered for 8-weeks in addition to a fixed-dose of an 
ACEi in mildly hypertensive patients16. A larger study, reported an increase in serum 
aldosterone with eplerenone treatment that was dose-responsive19. Furthermore, in 
patients with resistant hypertension an inverse correlation between blood pressure and 
serum aldosterone was demonstrated after treatment with eplerenone for 12 weeks20, 
and another study demonstrated a time-dependent aldosterone increased in response 
to eplerenone13. The most robust explanation to this finding results from the 
demonstration that the main physiologic regulators of aldosterone synthase are 
angiotensin II and potassium21. Thus, increases in serum potassium and angiotensin II 
resulting from a decreased sodium and increased potassium reabsorption in the 
proximal tubules, would lead to an up-regulation of aldosterone synthase, consequently 
increasing aldosterone levels. Another potential explanation for the increase in 
aldosterone is a direct regulation of aldosterone synthase by mineralocorticoid 
receptor13. Our results can be very interesting and innovative, since MRA can probably 
improve outcomes in ADHF and also can increase renin and aldosterone levels, 
therefore higher levels of aldosterone may not held place for prognostic purposes when 
full MRA is provided. However, further studies are warranted to fully understand the 
mechanisms underlying the rise in aldosterone following MRA and the prognostic 
significance of MR blockade in the decompensated HF setting. 
The median aldosterone levels at admission appear higher than the median 
values found in previous reports of patients with acute and chronic heart failure after 
the widespread use of ACEi/ARB4-7,11. This finding may be explained by the lower 
proportion (only 44%) of the patients on baseline ACEi/ARB, potentially leading to 
higher levels of renin and aldosterone7,22, similar to the levels found before the 
widespread use of the RAAS inhibitors6,23.  
In the present study, higher levels of renin and aldosterone at admission were 
associated with higher RDW and lower urinary Na/K ratio levels. Additionally, higher 
aldosterone levels alone were associated with higher NTproBNP and higher levels of 
renin alone were associated with longer length of stay. Despite these side findings do 
not compose the bulk of our study, we think they deserve a brief discussion. 
Higher levels of renin and aldosterone at admission were associated with higher 
RDW. RDW is a percentual measure of the variability in the size of circulating 
erythrocytes24. Disorders related to ineffective erythropoiesis or increased destruction 
cause greater heterogeneity in size and a higher RDW25. In patients with ADHF higher 
RDW has been associated with slower diuretic response26 and increased long-term 
mortality27. The relationship between elevated hormone levels and poor outcome can 
93 
 
reflect the possibility that hormonal activation is not only serving as a marker for the 
severity of the disease, but is also contributing to progression of HF5.  
Higher aldosterone levels were associated with higher NTproBNP. To the best 
of our knowledge this is the first study to demonstrate a significant association between 
increased aldosterone levels and increased natriuretic peptides. However, previous 
studies demonstrated that aldosterone receptor antagonism with spironolactone 
induces a more noticeable decreases in plasma BNP levels than placebo or no 
spironolactone12,28, suggesting that aldosterone may have an important role in the 
process of left ventricular remodeling28. 
As described above, increased neurohormonal activation is associated is worse 
outcome11. Our study was underpowered to detect major events, but length of stay 
could serve as a potential indirect severity measure. However length of stay may be 
affected by co-morbidities other than HF and in-hospital complications. Despite the 
association of higher levels of renin at admission and longer length of stay may appear 
to be an attractive result, the lack of correspondence in aldosterone and the bias 
inherent to length of stay, make this result less appealing and with dubious external 
validity. 
Activation of the RAAS causes reabsorption of Na+ and the excretion of K+ in 
various epithelia such as the distal nephron29. Higher renin and aldosterone levels at 
admission were also associated with lower urinary Na/K ratio levels, these findings 
were not reproduced when patients were submitted to MRA. These observations are 
consistent with the RAAS effects on distal nephron, i.e. higher levels of renin and 
aldosterone lead to higher Na+ reabsorption and K+ excretion, decreasing uNa/K ratio. 
On the other hand, in the group of patients submitted to spironolactone treatment, 
uNa/K ratio increased probably reflecting the MRA effect. These dynamic changes 
suggest that uNa/K ratio can serve as a potential biomarker for MRA13. 
Our study has several limitations that should be noticed. First, it was a single-
centre of a small sample size study. Second, no randomization or concealed allocation 
was performed, therefore we cannot exclude a selection bias potentially affecting the 
external validity of our results, particularly on outcome results like length of stay, 
however we included internal control variables like renin, aldosterone and NTproBNP 
that are less likely to be affected by bias and appear to be consistent with previous 
reports. Third, this study was performed post-hoc, therefore it is subject to the potential 
biases inherent to analyses of observational data. Fourth, baseline blood samples were 
collected in the first 24h after admission and before spironolactone administration, but 
most patients had already received diuretics and/or vasodilators, as a consequence 
renin and aldosterone admission levels may not reflect the real decompensation 
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values. Fifth, high aldosterone cutoff was lowered to 100 ng/dL to increase test 
sensitivity, despite losing specificity we were able to detect a higher proportion of 
patients with aldosterone increments. Finally, our inclusion criteria by restricting the 
enrolment of patients with hyperkalemia, impaired renal function, and severe valvular 
disease may be responsible for the good treatment response of our population and 
therefore limit the external validity of our conclusions.  
 
Conclusion 
Higher levels of aldosterone are associated with higher mortality risk in ADHF 
patients. High-dose spironolactone added to standard ADHF therapy induces an 
additional increase in renin and aldosterone levels. Whether higher levels of renin and 
aldosterone due to the reactive response to full MRA still have prognostic value 
requires further investigation. 
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Tables 
Table 1. Population Characteristics, Laboratory Results and Spironolactone Dose at 
Admission Day (Day 1) and Day 3 
Age (yrs) 76,0 ± 10,88 
Male Sex – % 39 
DM - % 45 
Ischemic HF - % 50 
EF < 40 - % 32 
AF - % 59 
RDW (%) 15,20 [14,40 – 16,0] 
Hemoglobin (g/dL) 12,43 ± 2,07 
Length of Stay (days) 8,86 ± 3,36 
 Day 1 Day 3 p Value 
Spironolactone - % 50 50 1** 
Spironolactone Dose (mg) 94,50 ± 23,31 62,74 ± 24,33 <0,001 
ACEi/ARB - % 44 61 0,069** 
ACEi/ARB Dose (mg) 4,79 ± 3,01 3,79 ± 2,63 0,034 
Beta-Blocker - % 37 57 0,143** 
Beta-Blocker Dose (mg) 4,06 ± 1,77  3,19 ± 1,54 0,026 
Furosemide IV Dose (mg) 81,08 ± 22,08 67,57 ± 25,54 0,001 
Oral Furosemide - % 0 63 <0,001** 
Oral Furosemide Dose (mg) 0 74,60 ± 28,10 <0,001 
SBP (mmHg) 139,79 ± 25,86 121,97 ± 16,20 <0,001 
Sodium (mmol/L) 140,54 ± 4,38 140,68 ± 3,95 0,718 
Potassium (mmol/L) 4,03 ± 0,51 4,04 ± 0,54 0,950 
Plasma Creatinine (mg/dL) 1,04 [0,89 – 1,31] 1,06 [0,85 – 1,40] 0,082* 
Plasma Urea (mg/dL) 55,21 ± 20,84 62,3 ± 25,47 0,001 
Proteinuria (g/g) 0,289 [0,188 – 0,629] 0,299 [0,160 – 
0,097] 
0,045* 
NTproBNP (pg/mL) 2750 [1672 – 6032] 1835 [902 – 3837] <0,001* 
UNa/K ratio 3,04 [1,52 – 5,76] 2,80 [1,50 – 4,78] 0,341* 
Renin (pg/mL) 4,35 [2,30 – 10,78] 5,34 [3,14 – 16,30] 0,011* 
Aldosterone (ng/dL) 35,0 [12,0 – 92,5] 67,0 [21,3 – 125,0] 0,002* 
hsTnT (ng/mL) 0,033 [0,193 – 0,050] 0,030 [0,018 – 
0,051] 
0,039* 
Continuous variables are presented as mean value ± standard deviation [SD], p value 
or median [inter-quartile range, IQR], p value. Categorical variables are presented as 
absolute number (%), p value.  
*Non-parametric paired sample test; **Chi-square test. 
Note: day 1 analysis were collected before spironolactone administration.  
Legend: DM = diabetes mellitus; EF = left ventricular ejection fraction; HF = heart 
failure; AF = atrial fibrillation; SBP, systolic blood pressure; ACEi/ARB = angiotensin 
converting enzyme inhibitors/angiotensin receptor blockers; RDW = red cell distribution 
width; NTproBNP = N-terminal pro brain natriuretic peptide; UNa/K = urinary sodium to 
potassium; hsTnT = high sensitivity troponin T. 
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Table 2. Comparison Between Normal and High Renin and Aldosterone Values at Admission. 
 Renin < 16,5 
(n=80) 
Renin ≥ 16,5 
(n=20) 
p Value Aldosterone < 
100 
(n=77) 
Aldosterone ≥ 
100 
(n=23) 
p Value 
Age 75,99 ± 
10,33 
76,05 ± 
13,13 
0,982 74,91 ± 10,70 76,65 ± 10,88 0,066 
Male Sex – no. (%) 30 (37,5) 9 (45) 0,539 35 (45,5) 4 (17,4) 0,015 
DM – no. (%) 38 (47,5) 7 (35) 0,315 34 (44,2) 11 (47,8) 0,756 
EF <40% – no. (%) 26 (32,5) 5 (25) 0,517 25 (32,5) 6 (26,1) 0,562 
Ischemic HF – no. 
(%) 
37 (46,3) 13 (65) 0,134 37 (48,1) 13 (58,5) 0,476 
AF – no. (%) 42 (52,5) 17 (85) 0,008 44 (57,1) 15 (65,2) 0,490 
SBP 140,93 ± 
26,08 
135,25 ± 
25,11 
0,383 140,84 ± 26,72 136,26 ± 22,94 0,459 
Beta Blocker – no. 
(%) 
31 (38,8) 5 (25) 0,252 27 (35,1) 9 (39,1) 0,722 
ACEi/ARB – no. (%) 34 (42,5) 8 (40) 0,839 32 (41,6) 10 (43,5) 0,870 
Sodium 140,75 ± 
4,41 
139,70 ± 
4,26 
0,340 140,84 ± 4,54 139,52 ± 3,69 0,205 
Potassium 4,05 ± 0,50 3,98 ± 0,55 0,586 3,97 ± 0,47 4,24 ± 0,57 0,023 
Log Creatinine 0,02 ± 0,11 0,02 ± 0,14 0,888 0,02 ± 0,12 0,04 ± 0,11 0,495 
Log Proteinuria -0,44 ± 0,40 -0,45 ± 0,47 0.962 -0,51 ± 0,39 -0,23 ± 0,42 0,008 
Log RDW 1,18 ± 0,03 1,21 ± 0,06 0,004 1,18 ± 0,04 1,20 ± 0,04 0,047 
Log NTproBNP 3,49 ± 0,45  3,41 ± 0,35 0,444 3,42 ± 0,41 3,67 ± 0,47 0,014 
Log UNa/K ratio 0,50 ± 0,38 0,22 ± 0,31 0,003 0,49 ± 0,37 0,29 ± 0,37 0,026 
Log Aldosterone 1,53 ± 0,43 1,70 ± 0,49 0,135 1,39 ± 0,34 2,15 ± 0,12 <0,001 
Log Renin 0,52 ± 0,33 1,46 ± 0,22 <0,001 0,69 ± 0,48 0,78 ± 0,50 0,402 
Log hsTnT -1,47 ± 0,39 -1,47 ± 0,33 0,995 -1,47 ± 0,39 -1,47 ± 0,34 0,988 
Urea 53,78 ± 
19,68 
60,95 ± 
24,68 
0,170 52,44 ± 20,52 64,48 ± 19,60 0,014 
Hemoglobin 12,50 ± 1,98 12,16 ± 2,44 0,512 12,39 ± 2,06 12,59 ± 2,17 0,689 
Log Length of Stay 0,89 ± 0,17 1,01 ± 0,15 0,003 0,91 ± 0,16 0,91 ± 0,19 0,958 
Legend: DM = diabetes mellitus; EF = left ventricular ejection fraction; HF = heart failure; AF = 
atrial fibrillation; SBP, systolic blood pressure; ACEi/ARB = angiotensin converting enzyme 
inhibitors/angiotensin receptor blockers; RDW = red cell distribution width; NTproBNP = N-terminal 
pro brain natriuretic peptide; UNa/K = urinary sodium to potassium; hsTnT = high sensitivity 
troponin T. 
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Table 3. Comparison Between Normal and High Renin and Aldosterone Values at Day 3. 
 Renin < 16,5 
(n=76) 
Renin ≥ 16,5 
(n=24) 
p Value Aldosterone < 
100 
(n=66) 
Aldosterone ≥ 
100 
(n=34) 
p Value 
Age 76,58 ± 9,61 74,17 ± 
14,25 
0,346 78,02 ± 9,28 72,09 ± 12,70 0,009 
Male Sex – no. (%) 28 (36,8) 11 (45,8) 0,431 25 (37,9) 14 (41,2) 0,749 
DM – no. (%) 37 (48,7) 8 (33,3) 0,188 29 (43,9) 16 (47,1) 0,766 
EF <40% – no. (%) 22 (28,9) 9 (37,5) 0,430 18 (27,3) 13 (38,2) 0,262 
Ischemic HF – no. (%) 36 (47,4) 14 (58,3) 0,241 30 (45,5) 20 (68,8) 0,205 
AF – no. (%) 43 (56,6) 16 (66,7) 0,264 42 (63,6) 17 (50) 0,189 
SBP 123,55 ± 
16,73 
116,96 ± 
13,52 
0,082 122,55 ± 15,76 120,85 ± 17,20 0,623 
Beta Blocker – no. 
(%) 
46 (60,5) 11 (45,8) 0,205 38 (57,6) 19 (55,9) 0,871 
ACEi/ARB – no. (%) 48 (63,2) 13 (54,2) 0,431 41 (62,1) 20 (58,8) 0,749 
IV Furosemide – no. 
(%) 
27 (35,5) 10 (41,7) 0,587 25 (37,9) 12 (35,4) 0,800 
Spironolactone – no. 
(%) 
34 (44,7) 16 (66,7) 0,050 28 (56) 22 (64,7) 0,035 
Spironolactone Dose 63,89 ± 
24,96 
60,29 ± 
23,48 
0,620 60,00 ± 23,31 66,30 ± 25,68 0,355 
Sodium 141,11 ± 
3,85 
139,33 ± 
4,05 
0,055 141,12 ± 4,33 139,82 ± 2,96 0,121 
Potassium 4,01 ± 0,56 4,14 ± 0,49 0,299 4,00 ± 0,50 4,10 ± 0,61 0,402 
Log Creatinine 0,03 ± 0,14 0,05 ± 0,16 0,675 0,02 ± 0,14 0,07 ± 0,14 0,058 
Log Proteinuria -0,46 ± 0,38 -0,59 ± 0,31 0.132 -0,49 ± 0,35 -0,49 ± 0,41 0,955 
Log RDW 1,18 ± 0,03 1,21 ± 0,06 0,007 1,19 ± 0,04 1,18 ± 0,04 0,658 
Log NTproBNP 3,27 ± 0,50  3,29 ± 0,51 0,881 3,28 ± 0,49 3,24 ± 0,52 0,679 
Log UNa/K ratio 0,42 ± 0,40 0,34 ± 0,37 0,378 0,44 ± 0,38 0,31 ± 0,40 0,120 
Log Aldosterone 1,64 ± 0,45 1,94 ± 0,51 0,007 1,47 ± 0,38 2,21 ± 0,19 <0,001 
Log Renin 0,59 ± 0,34 1,52 ± 0,25 <0,001 0,69 ± 0,45 1,07 ± 0,54 <0,001 
Log hsTnT -1,51 ± 0,33 -1,52 ± 0,42 0,838 -1,51 ± 0,33 -1,51 ± 0,39 0,942 
Urea 60,86 ± 
25,20 
66,92 ± 
26,32 
0,312 60,70 ± 26,83 65,44 ± 22,64 0,380 
Hemoglobin 12,52 ± 2,11 12,16 ± 1,96 0,465 12,38 ± 2,11 12,53 ± 2,03 0,728 
Log Length of Stay 0,89 ± 0,17 0,99 ± 0,13 0,008 0,89 ± 0,18 0,96 ± 0,13 0,043 
Legend: DM = diabetes mellitus; EF = left ventricular ejection fraction; HF = heart failure; AF = 
atrial fibrillation; SBP, systolic blood pressure; ACEi/ARB = angiotensin converting enzyme 
inhibitors/angiotensin receptor blockers; RDW = red cell distribution width; NTproBNP = N-terminal 
pro brain natriuretic peptide; UNa/K = urinary sodium to potassium; hsTnT = high sensitivity 
troponin T. 
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Table 4. Comparison of Renin and Aldosterone Levels at Admission and Day 3 within 
Spironolactone and Control Groups 
 Day 1  Day 3  
 Spironolactone Control p Value Spironolactone Control p 
Value 
Renin > 16,5 – no. (%) 12 (24) 8 (16) 0,317 16 (32) 8 (16) 0,050 
Aldosterone > 100 – no. 
(%) 
8 (16) 15 (30) 0,096 22 (44) 12 (24) 0,035 
Note: Day 1 analysis were performed before spironolactone administration 
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Figures 
Figure 1. Comparison of Urinary Sodium to Potassium Ratio According to Renin and 
Aldosterone Levels at Admission. 
 
 
 
Legend: Renin = Log Renin; Aldosterone = Log Aldosterone; U Na/K = urinary sodium 
to potassium. 
Patients with higher renin and aldosterone levels at admission had lower urinary 
sodium to potassium ratios. 
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Figure 2. Comparison of Renin and Aldosterone Levels Before and After Spironolactone 
Treatment
 
Legend: Results are presented in percentage (%) of total. Renin is expressed in pg/mL and 
Aldosterone in ng/dL. 
The proportion of patients with increased levels of renin and aldosterone is significantly 
higher in patients submitted to spironolactone treatment. The proportion of patients with renin 
levels above 16,5 pg/mL increases from 24% before spironolactone administration to 32% 
after spironolactone administration, p value = 0,003. The proportion of patients with 
aldosterone levels above 100 ng/dL increases from 16% before spironolactone 
administration to 44% after spironolactone administration, p value < 0,001. 
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V. High Sensitivity Troponin T: A Biomarker for Diuretic 
Response in Decompensated Heart Failure Patients? 
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Abstract 
Background: Patients presenting with acutely decompensated heart failure (ADHF) and 
positive circulating cardiac troponins were found to be a high-risk cohort. The advent of 
high-sensitive troponins resulted in a detection of positive troponins in a great 
proportion of heart failure patients. However, the pathophysiological significance of this 
phenomenon is not completely clear. 
Objectives The aim of this study is to determine the early evolution and clinical 
significance of high-sensitivity troponin T (hsTnT) in ADHF.  
Methods: Retrospective, secondary analysis of a prospective study including 100 
patients with ADHF. 
Results: Globally, high-sensitivity troponin T decreased from day 1 to day 3 (p = 0,039). 
However, in the subgroup of patients who remained decompensated no significant 
differences in hsTnT from day 1 to day 3 were observed (p = 0,955), whereas in 
successfully compensated patients a significant reduction in hsTnT levels was 
observed (p = 0,025). High sensitivity troponin T decrease was correlated with 
NTproBNP reduction (p = 0,007). Patients with hsTnT increase had longer length of 
stay (p = 0,033). 
Conclusions: Episodes of ADHF are associated with transient increases in the blood 
levels of hsTnT that are reduced with effective acute episode treatment. The decrease 
in hsTnT can translate less myocardial damage along with favourable ADHF treatment. 
Key-words: Acute Heart Failure. High-Sensitivity Troponin T. Biomarkers. N-Terminal 
Pro-Brain Natriuretic Peptide 
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Introduction 
Patients presenting with acutely decompensated heart failure (ADHF) and 
positive circulating cardiac troponins were found to be a high-risk cohort, requiring 
greater use of hospital resources, and having increased risk of in-hospital mortality1. 
Measurement of cardiac troponins in this setting adds important prognostic information 
and should be considered as part of an early assessment of risk1,2. 
Detectable troponins, even in the absence of acute coronary syndrome, are 
associated with impaired hemodynamics, progressive decline in left ventricular systolic 
function, and shortened survival3-5.  
Recent improvements in the sensitivity of troponin assays added additional 
challenges in the interpretation of these biomarkers in heart failure (HF). The 
increasing sensitivity of more contemporary assays has resulted in the detection of 
circulating troponin in a progressively greater proportion of HF patients. This 
phenomenon has led to increasing uncertainty about the clinical interpretation of 
troponin data from contemporary assays, particularly in patients with ADHF, since a 
substantial proportion of these patients have elevations of circulating troponins1,6,7. 
The aim of this study is to determine the early evolution, associations, and 
correlations of high-sensitivity troponin T (hsTnT) in ADHF.  
 
Methods 
Study Design 
We analysed a database from a previous conducted prospective, interventional 
trial that we performed8. In that study we enrolled a 100 consecutive patients who 
presented in a Portuguese tertiary hospital with ADHF, between February 2012 and 
February 2013. They were assigned in a sequential 1:1 ratio to spironolactone plus 
standard ADHF therapy or standard ADHF therapy alone. Patients were eligible for 
enrollment if they presented with decompensation of chronic HF with symptoms leading 
to hospitalization. ADHF was diagnosed on the basis of the presence of history of 
chronic HF and at least one symptom (dyspnea, orthopnea, or edema) and one sign 
(rales, peripheral edema, ascites, or pulmonary vascular congestion on chest 
radiography). Exclusion criteria were: chronic use of mineralocorticoid receptor 
antagonists (MRAs), cardiac surgery within 60 days of enrollment, cardiac mechanical 
support, cardiac resynchronization-therapy within the last 60 days, comorbid conditions 
with an expected survival of less than 6 months, acute MI at time of hospitalization, 
hemodynamically significant uncorrected primary cardiac valvular disease, patients 
requiring intravenous vasodilators or inotropic agents, supine systolic arterial blood 
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pressure <90 mmHg, plasma creatinine (pCr) level >1,5 mg/dL, serum potassium level 
>5,0 mmol/L, hemoglobin (HgB) level <9 g/dL, and sepsis. 
Institutional review board or ethics committee approval was obtained. All 
patients provided written informed consent to participate in the study. 
Study assessments 
Patient`s clinical assessment including physical examination, was prospectively 
recorded daily by the same assistant physician. 
Medications and respective dosages were prospectively recorded by the 
investigators according to the assistant physician prescriptions. 
Blood and spot urine samples were collected in the first 24 hours (h) after 
admission (day 1) of the patient to the hospital. The day 3 samples were collected 
between 72 and 96 h of hospitalization. An assessment of biomarkers, including pCr, 
plasma urea (pUr), electrolytes, N-terminal pro-brain natriuretic peptide (NTproBNP) 
and hsTnT was performed at a central core laboratory at day 1 and day 3. Clinical 
assessment and routine analyses were performed daily during hospital stay. Estimated 
glomerular filtration rate (eGFR) was determined using the Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) equation8. All patients performed a 
transthoracic echocardiography within 72 hours upon admission. Ejection fraction (EF) 
was calculated according to biplane Simpson method. 
High sensitive troponin T was measured using COBAS Troponin T hs (high 
sensitive) STAT (short turn around time) (Roche Diagnostics®). According to the 
manufacturer a positive hsTnT test was considered when the value was above the 
upper reference limit (99th percentile) of 0,014 ng/mL. 
Variable definitions 
  We studied hsTnT regarding the following covariates: comorbidities such as 
diabetes mellitus (DM), chronic obstructive pulmonary disease (COPD), and sleep 
apnea; body mass index (BMI); heart rate (HR); systolic blood pressure (SBP); atrial 
fibrillation (AF); HF etiology; echocardiographic parameters such as EF; furosemide 
dose, proportion of patients on angiotensin converting enzyme inhibitors (ACEi), beta-
blockers (BB), and spironolactone; pCr, pUr, NTproBNP, sodium, potassium; HgB and 
serum albumin. 
 In order to determine the differences in hsTnT concentration between patients 
with faster diuretic response and patients with slower diuretic response after 3 days of 
inpatient treatment, patients were considered faster diuretic responders if they had 
decreased intravenous (i.v.) furosemide dose or switched to oral furosemide in the first 
three days of in-hospital treatment. On the other hand, patients were considered to be 
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slower diuretic responders if the assistant physician increased or maintained i.v. 
furosemide dosage after three days of in-hospital treatment. 
Statistical Analysis 
Normally distributed continuous variables are expressed as mean ± standard 
deviation (SD), and skewed distributions are presented as median [inter-quartile range, 
IQR].  
Categorical variables are expressed in absolute numbers (no.) and proportions 
(%). 
Comparison between groups was performed using parametric, non-parametric 
tests, or chi-square tests, as appropriate. Significant association was defined by a 
probability (p) value ≤ 0,05.  
The positively skewed distributions were log transformed for analysis. 
Correlations of log hsTnT were first examined by single variable linear or logistic 
regression and presented as non-adjusted coefficient (NAC) and 95% confidence 
interval [95%CI]. Factors with a p value ≤ 0,05 by single variable regression analyses 
were included in a multivariable linear regression model, presented as adjusted 
coefficient (AC) [95%CI]. 
Statistical analysis was performed using SPSS software (version 19, Chicago, 
IL, USA). 
 
Results 
Baseline Characteristics and Early Changes 
Mean ± SD age of the 100 patients admitted due to ADHF was 76 ± 10,9 years. 
Thirty-nine (39%) patients were male; 50 patients had documented ischemic heart 
disease (IHD); 59 had AF; and mean ± SD EF (%) was 43,46 ± 11,73 - Table 1. All 
patients were admitted in New York Heart Association (NYHA) class IV. Patient 
characteristics, medications and comparison of lab results between admission day (day 
1) and the third day of inpatient treatment is shown in Table 1. 
Globally, high-sensitivity troponin T was likely to decrease from day 1 to day 3 
(median [IQR], 0,033 [0,019 – 0,050] vs. 0,030 [0,018 – 0,051], p = 0,039) – Table 1. 
However, in the subgroup of patients considered to have slower diuretic response no 
significant differences in hsTnT from day 1 to day 3 were observed (median [IQR], from 
0,046 [0,033 - 0,087] to 0,055 [0,032 - 0,072], p = 0,955), whereas in the group of 
patients considered to have a faster diuretic response a significant reduction in hsTnT 
levels was observed (median [IQR], from 0,032 [0,017 - 0,048] to 0,028 [0,017 - 0,045], 
p = 0,025) – Table 2 and Figure 1. The hsTnT variation did not differ between groups 
(median [IQR], -0,0005 [-0,043 to 0,004] vs. -0,0010 [-0,020 to 0,002], p = 0,51) – 
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Table 2. The majority of patients with negative hsTnT at day 1 remained negative at 
day 3 (76,9%). On the other hand only a small proportion (3,1%) of patients with 
positive hsTnT at day 1 turned negative at day 3 – Table 3. 
High-Sensitivity Troponin T Correlations  
Bivariate analysis of hsTnT at day 1 found positive correlations with day 1 Log 
NTproBNP (NAC [95%CI], 0,481 [0,267 to 0,574], p < 0,001), pUr (NAC [95%CI], 0,309 
[0,002 to 0,009], p = 0,002), and Log pCr (NAC, [95%CI], 0,345 [0,500 to 1,704], p < 
0,001). A negative correlation was found with Log eGFR (NAC [95%CI], -0,275 (-1,231 to 
-0,216), p = 0,006). Day 3 hsTnT was also positively correlated with day 3 Log 
NTproBNP (NAC [95%CI], 0,486 [0,218 to 0,464], p < 0,001), and Log pCr (NAC, [95%CI], 
0,439 [0,630 to 1,503], p < 0,001), and negatively correlated with Log eGFR (NAC 
[95%CI], -0,399 (-1,232 to -0,455), p = 0,006) – Table 4. High sensitivity troponin T 
decrease was correlated with NTproBNP reduction (NAC [95%CI], 0,267 [0,044 to 
0,276], p = 0,007) – Table 4. and Figure 2. By multivariate analysis, hsTnT correlated 
with NTproBNP at day 1 and day 3 (AC [95%CI], 0,400 [0,185 to 0,513], p < 0,001, and 
0,381 [0,146 to 0,389], p< 0,001, respectively) – Table 4. 
Determinants of hsTnT Change 
 High-sensitivity troponin T was transformed according to the pattern of change 
(decrease or increase) during the first 3 days of treatment – Table 5. 
 Patients with hsTnT increase had lower NTproBNP decrease (median [IQR], -
1167 [-2337 to -367] vs. -379 [-1273 to 319,5], p = 0,003), had longer length of stay 
(median [IQR], 8 [6 to 11] vs. [9 [7 to 12], p = 0,033), and had higher proportion of AF 
(49,2% vs. 75,7%, p = 0,009). Diuretic dosages, other HF medications, renal function 
and length of stay did no differ between groups – Table 5. 
 
Discussion 
The major finding of this study is that episodes of ADHF are associated with 
transient increases in the blood levels of hsTnT that are reduced with acute episode 
effective treatment. This statement is corroborated by the higher levels of hsTnT in 
patients who maintained or increased i.v. furosemide dose after 3 days of 
hospitalization, by a decrease in hsTnT levels in patients with faster response to 
diuretic therapy, by the correlation between troponin T decrease and NTproBNP 
reduction, and by the longer length of stay and lower decrease in NTproBNP levels in 
the group of patients who had increase in hsTnT from day 1 to day 3. 
 Improvements in analytical sensitivity have transformed circulating troponin 
from a biomarker that was only detectable in a minority of patients to one that is 
detectable in the vast majority of patients with HF1. The high sensitivity of the test can 
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detect very small changes in the circulating troponin levels1,7, providing a potential 
explanation for the high proportion of patients who remained above the 99th percentile 
after 3 days of treatment.  
In our study over 80% of the patients had hsTnT levels above the 99th 
percentile, this prevalence of detectable hsTnT was higher than in previously published 
reports1-3,6,9,10. The most likely explanation for this finding is the type of tests, assay 
platforms and the cutoff limits used in those studies. For example, the Acute 
Decompensated Heart Failure National Registry (ADHERE) study used a higher cutoff 
limit of 0,1 ng/mL and they did not control the assay platform1, and in the Enhanced 
Feedback for Effective Cardiac Treatment (EFFECT) study the cuttof limit used was 0,5 
ng/mL3. However, in the another study by Metra M., et al6 the used cutoff was 0,01 
ng/mL where levels above this value were considered abnormal. In that study, 51 
(48%) of the 107 patients discharged alive from the hospital had detectable troponin in 
at least one measurement. Despite the differences in the type of test and assay 
platform, the cutoff limit was similar to the cutoff used in our study. One possible 
explanation for this discrepancy is the mean ± SD age of the patients included in the 
present study. Our patients are older than patients included in the study by Metra et al 
(76 ± 10,9 vs. 66 ± 13 years, respectively). Troponin levels are likely to have a 
Gaussian or near Gaussian distribution, with higher levels found in older age groups11.  
Elevations in baseline troponin levels were demonstrated to be independent 
predictors of events during the acute hospitalization (worsening or persistent HF, 
death, and increased length of stay) and also independent predictors of post-discharge 
outcomes3,6,9,12-14. In our study, an increase in hsTnT levels was also associated with 
longer length of stay consistent with the previous cited reports.  
 Changes in troponin status during initial treatment for ADHF have been 
proposed as potentially important targets for drug development15.  In the biomarker 
analysis from the Relaxin in Acute Heart Failure (RELAX-AHF) development 
program16, changes in markers of cardiac (hsTnT), renal (pCr and cystatin-C), and 
hepatic (aspartate transaminase and alanine transaminase) damage and of 
decongestion (NTproBNP) at day 2, improved with Serelaxin administration. These 
findings were consistent with the prevention of organ damage and faster decongestion. 
Our study also showed a reduction in hsTnT levels in the first days of HF treatment in 
patients who were able to reduce i.v. furosemide dose or switch it to oral route and in 
patients with higher reduction in natriuretic peptides, possibly traducing less myocardial 
damage in patients with more favourable therapeutic response, i.e. faster 
decongestion. This finding provides additional data supporting the use of troponin as a 
biomarker for ADHF severity and therefore a potential therapeutic target. In addition, 
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NTproBNP and hsTnT are independent markers of increased mortality risk in HF6,14,17,18 
and natriuretic peptides have shown to correlate with changes in ventricular wall stress, 
being inversely related to the severity of left ventricular dysfunction17,19-21. A decline in 
NTproBNP plasma levels during the initial hospitalisation was observed in our study, a 
finding consistent with previous reports22-25. Furthermore, this study demonstrates that 
patients with hsTnT decrease have a more pronounced NTproBNP reduction, and a 
weak but positive correlation between hsTnT and NTproBNP was found. Despite the 
weak correlation between hsTnT and NTproBNP, these results may suggest that 
congestion and ventricular wall stress relief can be translated into natriuretic peptide 
and hsTnT reduction. However the different pathophysiological mechanisms targeted 
by these biomarkers may explain the weak correlation between them described in this 
study. Nevertheless, this finding was not observed in other studies involving patients 
with heterogeneous HF presentations6,26.  
The ADHF episodes are associated with increased mechanical strain on the 
heart, activation of neurohormonal systems, and increased and oxidative stress25. 
These stimuli are known to mediate myocardial injury, accelerating myocyte loss25. 
Troponin T is highly specific for cardiac myocytes, but circulating levels may also be 
elevated due to renal insufficiency. However, this mechanism does not seem to 
underlie our observations, since hsTnT is positively correlated with pCr and negatively 
correlated with eGFR at day 1 and day 3, but the changes in hsTnT during treatment 
are not correlated with changes in renal function. Thus, patients with impaired renal 
function are likely to have higher hsTnT levels, but hsTnT reduction is independent of 
renal function changes. Thus, we believe that the elevation in hsTnT reflects increased 
release from the myocardium, and thus, may indicate myocyte injury and/or death. 
In the group of patients with hsTnT increase a higher proportion of patients with 
AF was observed. These findings are consistent with previous larger trials, in which a 
positive hsTnT was detected in almost all patients with AF, with hsTnT levels carrying 
strong and independent prognostic information with a gradual increase in the risk of 
stroke, cardiac and total death27.  Our study was underpowered for major 
cardiovascular events and death, but a longer length of stay was observed in patients 
with hsTnT increase as discussed above. 
Limitations 
Our study has several limitations that need to be considered. It was a single-
centre investigation of a small sample, which limits our inferential analysis. The 
decision to withdraw diuretic therapy was based on subjective assessment of 
congestive signs and symptoms so we cannot rule out the inter-observer variability. 
However, in real-life clinical practice, the decision to step down diuretic therapy is also 
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based on subjective clinical evaluation. Our study protocol defined that the first blood 
sample would be collected in the first 24 h, so at the time of venous blood sampling 
patients could had been treated already with diuretics. Although we are not comparing 
diuretic-naïve patients at day 1 measurements, the overall effect of this bias would be 
an underestimated difference between day 1 and day 3, which does not significantly 
affect the internal validity of our study conclusions. Finally, the external validity of our 
conclusions is limited to normo-hypertensive and fluid overloaded HF patients with 
normal or mildly impaired renal function, since all these factors were considered 
inclusion criteria. On the other hand, our conclusions can be reproducible in this set of 
patients widely common in clinical practice. 
 
Conclusions 
Episodes of ADHF are associated with transient increases in the blood levels of 
hsTnT that are reduced with effective acute episode treatment. The decrease in hsTnT 
and NTproBNP can translate ventricular wall stress relief and less myocardial damage 
along with favourable ADHF treatment. Further studies are needed to examine the 
value of combining necrosis markers and natriuretic peptides in the clinical 
management of ADHF patients. 
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Tables 
Table 1. Population Characteristics, and Comparison of Clinical Variables, Laboratory 
Results and Medications Between Admission Day (Day 1) and Day 3 
Age (yrs)  76,0 ± 10,88  
Male Sex – %  39  
Diabetes Mellitus - % 
Glycated HgB (%) 
 45 
7,02 ± 0,96 
 
 
COPD - %  17  
Dementia - %  12  
Sleep Apnea - %  18  
Non-Invasive Ventilation - %  17  
Ischemic Heart Disease -%  50  
Atrial Fibrillation - %  59  
LV Ejection Fraction (%)  43,46 ± 11,73  
LV Ejection Fraction ≥ 40% - 
% 
 68  
 Day 1 Day 3 p Value 
Body Mass Index (Kg/m2) 29,44 ± 6,17 28,35 ± 6,23 < 0,001 
Heart Rate (bpm) 93,65 ± 24,35 76,41 ± 11,96 < 0,001 
SBP (mmHg) 139,79 ± 25,86 121,97 ± 16,2 < 0,001 
Plasma Creatinine (mg/dL) 1,04 [0,89 – 1,31] 1,06 [0,85 – 1,40] 0,082* 
eGFR (mL/min/1,73 m2) 58,0 [44,0 – 72,0] 58,0 [39,25 – 
72,75] 
0,171* 
Plasma Urea (mg/dL) 55,21 ± 20,84 62,3 ± 25,47 0,001 
Serum Potassium (mmol/L) 4,03 ± 0,51 4,04 ± 0,54 0,95 
Serum Sodium (mmol/L) 140,54 ± 4,38 140,68 ± 3,95 0,72 
Hemoglobin (g/dL) 12,43 ± 2,07 - - 
Albumin (mg/dL) 3,68 ± 0,40 - - 
NTproBNP (pg/mL) 2750 [1672 – 6032] 1835 [902 – 3837] < 0,001* 
hsTnT (ng/mL) 0,033 [0,019 – 
0,050] 
0,030 [0,018 – 
0,051] 
0,039* 
IV Furosemide - % 100 37 < 0,001** 
IV Furosemide Dose (mg/d) 75,80 ± 21,52 67,57 ± 25,54 0,001 
Oral Furosemide - % 0 63 - 
Oral Furosemide Dose (mg/d) 0 74,6 ± 28,1 - 
Furosemide Dose Reduction 
or Oral Route - % 
- 84 - 
ACEi - % 44 61 < 0,001** 
Ramipril Eq. Dose (mg/d) 3,15 ± 2,04 3,36 ± 2,14 0,474 
Beta-Blocker - % 37 57 < 0,001** 
Bisoprolol Eq. Dose (mg/d) 3,01 ± 1,08 2,96 ± 1,89 0,474 
Spironolactone - % 50 50 1** 
Spironolactone Dose (mg/d) 94,50 ± 23,31 62,74 ± 24,33 < 0,001 
Continuous variables are presented as mean value ± standard deviation [SD], p value 
or median [inter-quartile range, IQR], p value. Categorical variables are presented as % 
of total (100 patients), p value.  
*Non-parametric paired sample test; ** Chi-square test. 
Legend: COPD = chronic obstructive pulmonary disease; LV = left ventricular; eGFR = 
estimated glomerular filtration rate; NTproBNP = N-terminal pro brain natriuretic 
peptide; hsTnT = high sensitivity troponin T; IV = intra-venous; ACEi = angiotensin 
converting enzyme inhibitors. 
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Table 2. Comparison of TnT Levels Between Patients Who Responded to Diuretic Therapy 
versus Patients Who Needed to Increase Diuretic Dose 
 Furosemide 
Maintenance or 
Increase 
(n=16) 
Furosemide 
Decrease or Oral 
Administration 
(n=84) 
p Value 
Between 
Groups 
hsTnT (ng/mL) 
Day 1 
 
Day 3 
 
Δ hsTnT 
 
0,046 [0,033 to 
0,087] 
0,055 [0,032 to 
0,072] 
-0,0005 [-0,043 to 
0,004] 
 
0,032 [0,017 to 
0,048] 
0,028 [0,017 to 
0,045] 
-0,0010 [-0,020 to 
0,002] 
 
0,026* 
 
0,004* 
 
0,51* 
 p Value Within 
Group 
p Value Within 
Group 
 
 0,955* 0,025*  
Continuous variables are presented as median [inter-quartile range, IQR], p value. 
*Non-parametric test. 
Legend: hs TnT = high-sensitivity troponin T 
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Table 3. Comparison of hsTnT Values Below (Negative) and Above (Positive) the 99th 
Percentile (≥ 0,014 ng/mL) 
 Day 1  
Negative hsTnT – 
no. (%) 
Positive hsTnT – no. 
(%) 
Total p Value 
D
a
y
 3
 
Negative hsTnT – 
no. (%) 
10 (76,9) 3 (3,4) 13 (13) < 0,001** 
Positive hsTnT – no. 
(%) 
3 (23,1) 84 (96,6) 87 (87) < 0,001** 
Total 13 (13) 87 (87) 100  
** Chi-square test. Legend: hsTnT = high sensitivity troponin T. 
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Table 4. Associations With Log hsTnT at Day 1, Day 3, and Changes Between Day 1 
and Day 3 (Δ) 
 Nonadjust
ed 
Coefficient 
for Log 
hsTnT 
95%CI p Value Adjusted 
Coefficient 
for Log 
hsTnT 
95%CI p Value 
Age 0,119 -0,001 to 
0,005 
0,240    
Male Sex -0,066 -0,086 to 
0,043 
0,515    
DM 0,095 -0,033 to 
0,093 
0,349    
HgBA1c 0,058 -0,046 to 
0,067 
0,707    
LVEF 0,089 -0,001 to 
0,004 
0,376    
Ischemic HF -0,078 -0,087 to 
0,038 
0,442    
Beta Blocker -0,004 -0,065 to 
0,062 
0,969    
ACEi 0,023 -0,057 to 
0,072 
0,820    
Spironolactone -0,116 -0,099 to 
0,026 
0,251    
BMI       
Day 1 -0,205 -0,025 to 
0,000 
0,042    
Day 3 -0,087 -0,016 to 
0,006 
0,391    
Δ BMI -0,008 -0,019 to 
0,018 
0,937    
HR       
Day 1 0,063 -0,002 to 
0,004 
0,533    
Day 3 -0,078 -0,008 to 
0,004 
0,438    
Δ HR 0,013 -0,001 to 
0,001 
0,899    
SBP       
Day 1 0,102 -0,001 to 
0,004 
0,314    
Day 3 0,098 -0,002 to 
0,006 
0,333    
Δ SBP 0,207 0,000 to 
0,003 
0,039    
Log NTproBNP       
Day 1 0,481 0,267 to 
0,574 
<0,001 0,400 0,185 to 
0,513 
<0,001 
Day 3 0,486 0,218 to 
0,464 
<0,001 0,381 0,146 to 
0,389 
<0,001 
Δ Log NTproBNP 0,267 0,044 to 
0,276 
0,007 - - - 
Log Albuminuria       
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Day 1 0,131 -0,035 to 
0,172 
0,193    
Day 3 0,220 0,012 to 
0,203 
0,028 0,088 -0,041 to 
0,128 
0,311 
Δ Log Albuminuria 0,099 -0,038 to 
0,113 
0,325    
Log eGFR       
Day 1 -0,275 -1,231 to -
0,216 
0,006 0,165 -0,503 to 
1,372 
0,360 
Day 3 -0,399 -1,232 to -
0,455 
<0,001 0,034 -0,812 to 
0,957 
0,870 
Δ Log eGFR 0,068 0,203 to 
0,413 
0,502    
Log pCr       
Day 1 0,345 0,500 to 
1,704 
<0,001 0,270 -0,224 to 
1,951 
0,118 
Day 3 0,439 0,630 to 
1,503 
<0,001 0,256 -0,393 to 
1,641 
0,226 
Δ Log pCr -0,040 -0,443 to 
0,297 
0,696    
pUrea       
Day 1 0,309 0,002 to 
0,009 
0,002 0,116 -0,002 to 
0,007 
0,342 
Day 3 0,382 0,003 to 
0,008 
<0,001 0,121 -0,002 to 
0,005 
0,335 
Δ pUrea -0,172 -0,003 to 
0,000 
0,087    
Albumin at Day 1 -0,049 -0,099 to 
0,060 
0,626    
Hemoglobin at Day 
1 
0,076 -0,009 to 
0,021 
0,451    
Day 1 values are compared with day 1 hsTnT; day 3 values are compared with day 3 hsTnT; Δ, 
age, sex, DM, HgBA1c, LVEF, ischemic HF, and medications are compared with changes (Δ) in 
hsTnT between day 1 and day 3 (day 3 – day 1). 
Legend: DM = diabetes mellitus; HgBA1c = glycated hemoglobin; LVEF = left ventricular ejection 
fraction; HF = heart failure; ACEi = angiotensin converting enzyme inhibitors; BMI = body mass 
index; HR = heart rate; SBP = systolic blood pressure; NTproBNP = N-terminal pro brain natriuretic 
peptide; hsTnT = high sensitivity troponin T; eGFR = estimated glomerular filtration rate; pCr = 
plasma creatinine; pUrea = plasma urea; Δ = changes between day 3 and day 1 (day 3 – day 1). 
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        Table 5. Determinants of hsTnT Dichotomic Changes  
 hsTnT  
 Decrease (n = 63) Increase ( = 37) p Value 
Age (years) 75,94 ± 11,92 76,11 ± 8,97 0,940 
Male Sex – no. (%) 22 (34,9) 17 (45,9) 0,275** 
DM – no. (%) 24 (38,1) 21 (56,8) 0,070** 
HGA1c (%) 6,93 ± 0,94 7,13 ± 1,00 0,475 
Sleep Apnea – no. 
(%) 
7 (36,8) 11 (44) 0,632** 
NIV – no. (%) 10 (15,9) 7 (18,9) 0,695** 
IHD – no. (%) 32 (50,8) 18 (48,6) 0,836** 
AF – no. (%) 31 (49,2) 28 (75,7) 0,009** 
LVEF (%) 43,37 ± 12,68 43,62 ± 10,08 0,917 
LVEF ≥ 40% - no. 
(%) 
41 (65,1) 26 (70,3) 0,594** 
HgB (g/dL) 12,32 ± 1,95 12,62 ± 2,28 0,478 
Albumin (mg/dL) 3,68 ± 0,41 3,67 ± 0,39 0,924 
Δ BMI (Kg/m2) -1,08 ± 1,70 -1,10 ± 1,76 0,964 
Δ HR (bpm) -17,05 ± 20,71 -17,57 ± 29,15 0,917 
Δ SBP (mmHg) -18,56 ± 23,32 -16,57 ± 27,63 0,702 
Δ pCr (mg/dL) 0,03 [-0,1 to 0,18] 0,02 [-0,06 to 
0,11] 
0,803* 
Δ eGFR 
(ml/min/1,73m2) 
-2,0 [-9,0 to 7,0] -1,0 [-11,0 to 6,0] 0,937* 
Δ pUrea (mg/dL) 7,40 ± 20,59 6,59 ± 20,65 0,851 
Δ NTproBNP 
(pg/mL) 
-1167 [-2337 to -
367] 
-379 [-1273 to 
319,5] 
0,003* 
Δ hsTnT (ng/mL) -0,004 [-0,014 to -
0,001] 
0,004 [0,002 to 
0,009] 
<0,001* 
Δ Albuminuria 
(mg/g) 
-6,10 [-38,50 to 
2,40] 
-23,70 [-90,75 to 
11,05] 
0,337* 
IV Furosemide at 
Day 1 (mg) 
78,83 ± 21,61 74,05 ± 21,53 0,537 
IV Furosemide 
Dose Maintenance 
or Increase at Day 
3 – no. (%) 
 
9 (14,3) 
 
7 (18,9) 
 
0,542** 
ACEi – no. (%) 30 (47,6) 14 (37,8) 0,341** 
Beta Blocker – no 
(%) 
22 (34,9) 15 (40,5) 0,574** 
Spironolactone – 
no. (%) 
30 (47,6) 20 (54,1) 0,534** 
Length of Stay 
(days) 
8,0 [6,0 to 11,0] 9,0 [7,0 to 12,0] 0,033* 
Continuous variables are presented as mean value ± standard deviation [SD], p value 
or median [inter-quartile range, IQR], p value. Categorical variables are presented as 
absolute number (%), p value.  
*Non-parametric paired sample test; ** Chi-square test. 
DM = diabetes mellitus; HgBA1c = glycated hemoglobin; NIV = non-invasive 
ventilation; IHD = ischemic heart disease; AF = atrial fibrillation; HgB = hemoglobin; 
BMI = body mass index; HR = heart rate; SBP = systolic blood pressure; eGFR = 
estimated glomerular filtration rate; pCr = plasma creatinine; pUrea = plasma urea; 
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NTproBNP = N-terminal pro brain natriuretic peptide; hsTnT = high sensitivity troponin 
T; IV = intra-venous; ACEi = angiotensin converting enzyme inhibitors; Δ = changes 
between day 3 and day 1 (day 3 – day 1). 
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Figures 
Figure 1. Differences in hsTnT Between Faster Diuretic Responders and Slower 
Diuretic Responders at Day 1 and Day 3 
 
Legend: hsTnT = high sensitivity troponin T (ng/mL) 
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Figure 2. Correlation Between Δ Log hsTnT and Δ Log NT-pro BNP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Legend: hsTnT = high sensitivity troponin T (ng/mL); NT-pro BNP = N-terminal pro-
brain natriuretic peptide (pg/mL); Δ = changes between day 3 and day 1 (day 3 – day 
1). 
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Abstract 
Acutely decompensated heart failure (ADHF) is characterized by abnormal 
neurohormonal activation. Reliable biomarkers are warranted to establish the activity of 
mineralocorticoid receptor antagonism (MRA). Urinary sodium to potassium (uNa/K) 
ratio is a candidate biomarker of MRA. The aim of the present study is to examine the 
uNa/K ratio as a potential biomarker of MRA in ADHF patients.  
This was a retrospective secondary analysis of a study including 100 patients with 
ADHF. In that study 50 patients were submitted to spironolactone treatment. Baseline 
log renin was negatively correlated with log uNa/K ratio (p=0,001), in control group, day 
3 log aldosterone and log renin were also negatively correlated with log uNa/K ratio 
(both, p<0,05). Higher levels of aldosterone, renin, and uNa/K ratio were observed in 
patients who were submitted to spironolactone treatment (all, p<0,05), and log 
aldosterone and log renin were correlated in this group (p=0,011). The variations (day 
3 – baseline) in the levels of aldosterone and renin were both correlated to the variation 
in uNa/K ratio levels (p<0,05). Furthermore, uNa/K ratio showed a fair accuracy for 
spironolactone use (AUC=0,657).   
Our pilot study results support the use of uNa/K ratio as a surrogate marker of MRA. 
Key-words: mineralocorticoid receptor antagonism; biomarkers; urinary sodium to 
potassium ratio. 
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Introduction 
 The pathophysiology of acutely decompensated heart failure (ADHF) is 
characterized by abnormal neurohormonal activation, including the renin-angiotensin-
aldosterone system (RAAS). A consequence of the perpetual RAAS overactivation is 
the increase of aldosterone.  This adrenal hormone acts on the epithelium of distal 
nephron promoting the luminal secretion of potassium and the reabsorption of sodium. 
Beyond this physiological role, by acting on the mineralocorticoid receptor (MR) that is 
widespread expressed in several non-renal tissues, aldosterone promotes fibrosis, 
increases oxidative stress and apoptosis, amongst others deleterious mechanisms. 
Neurohormonal modulation, including angiotensin-enzyme-converting inhibitors (ACEi), 
angiotensin II receptor blockers (ARB) and mineralocorticoid receptor antagonism 
(MRA), had demonstrated significant morbidity and mortality reductions in chronic heart 
failure (HF) and post-myocardial infarction patients (MI)1-3. In these patients, higher 
aldosterone and renin levels were associated with poor outcomes4,5. Regarding the 
acute setting, adding high dose spironolactone to standard ADHF therapy as shown to 
be safe and likely to induce greater congestion relief translated into a more pronounced 
natriuretic peptide reduction6. In agreement, quantifying plasma levels of different 
neurohormones (NH) have been proposed for risk stratification of patients with HF7,8. 
Although the pharmacological blockade of RAAS is one of the mainstays of HF 
treatment, a suboptimal neurohormonal inhibition is still a critical issue in standard 
practice. Measuring the activation and the effective blockade of RAAS would help us to 
enhance its inhibition and to tailor these therapies to the individual HF patients9. Thus 
reliable and practical biomarkers are warranted to establish the RAAS blockade in 
clinical practice10. Taking advantage of the renal physiological action of aldosterone, 
the urinary sodium to potassium (uNa/K) ratio is an interesting candidate biomarker of 
RAAS modulation and MRA10. 
 The aim of the present study is to examine the uNa/K ratio as a potential 
biomarker of MRA in ADHF patients.  
 
Methods 
Study Design 
This study is based on analysed data from a previous prospective, 
interventional, clinical trial that we performed6. In that study we enrolled 100 
consecutive patients who presented in a Portuguese tertiary hospital with ADCHF, 
between February 2012 and February 2013. They were non-randomly assigned in a 
sequential 1:1 ratio to spironolactone plus standard ADCHF therapy or standard 
ADCHF therapy alone, 50 patients within each arm (i.e. patients were alternatively 
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assigned to spironolactone arm or standard ADCHF therapy arm in a sequential 
manner - the first patient to one arm and the next to the other arm. This sequence was 
repeated until we reach 100 patients, 50 patients within spironolactone group and 50 
patients within control group). Patients were blinded to the allocation, and the clinicians 
were not blinded to the allocation. The recommended spironolactone dose was 100 
mg/day, however the assistant physician could decrease the spironolactone dose to 50 
mg/day after 48h upon admission. After 72h the study was open label. Furosemide 
dose and form of administration was liberal. 
Patients were eligible for enrollment if they presented with decompensation of 
chronic HF with symptoms leading to hospitalization. ADHF was diagnosed on the 
basis of the presence of history of chronic HF and at least one symptom (dyspnea, 
orthopnea, or edema) and one sign (rales, peripheral edema, ascites, or pulmonary 
vascular congestion on chest radiography). Exclusion criteria were: chronic use of 
MRAs, cardiac surgery within 60 days of enrollment, cardiac mechanical support, 
cardiac resynchronization-therapy within the last 60 days, comorbid conditions with an 
expected survival of less than 6 months, acute MI at time of hospitalization, 
hemodynamically significant uncorrected primary cardiac valvular disease, patients 
requiring intravenous vasodilators or inotropic agents, supine systolic arterial blood 
pressure <90 mmHg, plasma creatinine (pCr) level >1,5 mg/dL, serum potassium level 
>5,0 mmol/L, hemoglobin (HgB) level <9 g/dL, and sepsis. 
Institutional review board or ethics committee approval was obtained. All 
patients provided written informed consent to participate in the study. 
 
Study assessments 
Patient`s clinical status including physical examination and was prospectively 
recorded by the same assistant physician at day 1 and day 3. 
Medications and respective dosages were prospectively recorded by the 
investigators according to the assistant physician prescriptions. 
Blood and spot urine samples were collected in the first 24 hours (h) after 
admission (day 1) of the patient to the hospital. The first dose of spironolactone was 
only administered after samples collection. Fifty patients had daily oral spironolactone 
according to the study protocol described above. The day 3 samples were collected 
between 72 and 96 h of hospitalization. All samples were collected in the morning with 
the patient in supine position, and first-morning spot urine was used. All patients had 
low-salt, low-calorie hospital diet. Extra fruit and vegetables administration was not 
allowed. An assessment of biomarkers (including pCr, plasma urea [pUr], electrolytes, 
N-terminal pro-brain natriuretic peptide [NTproBNP], high-sensitivity troponin T [hsTnT] 
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and proteinuria) was performed at a central core laboratory at day 1 and day 3. Clinical 
assessment and routine analyses were performed daily during hospital stay. All 
patients performed a transthoracic echocardiography within 72 hours upon admission. 
Left ventricle ejection fraction (EF) was calculated according to biplane Simpson 
method. 
Aldosterone was measured using radioimmunoassay (RIA) Coat-a-Count® 
(Siemens) and renin with RIA (DiaSource). 
 
Variable definitions 
  We studied aldosterone (ng/dL) and renin (pg/mL) and their variation (delta) 
regarding the following covariates: age; sex; diabetes mellitus (DM); ischemic HF; EF 
(%); systolic blood pressure (SBP); intravenous (IV) furosemide dose; proportion of 
patients with furosemide dose reduction or switch to oral route from baseline to day 3; 
proportion of patients on angiotensin converting enzyme inhibitors (ACEi), angiotensin 
receptor blockers (ARB), beta-blockers (BB), and spironolactone; pCr (mg/dL), pUr 
(mg/dL), NTproBNP (pg/mL), hsTnT (ng/mL), sodium (mmol/L), potassium (mmol/L), 
uNa/K ratio, proteinuria (g/g) and HgB (g/dL). 
 
Statistical Analysis 
Normally distributed continuous variables are expressed as mean ± standard 
deviation (SD), and skewed distributions are presented as median [inter-quartile range, 
IQR].  
Because of the positively skewed distributions of aldosterone, renin, pCr, 
proteinuria, RDW, NTproBNP, hsTnT and uNa/K ratio, these variables were log 
transformed for analysis. 
Categorical variables are expressed in proportions (%). 
Comparison between groups was performed using parametric, non-parametric 
tests, or chi-square tests, as appropriate. Significant association was defined by a 
probability (p) value ≤0,05.  
Correlations of log aldosterone and log renin with the mentioned variables were 
first examined by single variable linear or logistic regression and presented as non-
adjusted coefficient (NAC) and 95% confidence interval [95%CI]. Factors with a p value 
≤0,05 by single variable regression analyses were included in a multivariable linear 
regression model, presented as adjusted coefficient (AC) [95%CI]. 
Statistical analysis was performed using SPSS software (version 19, Chicago, 
IL, USA). 
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Results 
Baseline Characteristics, Medications and Lab Results 
Mean ± SD age of the 100 patients admitted due to ADHF was 76,0 ± 10,9 
years. Thirty-nine (39%) patients were male; 50 patients had documented ischemic 
heart disease (IHD); 32 had EF < 40%; spironolactone was administered to 50 patients 
starting on the admission day.  
Patient characteristics, and comparison of systolic blood pressure (SBP), lab 
results and medication dosage between admission day (day 1) and the third day of 
inpatient treatment is shown in Table 1. 
Plasma urea, proteinuria, NTproBNP and hsTnT reduced between day 1 and 
day 3 (all, p < 0,05). Furosemide dose was reduced from day 1 to day 3 (75,80 ± 21,52 
vs. 67,57 ± 25,54, p < 0,001). Spironolactone dose was also reduced according to 
study protocol (94,50 ± 23,31 vs. 62,74 ± 24,33). The proportion of patients on 
ACEi/ARB, BB and oral furosemide increased from day 1 to day 3 (all, p < 0,05). Renin 
and aldosterone increased during the study period (these results were not compared 
because day 1 samples were all collected before spironolactone administration and at 
day 3 fifty patients were on spironolactone). No changes were found between day 1 
and day 3 regarding pCr and uNa/K ratio – Table 1. 
Day 1 Aldosterone and Renin Correlations  
Day 1 log aldosterone was positively correlated with ischemic HF (3,029 [1,197 
to 7,668], p = 0,019), pUr (0,231 [0,001 to 0,009], p = 0,021), and log proteinuria (0,215 
[0,021 to 0,443], p = 0,031). These associations remained significant after adjustment – 
Table 2. 
Day 1 log renin was negatively correlated with log uNa/K ratio (-0,332 [-0,671 to 
-0,184], p=0,001) and SBP (-0,223 [-0,008 to -0,001], p = 0,026). Correlation was 
positive with ischemic HF (2,743 [1,150 to 6,542], p=0,023). After adjustment log renin 
remained significantly correlated with log uNa/K ratio and SBP – Table 2. 
Aldosterone, Renin, and uNa/K ratio Changes 
 Previous to spironolactone administration (day 1) log aldosterone levels did not 
differ between groups, although a trend to higher log aldosterone levels was observed 
in control group (1,484 ± 0,436 vs. 1,651 ± 0,446, p=0,062), this tendency was inverted 
after 3 days of spironolactone use (1,789 ± 0,461 vs. 1,654 ± 0,500, p=0,166) with 
higher levels of aldosterone in spironolactone group and a significant variation in the 
log aldosterone levels (0,305 ± 0,484 vs. 0,004 ± 0,432, p=0,001) – Table 3. 
 At day 1 log renin levels were not significantly different between groups, but in 
this case higher log renin levels were observed in spironolactone group (0,801 ± 0,491 
vs. 0,625 ± 0,475, p=0,071), these differences were accentuated after spironolactone 
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administration (0,934 ± 0,547 vs. 0,704 ± 0,454, p=0,025) – Table 3. A similar scenario 
was found in uNa/K ratio analysis with significant differences being achieved after 
spironolactone administration (0,487 ± 0,394 vs. 0,312 ± 0,370, p=0,024) – Table 3. 
Day 3 Aldosterone and Renin Correlations Within Spironolactone and Control 
Groups 
  Within control group, both day 3 log aldosterone and log renin were correlated 
with log uNa/K ratio (-0,450 [-0,955 to -0,257], p = 0,001 and -0,347 [-0,756 to 0,091], p 
= 0,014, respectively) – Table 4. and Figure 1; log aldosterone was also associated 
with log pUr (0,302 [0,069 to 1,588], p = 0,033) – Table 4., and log renin was correlated 
to log pCr (0,297 [0,062 to 1,750], p = 0,036), and negatively correlated to beta-blocker 
use (-0,290 [-0,512 to -0,011], p = 0,041) – Table 4. 
Within spironolactone group log aldosterone and log renin were correlated 
(0,359 [0,074 to 0,530], p = 0,011) – Table 4.; log aldosterone was also positively 
correlated with furosemide dose reduction (0,334 [0,142 to 1,415], p = 0,018), and log 
renin was negatively correlated with serum sodium (-0,337 [-0,094 to -0,010], p = 
0,017) – Table 4. 
Associations Between Delta (Δ) Log Renin, Δ Log Aldosterone and Δ Log UNa/K 
ratio 
 Changes (day 3 – day 1) in log aldosterone and log renin were correlated with 
the changes in log uNa/K ratio within spironolactone group (-0,288 [-0,518 to -0,009], 
p=0,042 and -0,512 [-0,740 to -0,256], p <0,001, respectively) – Table 5. 
Na/K ratio: Receiver Operating Curve Analysis 
 Na/K ratio showed a sensitivity of 86% and a specificity of 44% (area under 
curve [AUC], 0,657 [0,550 to 0,765], p = 0,007) in predicting spironolactone use – 
Figure 2. 
Comparison Between Spironolactone and Control Groups Regarding Potential 
Confounders 
 No differences were observed regarding SBP, serum sodium and potassium, 
ACEi/ARB and beta-blocker use, and i.v. furosemide dose. A greater proportion of 
patients were on oral furosemide at day 3 within spironolactone group (22 vs. 41, p < 
0,001). 
 
Discussion 
The present study tested if uNa/K ratio was independently associated with 
plasma levels of aldosterone and renin, and if the levels of these biomarkers changed 
with the introduction of spironolactone in a cohort of patients with ADHF, half of them 
treated with spironolactone. Renin, aldosterone and uNa/K ratio levels increased in the 
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group of patients submitted to spironolactone treatment. In this group of patients, the 
variation in aldosterone and renin levels from baseline to day 3 were correlated with the 
variation in the uNa/K ratio levels.  In addition, uNa/K ratio showed a fair accuracy for 
spironolactone use. Taken together, our results support the potential usefulness of this 
simple urinary measure as biomarker of MRA. 
Aldosterone regulates sodium balance by increasing the expression of the 
epithelial Na+ channel and the Na+/K+-ATPase pump found on the distal nephron 
epithelial cells11, promoting reabsorption of Na+ and the excretion of K+12. Previous 
reports had indicated a measurable effect of MRA on uNa/K ratio consistent with 
effects of aldosterone on electrolyte balance13,14. Mineralocorticoid receptor blockade 
elicited an increase in uNa/K ratio in rats in a dose-dependent manner10, supporting the 
use of uNa/K ratio as a translatable biomarker of MRA with the potential to enable dose 
selection for clinical trials10. In our study, renin was negatively associated with uNa/K 
ratio at day 1, and at day 3 both renin and aldosterone were independently associated 
with uNa/K ratio in the group of patients not submitted to spironolactone treatment. 
These findings are consistent with the RAAS effects on distal nephron, i.e. higher 
levels of renin and aldosterone lead to higher Na+ reabsorption and K+ excretion, 
decreasing uNa/K ratio15. In addition, we also observed an increase of uNa/K ratio in 
the group of spironolactone-treated patients, despite the higher increase in aldosterone 
and renin levels in this group of patients, suggesting a compensatory response to 
MRA10,16,17. These observations were supported by the significant correlation between 
the variation (day 3 – baseline) in aldosterone and renin levels with the variation in the 
uNa/K ratio levels. Together, these dynamic changes demonstrate an effective MRA by 
spironolactone and suggest that uNa/K ratio can serve as a surrogate biomarker for 
MRA. No significant differences between groups (spironolactone vs. control) were 
observed regarding ACEi/ARB use, IV furosemide dose, SBP, plasma potassium, 
serum sodium or diet, therefore it is likely that the observed dynamic changes were due 
to the spironolactone effect. Noteworthy, a higher proportion of patients on oral 
furosemide at day 3 was observed in spironolactone group, potentially translating a 
faster diuretic response within this group18, however the less aggressive diuretic 
strategy would theoretically decrease urinary sodium excretion leading to a lower 
uNa/K, yet this was not observed in our study, by the contrary, spironolactone treated 
patients had higher uNa/K ratio corroborating that the observed dynamic changes in 
uNa/K ratio were driven by MRA effect.  
Our preliminary results, are the first to show the potential usefulness of uNa/K 
as a surrogate marker for MRA. The implications of these observations have the 
133 
 
potential to be translated into clinical trials and also to daily practice, helping in the 
MRA dose titration and clinical effect monitorization.  
In our study uNa/K ratio has demonstrated to have a fair accuracy in 
determining spironolactone use, with patients on spironolactone having higher uNa/K 
ratio (high sensitivity), but the test has not demonstrated to be accurate in excluding 
patients without spironolactone treatment (low specificity). Whether the accuracy of the 
test can be increased with higher MRA dose or tighter potential confounder control (in a 
randomized and controlled trial) needs to be determined in future studies. However we 
find our results very encouraging towards the use of this inexpensive and readily 
available biomarker.   
We validated uNa/K ratio against aldosterone and renin plasma concentrations. 
Although there are some caveats in the interpretation of these tests, they are 
recommended and used in standard clinical practice to screen and diagnose diseases 
associated to increased SRAA activity. The median aldosterone and renin levels found 
in our study were higher than the median values found in previous reports of patients 
with chronic HF4,5,7,19 and acute HF9. This finding may be explained by the lower 
proportion (only 44%) of the patients on baseline ACEi/ARB, potentially leading to 
higher levels of renin and aldosterone19,20, similar to the levels found before the 
widespread use of the RAAS inhibitors7,8. MRA induced an increase in serum 
aldosterone and renin levels. These findings are concordant with previous reports in 
which the physiological elevation in plasma renin activity (PRA) and aldosterone were 
demonstrated in response to eplerenone and spironolactone treatment10,16,17,21,22. 
Our study has several limitations that need to be considered. First, it was a 
single-centre of a small sample size study. Second, diuretic therapy is could 
independently increase both renin and aldosterone plasma concentrations and uNa/K 
ratio. However, this would attenuate the inverse correlation between these variables 
that we found.  Third, the plasma renin and aldosterone measure the circulating RAAS 
ativity, while uNa/K ratio is influenced by systemic and intra-renal SRAA activity. 
Fourth, whether the accuracy of uNa/K ratio as a biomarker for MRA use can be 
increased with higher MRA doses or tighter variable control is yet to be determined. 
Finally, our inclusion criteria by restricting the enrolment of patients with hyperkalemia, 
severe impaired renal function limit the external validity of our conclusions.  
 
Conclusions 
 In an ADHF patients cohort, we demonstrated that uNa/K ratio is 
independently associated with renin and aldosterone at different time points and is also 
influenced by MRA therapy. Therefore, our findings disclose the potential role of uNa/K 
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ratio as a non-invasive and inexpensive biomarker of MRA therapy in acute HF 
patients.  Nevertheless, how clinical management will be tailored according to the 
activation level of the RAAS is still unclear. 
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Tables 
Table 1. Population Characteristics, Laboratory Results and Spironolactone Dose at 
Admission Day (Day 1) and Day 3 
Age (yrs) 76,0 ± 10,88 
Male Sex – % 39 
DM - % 45 
Ischemic HF - % 50 
EF < 40 - % 32 
Hemoglobin (g/dL) 12,43 ± 2,07 
 Day 1 Day 3 p Value 
SBP (mmHg) 139,79 ± 25,86 121,97 ± 16,2 < 0,001 
IV Furosemide - % 100 37 < 0,001** 
IV Furosemide Dose (mg/d) 75,80 ± 21,52 67,57 ± 25,54 0,001 
Oral Furosemide - % 0 63 - 
Oral Furosemide Dose 
(mg/d) 
0 74,6 ± 28,1 - 
ACEi - % 44 61 < 0,001** 
Ramipril Eq. Dose (mg/d) 3,15 ± 2,04 3,36 ± 2,14 0,474 
Beta-Blocker - % 37 57 < 0,001** 
Bisoprolol Eq. Dose (mg/d) 3,01 ± 1,08 2,96 ± 1,89 0,474 
Spironolactone - % 50 50 1 
Spironolactone Dose (mg/d) 94,50 ± 23,31 62,74 ± 24,33 < 0,001 
Plasma Creatinine (mg/dL) 1,04 [0,89 – 1,31] 1,06 [0,85 – 1,40] 0,082* 
Plasma Urea (mg/dL) 55,21 ± 20,84 62,3 ± 25,47 0,001 
Plasma Potassium (mmol/L) 4,03 ± 0,51 4,04 ± 0,54 0,950 
Serum Sodium (mmol/L) 140,54 ± 4,38 140,68 ± 3,95 0,72 
Proteinuria (g/g) 0,289 [0,188 – 0,629] 0,299 [0,160 – 
0,970] 
0,045* 
NTproBNP (pg/mL) 2750 [1672 – 6032] 1835 [902 – 3837] < 0,001* 
UNa/K ratio 3,04 [1,52 – 5,76] 2,80 [1,50 – 4,78] 0,341* 
Renin (pg/mL) 4,35 [2,30 – 10,78] 5,34 [3,14 – 16,30] - ** 
Aldosterone (ng/dL) 35,0 [12,0 – 92,5] 67,0 [21,3 – 125,0] - ** 
hsTnT (ng/mL) 0,033 [0,019 – 0,050] 0,030 [0,018 – 
0,051] 
0,039* 
Continuous variables are presented as mean value ± standard deviation [SD], p value 
or median [inter-quartile range, IQR], p value. Categorical variables are presented as 
absolute number (%), p value.  
*Non-parametric paired sample test. 
**These results were not compared because day 1 samples were all collected before 
spironolactone administration and at day 3 fifty patients were on spironolactone. 
Note: day 1 analysis were collected before spironolactone administration.  
Legend: DM = diabetes mellitus; HF = heart failure; EF = ejection fraction; ACEi/ARB = 
angiotensin converting enzyme inhibitors/angiotensin receptor blockers; NTproBNP = 
N-terminal pro brain natriuretic peptide; UNa/K = urinary sodium to potassium; hsTnT = 
high sensitivity troponin T.  
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Table 2. Day 1 Log Aldosterone and Log Renin Associations 
 NAC for 
Log 
Aldosterone 
95%CI p Value AC for Log 
Aldosterone 
95%CI p 
Value 
Age 0,102 -0,004 to 0,120 0,311    
Male Sex 0,458 -0,180 to 1,162 0,100    
DM 0,965 -0,398 to 2,342 0,938    
EF <40% 0,515 -0,194 to 1,370 0,184    
Ischemic HF 3,029 1,197 to 7,668 0,019 0,259 0,068 to 0,393 0,006 
SBP -0,154 -0,006 to 0,001 0,126    
IV Furosemide 
Dose 
0,096 -0,002 to 0,006 0,340    
Beta Blocker 1,690 -0,669 to 4,271 0,267    
ACEi/ARB 1,088 -0,455 to 2,659 0,853    
Spironolactone -0,187 -0,342 to 0,008 0,062    
Log Creatinine 0,150 -0,170 to 1,310 0,130    
Urea 0,231 0,001 to 0,009 0,021 0,200 0,000 to 0,008 0,034 
Potassium 0,145 -0,047 to 0,303 0,149    
Sodium -0,011 -0,032 to 0,009 0,267    
Log 
Proteinuria 
0,215 0,021 to 0,443 0,031 0,202 0,020 to 0,416 0,031 
Log 
NTproBNP 
0,189 -0,008 to 0,397 0,059    
Log UNa/K 
ratio 
-0,180 -0,440 to 0,020 0,073    
Log Renin 0,156 -0,039 to 0,323 0,122    
Log hsTnT -0,032 -0,273 to 0,198 0,754    
Hemoglobin 0,087 -0,024 to 0,062 0,388    
 NAC for 
Log Renin 
95%CI p Value AC for Log 
Renin 
95%CI p 
Value 
Age 0,001 -0,008 to 0,010 0,804    
Male Sex 1,217 -0,533 to 2,777 0,642    
DM 0,634 -0,277 to 1,449 0,280    
EF <40% 0,691 -0,283 to 1,685 0,416    
Ischemic HF 2,743 1,150 to 6,542 0,023 0,173 -0,010 to 0,347 0,064 
SBP -0,223 -0,008 to -0,001 0,026 -0,232 -0,008 to -
0,001 
0,013 
IV Furosemide 
Dose 
-0,09 -0,002 to 0,007 0,372    
Beta Blocker 0,639 -0,270 to 1,514 0,309    
ACEi/ARB 1,100 -0,487 to 2,488 0,819    
Spironolactone 0,181 -0,016 to 0,368 0,071    
Log Creatinine 0,108 -0,377 to 1,263 0,286    
Urea 0,169 -0,001 to 0,009 0,092    
Potassium -0,100 -0,289 to 0,096 0,322    
Sodium -0,034 -0,026 to 0,019 0,740    
Log 
Proteinuria 
-0,064 -0,312 to 0,160 0,525    
Log 
NTproBNP 
-0,038 -0,268 to 0,183 0,709    
Log UNa/K 
ratio 
-0,332 -0,671 to -0,184 0,001 -0,322 -0,651 to -
0,178 
0,001 
Log 0,156 -0,039 to 0,323 0,122    
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Aldosterone 
Log hsTnT -0,031 -0,055 to 0,040 0,759    
Hemoglobin -0,031 -0,055 to 0,040 0,759    
Note: day 1 analysis were collected before spironolactone administration.  
Legend: NAC = non-adjusted coefficient; AC = adjusted coefficient; DM = diabetes 
mellitus; LVEF = left ventricular ejection fraction; HF = heart failure; ACEi/ARB = 
angiotensin converting enzyme inhibitors/angiotensin receptor blockers; NTproBNP = 
N-terminal pro brain natriuretic peptide; UNa/K = urinary sodium to potassium; hsTnT = 
high sensitivity troponin T. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Comparison Between Groups (Spironolactone vs. No Spironolactone) at Day 1 and 
Day 3 
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 Spironolactone No Spironolactone p Value* 
Log Aldosterone 
Day 1 
Day 3 
ΔLog Aldosterone 
 
1,484 ± 0,436 
1,789 ± 0,461 
0,305 ± 0,484 
 
1,651 ± 0,446 
1,654 ± 0,500 
0,004 ± 0,432 
 
0,062 
0,166 
0,001 
Log Renin 
Day 1 
Day 3 
ΔLog Renin 
 
0,801 ± 0,491 
0,934 ± 0,547 
0,133 ± 0,513 
 
0,625 ± 0,475 
0,704 ± 0,454 
0,079 ± 0,309 
 
0,071 
0,025 
0,531 
Log UNa/K ratio 
Day 1 
Day 3 
ΔLog UNa/K ratio 
 
0,477 ± 0,407 
0,487 ± 0,394 
0,010 ± 0,528 
 
0,409 ± 0,350 
0,312 ± 0,372 
-0,097 ± 0,401 
 
0,374 
0,024 
0,255 
*Independent sample T test. 
Note: day 1 analysis were collected before spironolactone administration.  
Legend: UNa/K, urinary sodium to potassium; Δ, variation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Day 3 Log Aldosterone and Log Renin Associations Within Spironolactone 
and Control Groups 
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 Spironolactone Group Control Group 
 NAC for 
Log 
Aldosterone 
95%CI p Value NAC for Log 
Aldosterone 
95%CI p 
Value 
SBP -0,157 -0,012 to 0,004 0,277 -0,063 -0,011 to 0,007 0,685 
Furosemide 
Reduction 
0,334 0,142 to 1,415 0,018 -0,082 -0,409 to 0,229 0,572 
Beta Blocker 0,195 -0,083 to 0,447 0,174 -0,015 -0,303 to 0,274 0,920 
ACEi/ARB 0,123 -0,155 to 0,386 0,394 -0,166 -0,457 to 0,121 0,248 
Log Creatinine 0,021 -0,543 to 0,992 0,559 0,255 -0,086 to 1,798 0,074 
Urea 0,085 -0,940 to 1,090 0,883 0,302 0,069 to 1,588 0,033 
Potassium 0,088 -0,174 to 0,327 0,542 0,067 -0,205 to 0,328 0,646 
Sodium 0,011 -0,036 to 0,039 0,939 0,080 -0,024 to 0,043 0,581 
Log 
Proteinuria 
-0,031 -0,425 to 0,344 0,832 0,103 0,237 to 0,499 0,477 
Log 
NTproBNP 
-0,081 -0,351 to 0,197 0,575 -0,107 -0,398 to 0,183 0,460 
Log UNa/K 
ratio 
-0,006 0,347 to 0,332 0,964 -0,450 -0,955 to -
0,257 
0,001 
Log Renin 0,359 0,074 to 0,530 0,011 0,189 -0,105 to 0,522 0,188 
Log hsTnT 0,039 -0,348 to 0,457 0,787 0,053 -0,327 to 0,473 0,715 
 NAC for 
Log Renin 
95%CI p Value NAC for Log 
Renin 
95%CI p 
Value 
SBP -0,010 -0,010 to 0,005 0,944 -0,079 -0,011 to 0,006 0,587 
Furosemide 
Reduction 
-0,091 -1,051 to 0,546 0,528 -0,213 -0,497 to 0,070 0,137 
Beta Blocker -0,148 -0,480 to 0,154 0,307 -0,290 -0,512 to -
0,011 
0,041 
ACEi/ARB -0,106 -0,440 to 0,204 0,465 -0,073 -0,333 to 0,198 0,613 
Log Creatinine 0,102 -0,777 to 1,621 0,483 0,297 0,062 to 1,750 0,036 
Urea 0,162 -0,391 to 1,414 0,260 0,253 -0,070 to 1,330 0,077 
Potassium 0,070 -0,225 to 0,370 0,628 0,166 -0,100 to 0,378 0,249 
Sodium -0,337 -0,094 to -0,010 0,017 -0,006  -0,031 to 0,030 0,969 
Log 
Proteinuria 
-0,246 -0,830 to 0,055 0,084 -0,133 -0,487 to 0,180 0,359 
Log 
NTproBNP 
-0,028 -0,358 to 0,295 0,848 0,065 -0,205 to 0,324 0,655 
Log UNa/K 
ratio 
-0,172 -0,636 to 0,158 0,232 -0,347 -0,756 to 0,091 0,014 
Log 
Aldosterone 
0,359 0,074 to 0,530 0,011 0,189 -0,105 to 0,522 0,188 
Log hsTnT -0,065 -0,584 to 0,371 0,656 -0,002 -0,366 to 0,362 0,991 
Legend: SBP, systolic blood pressure; IV, intra venous; ACEi/ARB, angiotensin 
converting enzyme inhibitors/angiotensin receptor blockers; NTproBNP, N-terminal pro 
brain natriuretic peptide; UNa/K, urinary sodium to potassium; hsTnT = high sensitivity 
troponin T. 
 
 
 
Table 5. Associations Between Delta (Δ) Log Renin, Δ Log Aldosterone and Δ Log 
UNa/K ratio Within Spironolactone and Control Groups 
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 Spironolactone Group Control Group 
 NAC for Δ 
Log 
Aldosterone 
95%CI p Value NAC for Δ 
Log 
Aldosterone 
95%CI p 
Value 
Δ Log Renin 0,384 0,123 to 0,692 0,006 -0,119 -0,568 to 0,237 0,411 
Δ Log UNa/K 
ratio 
-0,288 -0,518 to -
0,009 
0,042 0,063 -0,244 to 0,380 0,663 
 NAC for Δ 
Log Renin 
  NAC for Δ 
Log Renin 
  
Δ Log 
Aldosterone 
0,384 0,123 to 0,692 0,006 -0,119 -0,568 to 0,237 0,411 
Δ Log UNa/K 
ratio 
-0,512 -0,740 to -
0,256 
<0,001 -0,165 -0,348 to 0,093 0,252 
Legend: NTproBNP, N-terminal pro brain natriuretic peptide; UNa/K, urinary sodium to 
potassium; Δ, changes (day 3 – day 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 
Figure 1. Log Aldosterone and Log Renin Correlations with Log UNa/K ratio at Day 3 in Control Group (No Spironolactone Use) 
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Legend: UNa/K, urinary sodium to potassium 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 2. Receiver Operating Curve: uNa/K ratio Biomarker Potential of Spironolactone Use 
 
p = 0,001 p = 0,014 
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Abstract 
Background: Matrix metalloproteinases (MMPs) are a family of enzymes important for 
the resorption of extracellular matrices (ECM), control of vascular remodelling and 
repair. Increased activity of MMP2 has been demonstrated in heart failure (HF) and in 
acutely decompensated heart failure (ADHF) a decrease of circulating MMPs has been 
demonstrated along with successful treatment.  
Objectives: Our aims are to test the influence of spironolactone in MMP2 levels. 
Methods: Secondary analysis of a prospective, interventional study including 100 
patients with ADHF. Fifty patients were non-randomly assigned to spironolactone 100 
mg/day plus standard ADHF therapy (intervention group) or standard ADHF therapy 
alone (control group).  
Results: Patients within spironolactone group were younger, had lower creatinine and 
urea levels (all p < 0,05). Baseline MMP2, NT-pro BNP and weight did not differ 
between spironolactone and control groups. A trend to a more pronounced decrease of 
MMP2 from baseline to day 3 was observed in spironolactone group (-21 [-50 to 19] vs 
1,5 [-26 to 38] ng/mL, p = 0,06), NT-pro BNP and weight also had a greater decrease 
in spironolactone group. The proportion of patients with a decrease in MMP2 levels 
from baseline to day 3, was also likely to be greater in spironolactone group (50% vs 
66,7%), but without statistical significance. Correlations between MMP2, NT-pro BNP 
and weight variation were not statistically significant. 
Conclusions: MMP2 levels are increased in ADHF. Patients submitted to 
spironolactone treatment may have greater reduction in MMP2 levels. 
Key-words: matrix metalloproteinase-2; decompensated heart failure; spironolactone. 
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Introduction 
Matrix metalloproteinases (MMPs) are a family of zinc-dependent interstitial 
enzymes important for the resorption of extracellular matrices (ECM) in both health and 
disease1. ECM are a dynamic structure central to the control of vascular remodelling 
and repair1, mostly due to the ability of MMPs to reabsorb and digest excessive 
amounts of ECM responsible for structural disruption2,3.  
Elevated MMPs promote loss of cardiac contractility via cell proteolysis and 
alterations in the ECM, contributing to cardiac and extra-cardiac remodelling 
processes4. In fact, clinical and experimental heart failure (HF) models of dilated and 
ischemic cardiomyopathy demonstrated an increased activity of matrix 
metalloproteinase-2 (MMP2)2,5-7.  In patients with HF, increased levels of MMP2 were 
associated with all-cause mortality8. Concordantly, in the acutely decompensated heart 
failure (ADHF) setting a decrease of circulating MMPs has been demonstrated along 
with successful ADHF treatment3,9. Previous studies have suggested a therapeutic 
benefit of spironolactone in ADHF setting10. But no studies had looked to the effect of 
spironolactone in the ECM remodelling. 
In the present study, we aimed to examine the influence of spironolactone on 
the ECM remodeling in ADHF patients. We hypothesized that MMP-2 plasma levels of 
ADHF patients will have steeper decrease if spironolactone is added to standard 
treatment. 
 
Methods 
Study Design 
We analysed data from a previous pilot, prospective, interventional, clinical trial 
that we performed. That study was performed between February 2012 and February 
2013 and during that period we enrolled 100 consecutive patients who presented into a 
Portuguese tertiary hospital with ADHF. Patients were eligible for enrollment if they 
presented with decompensation of chronic HF with symptoms leading to 
hospitalization. ADHF was diagnosed on the basis of the presence of history of chronic 
HF and at least one acute symptom (dyspnea, orthopnea, or edema) and one sign 
(rales, peripheral edema, ascites, or pulmonary vascular congestion on chest 
radiography). Patients were non-randomly assigned in a sequential 1:1 ratio to 
spironolactone plus standard ADHF therapy or standard ADHF therapy alone, 50 
patients within each arm. Patients were alternatively assigned to spironolactone arm or 
standard ADHF therapy arm in a sequential manner - the first patient to one arm and 
the next to the other arm. This sequence was repeated until we reach 100 patients, 50 
patients within spironolactone group and 50 patients within control group. Patients were 
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blinded to the allocation, but not the clinicians. The recommended spironolactone dose 
was 100 mg/day, however the assistant physician could decrease the spironolactone 
dose to 50 mg/day after 48h upon admission. Furosemide dose and route of 
administration was adjusted clinically according to the hydration status of the patients. 
Exclusion criteria were: chronic use of mineralocorticoid receptor antagonists, 
cardiac surgery within 60 days of enrollment, cardiac mechanical support, cardiac 
resynchronization-therapy within the last 60 days, comorbid conditions with an 
expected survival of less than 6 months, acute myocardial infarction at time of 
hospitalization, hemodynamically significant uncorrected primary cardiac valvular 
disease, patients requiring intravenous vasodilators or inotropic agents, supine systolic 
arterial blood pressure <90 mmHg, plasma creatinine level >1,5 mg/dL, serum 
potassium level >5,0 mmol/L, hemoglobin level <9 g/dL, and sepsis. 
Institutional review board or ethics committee approval was obtained. All 
patients provided written informed consent to participate in the study. 
 
Clinical assessment of participants 
Patient`s clinical status including physical examination was prospectively 
recorded by the same assistant physician at day 1 and day 3. Medications and 
respective dosages were prospectively recorded by the investigators according to the 
assistant physician prescriptions. 
Blood samples were collected in the first 24 hours (h) after admission (baseline) 
of the patient to the hospital, and the day 3 samples were collected between 72 and 96 
h of hospitalization. Samples were analysed at a central core laboratory, and included 
plasma creatinine and urea, electrolytes, NT-pro BNP and MMP2. Clinical assessment 
and routine analyses were performed daily during hospital stay. Estimated glomerular 
filtration rate (eGFR) was determined using the Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) equation11. All patients performed a transthoracic 
echocardiography within 72 hours upon admission. Left ventricular ejection fraction 
(LVEF) was calculated according to biplane Simpson method. 
MMP2 was measured by enzyme-linked immunoabsorbent assays (ELISA) - 
Quantikine Elisa Human MMP-2 Immunoassay, by the manufacturer R&D Systems, 
Inc®. The normal range of MMP2 values published by the manufacturer are median 
[inter-quartile range25-75], 199 [161 – 301] ng/mL. The assay sensitivity is 0,047 ng/mL. 
Of the 100 studied patients we analysed baseline (day 1) and day 3 blood 
samples from 87. Thirteen (13) samples were not analysed due to transport and/or 
sampling processing errors. Samples were collected in the morning with patients 
supine. Serum was separated and stored at -80 ºC until sample analysis. 
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Variable definitions 
We classified patients according to spironolactone use and their response to 
diuretic therapy.  
We studied the relationships between baseline characteristics, day 3 and 
changes (Δ, difference between day 3 and baseline values) in MMP2, NT-proBNP and 
weight regarding the spironolactone use and diuretic response.  
 
Statistical Analysis 
Normally distributed continuous variables are expressed as mean ± standard 
deviation (SD), and skewed distributions are presented as median [inter-quartile 
range25-75, IQR].  
Categorical variables are expressed in proportions (%). 
Comparison between groups was performed using parametric (independent 
samples t-test), non-parametric (Mann-Whitney test), or Chi-square tests, as 
appropriate.  
Correlations of MMP2 were examined by single variable linear regression and 
presented as correlation coefficient and 95% confidence interval [95%CI].  
A p value < 0,05 was considered statistically significant. 
Statistical analysis was performed using SPSS software (version 19, Chicago, 
IL, USA). 
 
Results 
Baseline Patients Characteristics in Control and Spironolactone Groups 
Patients in control group were older (78,8 ± 9,3 versus [vs.] 73,2 ± 11,7 years, p 
= 0,01), and had higher creatinine and urea levels (1,15 ± 0,27 vs. 1,03 ± 0,30 mg/dL, p 
= 0,026 and 59,32 ± 22,27 vs. 51,10 ± 18,63 mg/dL, p = 0,048). No differences 
between groups were found regarding sex, diabetes mellitus, chronic obstructive 
pulmonary disease, dementia, sleep apnea, non-invasive ventilation, ischemic heart 
disease, atrial fibrillation, LVEF, weight, systolic blood pressure, potassium, sodium, 
hemoglobin, albumin, NT-pro BNP, MMP2, furosemide dose, hospital length of stay, 
and in the proportion of patients on angiotensin converting enzyme inhibitors and beta-
blockers – Table 1. 
Spironolactone Influence on MMP2, NT-pro BNP and Weight Dynamic Changes 
No differences between control and spironolactone groups were observed 
regarding baseline and day 3 MMP2 levels – Table 2. However, MMP2 decreased from 
baseline to day 3 in spironolactone group, while in control group MMP2 levels 
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increased, leading to a tendency for a reduction in MMP2 levels in spironolactone 
group (1,5 [-26 to 38] vs. -21 [-50 to 19] ng/mL, p = 0,06) – Table 2. and Figure 1. The 
proportion of patients in which a decrease in MMP2 levels, from baseline to day 3, was 
observed was also greater in spironolactone group, however this difference did not 
reach statistical significance – number (%), 21 (50) in controls versus 30 (66,7) in 
spironolactone group, p = 0,115. 
No differences were observed in NT-pro BNP levels at baseline, however at day 
3 the group of patients who underwent spironolactone treatment presented lower levels 
of NT-pro BNP (248 [923 – 5502] vs. 1555 [722 – 2554] pg/mL, p = 0,05). No 
differences between groups were observed in the variation of NT-pro BNP levels 
probably due to the lower levels (although not significantly lower) of NT-pro BNP at 
baseline in the spironolactone group, leading to a smaller amplitude of variation in this 
group – Table 2.  
A greater weight decrease was also observed in the spironolactone-treated 
patients (-2,9 ± 2,4 vs. -4,8 ± 2,8 Kg, p < 0,001) – Table 2. 
Δ MMP2, Δ NT-pro BNP and Δ Weight Correlations 
 No significant correlations were observed between Δ in MMP2, NT-pro BNP 
and weight - Table 3. 
 
Discussion 
In the present study we observed an increased baseline levels of MMP2 in 
patients with ADHF. Those patients treated with spironolactone showed a tendency to 
a greater reduction of MMP2 levels. These results are consistent with previous findings 
demonstrating the impact of mineralocorticoid receptor antagonists on the ECMs 
remodelling and highlight the potential interest of spironolactone in the treatment of 
ADHF where those mechanisms are strongly exacerbated. 
 Increased serum levels of MMP2 have been demonstrated in the ADHF 
setting3,9. In our study the median [IQR] MMP2 levels at admission day were 260 [225 - 
312] ng/mL. These values are above the normal range defined by the manufacturer, 
199 [161 – 301] ng/mL, and are concordant with previous reports on patients with HF 
decompensation. A previous study by Shirakabe A., et al3, also showed increased 
serum MMP2 levels in ADHF, with a rapid decrease along with HF compensation. 
Furthermore, an interventional placebo-controlled trial performed by Tziakas DN., et 
al9, showed a significant reduction in MMP2 levels in the group of patients treated with 
levosimendan.  In animal models, exacerbated neurohormonal activation leads to an 
increase in the levels of several myocardial MMPs subtypes12-14. MMPs are important 
for proteolysis that can affect the composition of ECM and consequently myocardial 
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remodelling. Additionally, increased ECM turnover may be associated with pathological 
myocardial remodelling, that may be accelerated in decompensated HF3,15. 
Consequently, a reduction in markers of ECM turnover may serve as a surrogate 
marker for deceleration of myocardial turnover and remodelling. Our study showed a 
greater decrease of MMP2 in the group of patients submitted to spironolactone 
treatment. Mineralocorticoid receptor antagonists improve survival and reduce 
morbidity in patients with heart failure with reduced ejection fraction, and mild-to-severe 
symptoms, and in patients with left ventricular systolic dysfunction and heart failure 
after acute myocardial infarction16-18, additionally, used in natriuretic doses, the 
mineralocorticoid receptor antagonists are likely to improve congestion in ADHF with 
good tolerability and few side effects19. Several proposed mechanisms explain how 
MRAs improve HF outcomes, and these pathways include a reduction of myocardial 
remodelling20. Our study provides important information towards a better understanding 
of ECM turnover processes. The steeper MMP2 reduction observed in patients 
submitted to spironolactone treatment provides a real demonstration of potential 
mitigation of harmful remodelling through spironolactone use. Interestingly, patients 
without MMP2 reduction or increase, after an acute HF episode, had poorer prognosis3. 
Therefore, changes in MMP2 levels are a potentially useful prognostic marker in 
patients admitted due to ADHF.  
NT-pro BNP is a well-validated, widely used, and very accurate biomarker for 
the diagnosis and risk stratification of HF21. Patients submitted to spironolactone 
treatment had lower levels of NT-pro BNP at day 3, and a more pronounced weight 
reduction when compared to controls, and patients with slower diuretic response had 
higher NT-pro BNP levels at day 3 of hospitalization, a tendency to lower NT-pro BNP 
reduction, and less weight loss. However, the changes in MMP2 values did not 
correlate with the variation in NT-pro BNP or weight. The small sample size, the NT-
proBNP and MMP2 elevated variance, and the different mechanisms influencing those 
biomarkers may all explain the absence of this correlation. 
Several limitations in our study should be noticed. First, this was a single-
centre, non-randomized trial with a small number of patients with mixed HF etiologies 
and treatments. Second, this post-hoc analysis has limitations inherent to observational 
studies. Third, the decision to withdraw diuretic therapy was based on subjective 
assessment of congestive signs and symptoms so we cannot rule out the inter-
observer variability. However, in real-life patients, the decision to step down diuretic 
therapy is also based on subjective clinical evaluation. Fourth, our study excluded HF 
patients significant renal impairment, since plasma creatinine level of less than 1,5 
mg/dL was an inclusion criteria, leading to a potential selection of a subset of low risk 
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patients, which can affect the external validity of our results. Fifth, the group of patients 
submitted to spironolactone treatment were younger and had lower plasma creatinine 
and urea levels which can positively affect the response to this drug. Finally, only 
MMP2 was evaluated and other forms of MMPs may have different effects and 
responses in ADHF patients.  
 
Conclusion 
The present study showed that MMP2 levels can be increased in ADHF, and 
that patients treated with spironolactone may have greater reduction in MMP2 levels. 
Whether these findings have prognostic significance requires further investigation. 
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Tables 
Table 1. Baseline Population Characteristics, Laboratory Results, Medications, and 
Hospital Length of Stay in Treatment and Control Groups 
 Control Group 
(n = 50) 
Spironolactone 
Group 
(n = 50) 
p Value 
Age (yrs) 78,8 ± 9,3 73,2 ± 11,7 0,010 
Male Sex – % 34 44 0,31** 
Diabetes Mellitus - % 50 40 0,31** 
COPD - % 10 26 0,32** 
Dementia - % 16 8 0,22** 
Sleep Apnea - % 10 26 0,32** 
Non-Invasive Ventilation - % 14 20 0,42** 
Ischemic Heart Disease -% 48 52 0,69** 
Atrial Fibrillation - % 68 50 0,07** 
LV Ejection Fraction < 40% - 
% 
56 68 0,22** 
Weight (Kg) 75,6 ± 16,3 76,1 ± 16,4 0,89 
SBP (mmHg) 140,5 ± 23,9 139 ± 27,9 0,80 
Plasma Creatinine (mg/dL) 1,15 ± 0,27 1,03 ± 0,30 0,03 
eGFR (mL/min/1,73 m2) 54,5 ± 16,5 68,3 ± 23,6 0,001 
Plasma Urea (mg/dL) 59,3 ± 22,3 51,1 ± 18,6 0,05 
Serum Potassium (mmol/L) 4,1 ± 0,4 4,0 ± 0,6 0,33 
Serum Sodium (mmol/L) 140,5 ± 5,0 140,6 ± 3,7 0,96 
Hemoglobin (g/dL) 12,2 ± 1,8 12,7 ± 2,3 0,22 
Albumin (mg/dL) 3,7 ± 0,4 3,6 ± 0,4 0,63 
NTproBNP (pg/mL) 3102 [1797 – 8204] 2701 [1463 – 5004] 0,17* 
MMP2 (ng/mL) 260 [226 – 299] 268 [207 – 336] 0,52* 
IV Furosemide Dose (mg/d) 75,6 ± 20,7 76,0 ± 25,5 0,93 
ACEi/ARB – % 38 50 0,20** 
Beta-Blocker - % 42 32 0,30** 
Spironolactone - % - 100 - 
Spironolactone Dose (mg/d) - 94,5 ± 23,3 - 
Hospital Length of Stay 
(days) 
9,0 ± 3,7 8,7 ± 3,0 0,59 
Continuous variables are presented as mean value ± standard deviation [SD], p value 
or median [inter-quartile range, IQR], p value. Categorical variables are presented as 
absolute number (%), p value.  
*Non-parametric paired sample test; ** Chi-square test. 
Legend: COPD - chronic obstructive pulmonary disease; LV - left ventricular; eGFR - 
estimated glomerular filtration rate; NT-pro BNP - N-terminal pro brain natriuretic 
peptide; hsTnT - high sensitivity troponin T; MMP2 - matrix metalloproteinase -2; IV - 
intra-venous; ACEi - angiotensin converting enzyme inhibitors 
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Table 2. Comparison of MMP2, NT-pro BNP and Weight at Baseline, Day 3, and 
Change (Delta, Δ) from Baseline to Day 3 Between the Study Groups 
 Control Group Spironolactone Group p Value 
MMP2 
Baseline 
Day 3 
Δ (day 3 – 
baseline) 
 
260 [226 – 299] 
266 [227 – 298] 
1,5 [-26 to 38] 
 
268 [207 – 336] 
261 [212 – 307] 
-21 [-50 to 19] 
 
0,52* 
0,49* 
0,06* 
NT-pro BNP 
Baseline 
Day 3 
Δ (day 3 – 
baseline) 
 
3102 [1792 – 8204] 
2488 [923 – 5502] 
-945 [-2249 to -62] 
 
2701 [1463 – 5004] 
1555 [722 – 2554] 
-816 [-1833 to -106] 
 
0,17* 
0,05* 
0,75* 
Weight 
Baseline 
Day 3 
Δ (day 3 – 
baseline) 
 
75,6 ± 16,3 
72,8 ± 16,3 
-2,9 ± 2,4 
 
76,1 ± 16,4 
71,3 ± 16,2 
-4,8 ± 2,8 
 
0,89 
0,66 
<0,001 
Continuous variables are presented as mean value ± standard deviation [SD], p value 
or median [inter-quartile range, IQR], p value and independent samples t-test or 
independent samples non-parametric test were used, respectively. 
*non-parametric test. 
Legend: NT-pro BNP - N-terminal pro brain natriuretic peptide; MMP2 - matrix 
metalloproteinase -2; Δ - delta or difference between day 3 and baseline values. 
 
 
 
 
 
 
155 
 
Table 3. Correlation Coefficients and 95% Confidence Intervals (CI) Between Delta (Δ) 
MMP2, Δ NT-pro BNP, and Δ Weight 
 Δ MMP2 Correlation 
Coefficient 
95%CI p Value 
Δ NT-pro BNP 0,11 -0,003 to 0,01 0,33 
Δ Weight 0,12 -1,97 to 7,05 0,27 
Legend: MMP2 - matrix metaloproeinase-2; NT-pro BNP - N-terminal pro-brain 
natriuretic peptide; Δ - delta or difference between day 3 and baseline values 
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Figures 
Figure 1. Comparison of Δ MMP2 Levels from Baseline to Day 3 Between Control and 
Spironolactone Groups. 
 
A trend towards a more pronounced reduction in MMP2 levels was observed in 
spironolactone group.  
Analysis was performed comparing the variation (Δ, day 3 - baseline) of MMP2 levels 
between control and spironolactone groups using non-parametric independent sample 
tests (1,5 [-26 to 38] vs. -21 [-50 to 19], p = 0,06). 
Legend: MMP2 = matrix metalloproteinase-2; vs. = versus. 
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Figure 2. Proportion (%) of Patients with MMP2 Decrease from Day 1 to Day 3 
 
Legend: The proportion of patients in which a decrease in MMP2 levels, from baseline 
to day 3, was observed was greater in spironolactone group, however this difference 
did not reach statistical significance, p = 0,115 
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General Discussion and Limitations  
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 This pilot study and its sub-analysis provide original evidence towards the use 
of natriuretic spironolactone doses in ADHF, particularly regarding its safety profile, 
natriuretic effect and mitigation of end-organ damage.  
This discussion will focus three cornerstone findings: safety, congestion relief 
and end-organ protection. 
Our results suggest that the use of spironolactone in ADHF is safe and not 
associated with renal dysfunction or hyperkalemia. The concomitant use of intravenous 
diuretics with kaliuretic properties could have contributed to the absence of 
hyperkalemia, however we observed a trend to hypokalemia in the group of patients 
not receiving spironolactone, and reducing the risk of hypokalemia is a significant issue 
due to the fact that low potassium levels are deleterious in heart failure. Moreover, 
worsening renal function occurred more frequently in control group, possibly due to the 
lack of an adequate neurohormonal blockade in patients not taking spironolactone, with 
subsequent arteriolar vasoconstriction and greater renal damage. 
We also found that patients submitted to high-dose spironolactone had a faster 
resolution of congestive signs and an earlier switch to oral furosemide. The diuretic 
effect of doses greater than 50 mg per day of spironolactone can provide a plausible 
explanation to this finding, which was corroborated by a greater reduction in natriuretic 
peptides within the spironolactone group.  
Additionally, our study was the first to demonstrate a greater reduction in 
albuminuria in ADHF patients submitted to spironolactone treatment. The rationale for 
this effect may rely on effective neurohormonal blockade, suggesting a potential renal 
protective effect of this treatment. Patients in spironolactone group also had a more 
pronounced matrix metalloproteinase-2 reduction, which may represent a potential 
reduction of harmful remodelling. Additionally, this study also showed a tendency to a 
greater cardiac troponin reduction in patients submitted to spironolactone treatment 
that can represent a potential reduction of myocardial injury. 
We also would like to highlight the potential use of urinary sodium to potassium 
ratio as a simple, inexpensive and widely available surrogate marker for 
mineralocorticoid receptor antagonism. 
  
This study has several limitations. The most important general limitations are: 1) 
the lack of true randomization or concealed allocation, which can determine a selection 
bias with impact on the external validity of our results; 2) the assistant physicians 
performed the congestive signs assessment, therefore, we cannot exclude an 
ascertainment bias that can affect the internal validity of the comparison of subjective 
outcomes such as congestive signs or symptoms. Though, we had included an 
163 
 
important internal control such as plasma NTproBNP that is unaffected by this bias and 
appear to be consistent with the earlier resolution of the congestive signs in the 
treatment group; 3) our study was underpowered to detect the differences of the 
expected low rate of adverse events between groups; 4) the post-hoc analysis have the 
limitations inherent to observational studies. 
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Conclusions 
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The use of high-dose spironolactone in ADHF is safe, and possibly associated 
with greater congestion relief, faster diuretic response and less end-organ injury. The 
urinary sodium to potassium may serve as a potential surrogate marker for 
mineralocorticoid receptor antagonism. 
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Abstract 
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We aimed to add original evidence on the use of high-dose spironolactone in 
acutely decompensated heart failure (ADHF).  
We demonstrated that doses equal or superior to 50 mg a day of spironolactone 
can provide a more intense mineralocorticoid receptor antagonism (MRA), mitigating 
neurohormonal activation inherent to ADHF and also providing a natriuretic effect that 
can help loop diuretics in congestion relief.  
In our pilot study we provided real-world evidence that higher spironolactone 
dosages are safe, can reduce natriuretic peptides - translating greater congestion 
relief, can decrease albuminuria - traducing less renal damage, and probably decrease 
matrix-metalloproteinases and cardiac troponins translating less myocardial injury. We 
also showed that spironolactone increases renin, aldosterone and urinary sodium to 
potassium ratio providing potential surrogate markers of MRA.  
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Resumo 
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A nossa intenção com este estudo era fornecer evidência original para o uso de 
doses elevadas de espironolactona na insuficiência cardíaca descompensada (ICD). 
Demonstrámos que a espironolactona em doses iguais ou superiores a 50 mg 
por dia pode proporcionar um bloqueio eficaz dos recetores mineralocorticóides, 
diminuindo a ativação neurohormonal presente na ICD e, concomitantemente, 
aumentado o efeito natriurético dos diuréticos da ansa, funcionando como uma 
terapêutica adjuvante para o alívio da congestão hídrica.  
Neste estudo piloto, em doentes do mundo-real, conseguimos demonstrar o 
perfil de segurança de doses elevadas de espironolactona na ICD, o potencial da 
espironolactona reduzir peptídeos natriuréticos traduzindo maior alívio congestivo, 
diminuir a albuminúria traduzindo menor lesão renal e o potencial de proporcionar uma 
maior redução nos níveis séricos de metaloproteinases da matriz e nas troponinas 
cardíacas traduzindo menor dano cardíaco potencial. Demonstrámos também que a 
espironolactona aumenta os níveis de renina, aldosterona e razão sódio-potássio 
urinário favorecendo a utilização destes marcadores como tradutores do uso deste 
fármaco. 
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